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SUMMARY
In the present study, a transplantable ra t  insulinoma was characterised 
and its  functional properties investigated. Immunocytochemical staining  
and radioimmunoassay techniques confirmed the presence of insulin and 
somatostatin in the tumour, but an absence of glucagon. The molecular 
heterogeneity of insulin and somatostatin in the insulinoma was also 
investigated by gel f i l t r a t io n  and HPLC techniques.
The metabolic effects of the insulinoma in response to various stimuli 
and inhibitors of insulin release were studied. Plasma insulin and 
glucose responses to glucose, arginine, glibenclamide and exogenous 
insulin were impaired in the tumour bearing ra ts , and diurnal variations  
of glucose homeostasis were abolished. Data from the metabolic studies 
indicate the s u i ta b i l i ty  of the ra t insulinoma as a model for studies 
on the spontaneous insulinoma in man.
Although surgical resection of the insulinoma resulted in a marked 
reversal of the metabolic abnormalities, tumour recurrence was never­
theless observed in a l l  rats. Methotrexate and alloxan fa i le d  to 
a llev ia te  the hypoglycaemia in contrast to streptozotocin. The diver­
gent responses of alloxan and streptozotocin may be related to the tumour 
defect.
The role of glucagon in normal physiology was re-examined. Neutralisation  
of endogenous glucagon by glucagon-specific antibodies was used as a tool 
in unravelling glucagon's role in glucose homeostasis. Glucagon did not 
prove to be important fo r  the maintenance of basal blood glucose in the ra t.
Furthermore, i ts  insulinotrophic e ffec t was substantiated. Arginine 
stimulated insulin release was inhibited by glucagon antibodies in 
in vivo experiments and in isolated is le ts  of Langerhans, suggesting 
an essential role for glucagon in mediating the insulinotrophic e ffec t  
of arginine. In contrast, glucose stimulated insulin release was not 
inhibited by glucagon antibodies indicating that d if fe re n t mechanisms 
are involved in the stimulation of insulin secretion by arginine and 
glucose.
In agreement with the in vivo data, glucose and arginine fa iled  to 
stimulate insulin release in the in v itro  insulinoma cell suspension, 
whilst glucagon evoked a marked response. I t  is suggested that the 
impaired response of glucose may be related to the tumour defect, but 
that fa i lu re  of arginine to stimulate insulin secretion in vivo and 
in v itro  was due to the absence of A-cells in the tumour. These obser­
vations provide further evidence for the role of glucagon in insulin  
secretion.. The absence of A-cells in the insulinoma suggests that i t  
might be a suitable model for studying B- and D-cell in ter-re la tionships  
in an A-cell free environment.
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CHAPTER ONF 
GENERAL INTRODUCTION
Chapter 1 General Introduction
1.1 The regulation of blood glucose
In man, despite enormous differences in carbohydrate intake, blood glu­
cose concentrations seldom rise above 6.5 mmol/1 a f te r  a large meal, or 
f a l l  below 2 mmol/I even a fte r  days or weeks without food. The homeostatic 
mechanisms responsible for the regulation of blood glucose have been 
studied intensively but are s t i l l  poorly understood due to the inherent 
complexity of the problem.
The glucose space in man has been estimated to be about 25-35% of the 
to ta l body volume. This represents the glucose of the blood, the 
in te r s t i t ia l  f lu id  and the free ex trace llu la r glucose of the 
l iv e r .  However the actual amount of glucose in the body is small, 
averaging about 15-20 g in resting subjects. This comprises the glucose 
pool in the body to which glucose may be e ither added or subtracted.
Glucose homeostasis consists of delicate ly  balancing the glucose inflow  
into the pool with the glucose outflow into the tissues. A change in 
blood glucose concentrations is caused by a temporary imbalance between 
glucose inflow and outflow.
Glucose homeostasis has been the subject of several excellent reviews 
(De Bobo et a l , 1963; Fehlig, 1975; Marks & Rose, 1981) and w i l l  only 
be b r ie f ly  discussed here. Fig (a) is a schematic representation of 
the various processes involved in the regulation of glucose concentrations.
1.1.1 Glucose Outflow
The only way that glucose normally leaves the pool is through entry of 
glucose into tissues where i t  is metabolised. Only under exceptional
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Fig(a) Schematic representation of glucose pool with 
autoregulatory controls of inflow and outflow. 
(Modified from Marks,1972)
circumstances e.g. diabetes m ellitus, does glucose actually  leave the 
body as glucose. Few types of mammalian cells  are readily  permeable 
to glucose, the most important being those of the l i v e r ,  brain, is le ts  
of Langerhans, kidney, in testinal mucosa and erythrocytes. Most other 
tissues such as striated muscle, fa t  and connective tissue, have a reg­
ulatory mechanism that control the rate at which glucose enters the 
c e l l .  Both insulin and glucose concentrations play essential roles in 
this regulatory mechanism.
The brain and erythron are quantitatively  and q u a lita t iv e ly  the two most 
important obligatory glucose-utilising tissues. In man, the brain alone 
accounts for 30-50% of the total glucose turnover of 170-260 g per day 
(B u tte rf ie ld , 1961). However, due largely to the work of Cahill and his 
colleagues (Owen et a l ,  1967) i t  is now known that during prolonged fasting  
or starvation the brain, l ike  other tissues of the body, can u t i l is e  end­
ogenous substrates notably the ketone b o d ie s ,-h y d ro x y b u ty ra te  and 
aceto-acetate, as a lternative sources of energy to glucose. Indeed, under 
these circumstances the uptake of glucose by the brain is very small and 
consequently even severe hypoglycaemia induced by the intravenous in je c t io jf  
of insulin can be tolerated without symptoms of neuroglycopenia developing 
(Drenick, 1972).
Although the l iv e r  is capable of both glycolysis and gluconeogenesis, 
i t  is doubtful whether, under physiological conditions, i t  ever exhib it  
a net flow in the direction of glycolysis since even under resting con­
d itions , lactate (and other glycogenic precursors) are released into the 
circulation by peripheral tissues, and must be cleared by the l iv e r  and 
reconverted into glucose.
1.1.2 Glucose Inflow
There are two equally important sources of inflow into the glucose pool.
In the fed state the main source is undoubtedly the preformed glucose 
absorbed from the gut following a meal. In the fasting state however, 
glucose released from hepatic glycogenolysis and gluconeogenesis con­
stitu tes  the major source of input. While a l l  tissues partic ipate  in 
removing glucose from the blood, only the l i v e r ,  and to a lesser extent 
the kidneys, have the capacity to add glucose to i t .  The unique role  
of the l iv e r  in glucose homeostasis is a ttributed largely to three pro­
perties of the l iv e r  ce lls :
* permeability!
(a) free to glucose allowing diffusion in and out of the 
ce lls ;
(b) presence of high concentration of glucose-6-phosphatase, the enzyme 
that acts on glucose-6-phosphate to give glucose;
(c) a b i l i t y  to carry out gluconeogenesis because of the presence of three 
key gluconeogenic enzymes, fructose-l,6-phosphatase, pyruvate carbo­
xylase and phosphoenol pyruvate carboxylase.
1.1.3 Glucose Homeostasis
A de licate ly  balanced homeostatic mechanism operates to maintain the 
blood glucose concentration within comparatively narrow lim its  regardless 
of the rap id ity  of flow-through in the glucose pool. I t  involves the 
autonomic nervous system, several of the endocrine glands and in t ra c e llu la r  
regulatory mechanisms that are s t i l l  only poorly understood. I t  exerts 
i ts  e ffec t  by adjusting the rate of glucose inflow to and outflow from 
the pool. When glucose is administered, for example, the homeostatic 
mechanism responds by increasing glucose outflow and decreasing (endogenous)
glucose inflow, the former process being quantita tive ly  the most 
important. When food is with-held the homeostatic mechanism responds 
by decreasing glucose outflow (and 'encouraging' the use of ketones as 
a lternative  sources of energy) and increasing glucose inflow, though 
quantita tively  this is much less important. A defect in any part of 
the homeostatic mechanism, in the sensor, regulator or e ffector organs, 
can lead to diseases characterised by abnormal glucose metabolism.
1.2 Hypoglycaemia
Whatever i ts  aetiology, hypoglycaemia is invariably the resu lt of glucose 
outflow from the glucose pool temporarily exceeding the glucose inflow. 
The word neuroglycopenia was coined by Marks e t a l , (1961) to describe 
the signs and symptoms that develop when during hypoglycaemia, the supply 
of metabolisable carbohydrate to the neurone is inadequate fo r  normal 
function.
Four d is t in c t ,  but not mutually exclusive, neuroglycopenic syndromes 
have been recognised (Marks & Rose, 1981).
(a) Acute neuroglycopenia - this is common and almost always the resu lt  
of rapid onset of hypoglycaemia (*j 30 min) from overtreatment with 
soluble insulin or spontaneously from reactive hypoglycaemia.
(b) Subacute neuroglycopenia - commonest type encountered and results  
from a gradual fa l l  in blood glucose over an hour or more. Symptoms 
and signs o f acute neuroglycopenia are completely absent. Instead 
there is a reduction in spontaneous a c t iv ity  and conversation and 
movements become minimal.
(c) Chronic neuroglycopenia - this is rare and is exclusively due to 
to insulin-secreting tumours. Insidious changes of personality, 
defective memory, psychotic behaviour and dementia are presented.
(d) Hyperinsulin neuronopathy - this is exceedingly rare and is also 
exclusively caused by insulinomas. The signs and symptoms are those 
of progressive motor neuropathy and peripheral muscular wasting.
Of the many c lass ifica tions, the most useful c l in ic a l ly ,  is into  
‘ fasting-provoked1 and ‘ stimulus-provoked' hypoglycaemias (Marks & Rose, 
1981) as shown in Table (a ) .  'Fasting hypoglycaemias' are due mainly, 
i f  not e n t ire ly ,  to impaired glucose release from the l iv e r .  C lin ic a lly  
the most important of these, are the insulin-secreting tumours of the 
pancreas; th e ir  pathology, histology and management w i l l  be described 
in Chapter 2. Disorders that decrease the turnover rate of glucose by 
affecting the l iv e r ,  such as the glycogen storage diseases and congestive 
l iv e r  disease, can also result in hypoglycaemia.
In contrast to the 'fasting hypoglycaemias' patients with 's tim ula tive ' 
hypoglycaemia do not experience a low blood glucose concentration unless 
provoked by appropriate stimuli such as insu lin , alcohol or drugs. 
'Essential reactive hypoglycaemia' is the commonest type of stimulative  
hypoglycaemia and is produced as a resu lt of ingestion of large doses 
of glucose or sucrose.
A. Fasting hypoglycaemia:
1. Hyperinsulinism; benign, malignant and multiple insulinomas, 
microadenomatosis and nesidioblastosis.
2. Non-pancreatic tumours - mesenchymal tumours, primary hepatic 
carcinoma, adrenal tumours.
3. Liver and kidney diseases.
4. Endocrine diseases: p i tu ita ry ,  adrenal, hypothalamic.
5. Inborn errors of metabolism, e.g. glycogen storage diseases.
6. Substrate l im ita t io n , e.g. anorexia nervosa.
7. Various types of neonatal hypoglycaemia.
8. Autoimmunity -  insulin autoimmune disease.
B. Stimulative hypoglycaemia:
1. Exogenous hypoglycaemic agents, drugs and poisons.
2. Essential reactive hypoglycaemia.
3. Hereditary fructose intolerance.
4. Galactosaemia.
5. Drug-induced hypoglycaemia, e.g. alcohol, aspirin .
Table (a ) C lassification of Hypoglycaemia
1.3 Role of the Pancreas in Glucose Homeostasis
The importance of the pancreas in the regulation of the blood glucose 
concentration has been recognised since the important discovery by von 
Mering and Minkowski at the close of the 19th century, that to ta l surgical 
removal of the pancreas in the dog induces a condition resembling severe 
diabetes mellitus in man. The id e n tif ica t io n , isolation and purif ication  
of insulin by Banting and Best in 1921 firm ly established the importance 
of the endocrine pancreas in glucose homeostasis. This was further  
emphasised by the purification of a second pancreatic hormone with hyper- 
glycaemic properties called glucagon (Staub et a l , 1955).
In the l ig h t  of the hypoglycaemic a c t iv ity  of insulin and the hyper- 
glycaemic properties of glucagon, a bihormonal model for blood glucose 
regulation was proposed by Unger (1976) and Unger & Orci (1981).
According to this view, the B-cells and A-cells function as a coupled 
bihormonal secretory unit releasing appropriate mixtures of insulin and 
glucagon to regulate blood glucose levels under d if fe re n t conditions of 
glucose supply and need. Under the primary and dominant control of 
ambient glucose concentrations, this bihormonal secretory unit is also 
influenced by other nutrients, hormones and neural signals. These 
authors (Unger & Orci 1975) have further proposed that diabetes mellitus  
is a consequence of a "bihormonal disorder". They suggest that insulin  
deficiency by i t s e l f  cannot explain a l l  the metabolic manifestations of 
the condition, and proposed that the principal consequence o f the insulin  
deficiency is the under-utilization of glucose, and that the overproductf 
of glucose by the l iv e r  is largely the consequence of the absolute or 
re la t iv e  excess of pancreatic and/or gastroduodenal glucagon that is 
invariably present when insulin is defic ien t. This bihormonal model for  
glucose homeostasis w i l l  be investigated and discussed in the present 
study.
1.4 Anatomy of the Pancreas
The pancreas is a complex, mixed exocrine-endocrine organ found in a l l  
but the most primitive of the vertebrates. There are an estimated one 
m illion is le ts  of Langerhans in the human pancreas comprising less than 
1 % o f the total bulk of the pancreas. Each is le t  is roughly spherical 
and varies from 50-400 u in diameter.
The is le ts  are composed of insulin producing B -ce lls , glucagon producing 
A -ce lls , somatostatin producing D-cells and pancreatic polypeptide pro­
ducing PP-cells. I t  used to be thought that is le t -c e l l  composition was 
the same regardless of where the is le ts  were located in the pancreas.
Orci et a l , (1980) have shown by immunocytochemical techniques that this  
is not so. Is le ts  from the head (duodenal) region of the pancreas have 
been shown to contain numerous peripherally located PP-cells but very 
few glucagon c e l ls ,  while a l l  is le ts  from the t a i l  (splenic part) 
showed a peripheral rim of A-cells with a scarcity of PP-cells.
1.4.1 Microanatomy of the Is le ts  of Langerhans
The topography of the various cell-types within the is le t  is an important 
consideration in understanding is le t  function. Orci and Unger (1975) 
using immunofluorescent staining for insu lin , glucagon and somatostatin 
in serial sections of human and ra t is le ts  have c learly  defined the top­
ographical relationships of the cells that contain these hormones as 
schematised in Fig ( b ) .
The insulin-containing B -cells , which form more than 60% of the is le t  
cell populations, are arranged in a re la t iv e ly  homogenous central mass.
The glucagon-containing A-cells are situated around the periphery of the 
i s le t ,  often only one cell in thickness and, in man, penetrate the in te r io r  
of the is le t  mainly along the main vessels. Between the central B-cell 
mass, and the outer rim of A -ce lls , are scattered the somatostatin-containing 
D-cells which form approximately 10% of the is le t  cell population. This 
is the only region where afferent vessels and nerves enter the is le t .
(^  G lucagon 
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Fig (b ) Schematic representation of the number and d istr ibution  of 
insu lin , glucagon, somatostatin-containing cells  in the 
normal human is le t  ( l e f t ) .  Large vascular channels penetrate 
the is le ts  and are followed by glucagon and somatostatin- 
containing cells ( r ig h t) .  (Modified from Orci and Unger, 
1975a).
I t  may be functionally important that almost a l l  A-cells have contact 
with one or more of the other cell types, as do D -cells , whereas the 
vast majority of B-cells have contact only with other B -cells .
1.4.2 Junctions
Small areas of contact have been seen in the is le ts  and these are of two 
types, the gap junction and t igh t junctions, (Orci et a l , 1973). The
gap junctions exist between cells  and allow small inorganic ions and 
small molecules to pass from one cell to another without entering the 
in te rc e l lu la r  space. These structures are present not only between 
B-cells and B-cells and between A-cells and A -ce lls , but also between 
A-cells and B-cells . These gaps could be used to pass signals from 
one cell type to another, thereby playing a role in controlling is le t  
cell a c t iv ity .
The t ig h t junctions occur where the outer le a f le ts  of the plasma membranes 
of adjacent cells  are fused together. They are not stable structures, 
but are constantly undergoing remodelling. The functions of the t ig h t  
junctions are not known, but i t  seems that they create compartment^ or 
zones within the in te rc e l lu la r  space (Orci et a l , 1973).
1.4.3 Neurovascular Structure
Is le ts  of Langerhans are highly vascularised, and r ich ly  innervated by 
nerve fibres from the coeliac ganglion (sympathetic) and the vagus nerves 
(parasympathetic).
Morphologic studies of the is le ts  indicate that the endocrine cells  are 
arranged in short bands or cords of cells  separated by a network of cap­
i l la r ie s  (Bunnag e t a l , 1963). Each is le t  cell is close to a cap illa ry  
thus allowing for the rapid transport of hormones into the vascular 
system. Capillaries of the is le ts  are composed of fenestrated endothelial 
cells  (Lacy, 1955), a feature typical of cap il la r ies  of endocrine glands. 
The fenestrated areas permit the rapid exchange of material across the 
endothelium. Marked permeability of is le t  cap il la r ies  have been demon­
strated by electron microscopic studies on the transport of horseradish 
peroxidase (40,000 mol wt.) from the blood stream to the peri cap il la ry
space of the ra t  (Like, 1970). Forty seconds a fte r  intravenous 
in jection of the enzyme, peroxidase a c t iv ity  can be detected at the 
level of the basement membranes and, shortly thereafte r , throughout 
the in te rc e l lu la r  spaces.
The role of theautonomicnervous system in pancreatic is le t  function is 
not c learly  established (Meissner, 1976) but may have a modulating 
e ffec t on insulin secretion in the normal subject, and may play a role  
in the pathogenesis of abnormal is le t  function in the diabetic patient  
(Bloom and Polak, 1980).
1.5 I nsulin
Insulin has been the subject of many excellent reviews (C a h il l ,  1971;
Kissebah et a l , 1975; Lacy 1977) so that only the relevant features w i l l  
be described. Insulin is the major hormone of glucose homeostasis, and 
is produced exclusively by the B-cells of the is le ts  of Langerhans.
1.5.1 Biosynthesis
The gene for preproinsulin is transcribed in the is le ts  into a messenger 
RNA (mRNA) precursor, which is then spliced to produce mature mRNA. This 
mRNA is translated into preproinsulin which is then cleaved into proinsulin  
on ribosomes in the rough endoplasmic reticulum. In the Golgi apparatus, 
insulin is formed from the proinsulin by proteolytic cleavage at two 
points in the molecule to form one molecule of insulin and one of a connecting 
peptide, from which two further amino acids are cleaved at each end to 
produce the (proinsulin) C-peptide (Rubenstein et a l , 1975; E fs tra t ia d is , 
1981). The C-peptide and insulin are stored together in the p-granules 
of the B-cells until released into the in te rc e l lu la r  space by reverse
pinocytosis under the influence of s tim uli. Details of insulin bio­
synthesis are available in a number of excellent reviews (Steiner &
Tager, 1979; Lernmark et a l , 1976; Rubenstein e t al 1975).
1.5.2 Chemistry and Structure
The processing events that occur during insulin biosynthesis have 
defined the following regions of the preproinsulin molecule:
NH^-pre region—B chain — 2 basic amino a c id s ^  C-peptide—  2 basic amino 
acids —  A chain — COOH. In the ra t ,  human and chicken, the pre-region 
consists of 24 amino acids. Species variation exists for the C-peptides 
too, with human, ra t ,  monkey and horse C-peptide consisting of 31 amino 
acid residues.
The amino acid sequence of insulin was elucidated by the twice Nobel 
Prize winner, Frederick Sanger in the mid 1950's. Insulin consists of 
two peptide chains, A and B, connected together by two disulphide 
bridges and has a molecular weight of 5800. Insulins from d iffe re n t  
species d i f fe r  s l ig h t ly  in th e ir  detailed chemical structure, but to a 
much smaller extent than th e ir  respective proinsulins (Clark & Steiner,
1969; Steiner & Tager, 1979).
1.5.3 Regulation of Insulin Secretion
Glucose is the primary stimulus for the release of insulin in man and 
in most mammals. Although many other substances and metabolites, 
including several amino acids, ketones and fa t ty  acids, are capable of 
stimulating insulin secretion under pharmacological conditions, none 
of them seem as important as glucose fo r physiological regulation (Lacy, 
1977). The mechanism of glucose-stimulated insulin release has been the 
subject of controversy. I t  is not clear whether i t  acts mainly by activating
glucoreceptors on the B-cell membrance (Matschinsky e t a l , 1971) or 
by the formation of one or more intermediate metabolites during in tra ­
c e llu la r  glucose metabolism (Grodsky et a l , 1963).
Extracellu lar calcium is an essential requirement fo r  insulin secretion
to occur (Grodsky & Bennett, 1966). Malaisse-Lagae and Malaisse (1971)
45have shown that the accumulation of Ca is increased following glucose 
stimulation and that the amount of bound calcium accumulating in the 
is le t  cell is proportional to the degree of stimulation. Current evidence 
supports the contention that Ca++ plays a decisive role in the coupling 
of stimulus-recognition to the discharge of insulin from the B-cell 
(Heilman et a l , 1979; Malaisse-Lagae & Malaisse, 1971; Devis et a l ,
1975).
Since the microtubule-microfilament system is involved in the transloc­
ation of beta granules following glucose stimulation, i t  has been suggested 
that calcium may be the tr igger for the induction of contraction resulting  
in the in tra c e llu la r  transport of the granules to the cell surface where 
they are released by emiocytosis (Lacy, 1970; Malaisse & Malaisse-Lagae, 
1970).
The level of cAMP within the is le ts  is increased following acute stimu­
la tion with glucose (Charles et a l , 1973; G r i l l  & Cerasi, 1974). Measure­
ments of adenylate cyclase a c t iv ity  in homogenates of ra t is le ts  showed 
a stimulation with glucagon, whereas glucose did not a l te r  adenylate 
cyclase a c t iv ity  (Howell and Montague, 1973). I t  has been suggested that  
cAMP act by inducing a translocation of calcium from a bound form to a 
free form in which i t  could in teract with the microtubul e-microfilament 
system (Malaisse, 1973).
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A number of gastrointestinal hormones have been suggested as potential 
candidates for the role of the incretion factor responsible for the 
stimulation of insulin release following a meal (Marks & Turner, 1977).
Of these, only the insulinotrophic effects of gastric inh ib itory  poly­
peptide (GIP) and gut glucagon are well established. Lastly, a number 
of drugs, the most important of which are the sulphonylureas, are cap­
able of stimulating insulin release from the B-cells (Heilman & Ta ljeda l,
1975). Alloxan and streptozotocin lead to impaired insulin secretion 
by destroying the is le t  B-cells.
Although the mechanisms by which glucose, amino acids, the sulphonylureas 
and the insulinotrophic gut hormones stimulate insulin release are mani -  
fes tly  d if fe re n t for each class of substance, nevertheless, current 
evidence suggests that the secretion of insulin occurs by an exocytotic 
process which requires c e l lu la r  energy, movement o f calcium ions and the 
in te g r ity  of the microtubular system, and in which cyclic  nucleotides 
partic ipate .
1.5.4 Actions of Insulin
The major biochemical actions of insulin have been known for a long time.
The best known is i ts  a b i l i ty  in vivo to lower the blood glucose concen­
tra t io n . This is achieved by decreasing the output of glucose by the 
l i v e r ,  e ither with or without an increase of glucose uptake by peripheral 
tissues. Insulin fa c i l i ta te s  glucose transport across a l l  membranes and 
stimulates the synthesis of proteins, fa t ty  acids and glycogen. I t  also 
has an inhib itory e ffec t  upon gluconeogenesis and glycogenolysis. Details  
of the biochemical changes caused by insulin  have been reviewed by Cahill 
(1971), Kissebah (1975), Marks & Rose (1981), and w i l l  be further investigated
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and discussed in this study.
The mechanisms of insulin action at the c e llu la r  level remains unclear.
Our present understanding is that insulin acts d irec t ly  on receptors in 
the plasma membrane of target c e l ls ,  a ltering  th e ir  permeability and 
transport mechanisms (Levine & Goldstein, 1955; Crofford, 1975; Kahn,
1976). How the insulin-receptor complex activates membrane transport 
processes is not known. Furthermore according to the receptor/transducer/ 
in ternalisation  model proposed by Steiner (1977), the receptor-bound 
insulin is internalised in order to reach the in tra c e llu la r  sites where 
insulin degradation occurs.
1.6 G1ucagon
F irs t  recognised as a contaminant of insulin preparations, glucagon was 
named fo r  i ts  a b i l i t y  to raise the blood glucose concentration when admini­
stered parenterally to animals. Because of i ts  powerful pharmacological 
effec ts , glucagon has generally been accepted as being concerned with 
the regulation of glucose homeostasis, acting in an antagonistic manner 
to in su lin , and that diabetes is as much a disease of glucagon excess as 
of insulin deficiency (Unger & O rc i, 1975; 1981).
1.6.1 Biosynthesis and Structure
Like in su lin , glucagon is synthesised from a larger precursor molecule 
called proglucagon (Patze lt et a l , 1979; Steiner & Tager, 1979) or 
glicentin  (Sundby e t a l , 1976). Proglucagon is a 69 amino acid precur­
sor that is broken down into glucagon (residues 33-61) and two glucagon­
l ik e  immuno-reactive (GLI) fragments 1-33 and 62-69 (Thim and Moody,
1 9 8 1 ) .
Glucagon is a polypeptide containing 29 amino acids and has a molecular 
weight of 3485. I ts  amino acid sequence suggests that i t  belongs to the 
secretin family of gastrointestinal hormones that include GIP and vaso­
active in testina l polypeptide (VIP). The chemical differences between 
glucagon isolated from d iffe ren t species is less than between the corres­
ponding insulins, and a l l  mammalian glucagons appear to have an identical 
structure (Steiner & Tager, 1979).
1 .6.2 Regulation of Glucagon Secretion
Many stimuli and inhibitors of glucagon secretion have been reported. 
Amino acids, cAMP, the gut hormones-gastrin, GIP, VIP, neurotensin and 
substance P have a l l  been reported to stimulate glucagon secretion, 
whilst glucose, fa t ty  acids, ketone bodies in h ib it  i ts  release. How 
many of these stimuli and inhibitors are physiologically important is 
not known. In contrast to insu lin , whose secretion is stimulated by 
beta- and inhibited by alpha-adrenergic stimulation, glucagon secretion 
is stimulated by both types of adrenergic a c t iv ity  (Samols & Weir, 1979) 
though this has been disputed (M il le r  & Horton, 1979).
Diazoxide has been shown to suppress glucagon secretion (Samols & 
Harrison, 1976). Insulin , and even more so, somatostatin are potent 
inh ib itors  of glucagon release and can be considered as exerting nega­
t iv e  feedback control on is le t  A-cell function (Samols & Harrison, 1976a; 
Samols e t a l , 1972).
The rate of pancreatic glucagon secretion in man is extremely small.
Basal secretion rates of glucagon in normal man are not greater than
100-150 jjg/day and these values are probably an over-estimate (Fisher 
et a l , 1976). With improved radioimmunoassay techniques lower fasting  
glucagon concentration in normal subjects have been reported (Heding 
et a l , 1972). Alford et al (1977) using extremely sensitive assay tech­
niques have reported levels as low as 24 pg/ml. On the basis of these 
observations, most studies investigating the physiological role of glu­
cagon have c learly  used pharmacological doses.
1.6.3 Actions of Glucagon
Despite extensive studies, the physiological role of glucagon remains 
poorly understood. This is to a large extent due to d i f f ic u l t ie s  with 
i ts  measurement in biological f lu id s , the absence of an animal or human 
model of glucagon deficiency, i ts  wide range of biological a c t iv it ie s  
and close chemical s im ila r it ies  to other polypeptides. Above a l l ,  i t  
is due to heavy dependence upon pharmacologically, rather than physio­
lo g ic a l ly ,  derived data (Marks & Rose, 1981).
Important interspecies differences have been reported for the role of 
glucagon. In some grain-eating birds e.g. the duck and chicken, glu­
cagon is the most important pancreatic hormone and essential fo r  l i f e .  
Pancreactomy in these species and in lizards and snakes causes hypo- 
glycaemia rather than diabetes (Mikami and Ono, 1962; M i l le r  and Wurster, 
1958). In other species, including man, i t  appears to be re la t iv e ly  
unimportant and no particu lar i l l - e f f e c ts  can be attr ibu tab le  to its  
to ta l elimination, whether by pancreactomy (Barnes & Bloom, 1976) or 
chronic-pancreatitis (Persson et a l , 1971).
Glycogenolysis Glycogenolysis was one of the f i r s t  actions attributed  
to glucagon and the one a fte r  which i t  was named. Through the activation
of adenylate cyclase by binding of glucagon to its  receptors, cAMP is 
formed and this in turn triggers a series of reactions culminating in 
the release o f glucose from the liv e r . Glucagon has been reported to 
be one o f the most potent hepatic glycogenolytic agents (Sokal, 1966), 
producing glycogenolysis in every species studied.
Gluconeogenesis Unlike glycogenolysis, the action o f glucagon on glu- 
coneogenesis is more persistent and possibly more important in man. 
Glucagon stimulates amino acid uptake by the liv e r  and gluconeogenesis 
from a ll types of precursors including lactate  and pyruvate.
Both the glycogenolytic and gluconeogenic properties o f glucagon con­
tr ib u te  to its  hyperglycaemic e ffec t and are counteracted by in su lin .
L ip o ly tic  E ffect In mammalian adipose tissue, glucagon is a weak 
stimulus of lip o ly s is . I t  is however a potent lyp o ly tic  agent in birds 
in which insu lin  has no a n t i- l ip o ly t ic  e ffe c t.
Insulinotrophic Effect Samols et al (1965) were the f i r s t  to demon­
stra te  that glucagon is an extremely potent stimulus o f insu lin  secretion. 
This observation has since been confirmed by others (Turner & McIntyre, 
1966; Devrim & Recant, 1966; Crockford e t a l , 1966), That th is  in su lin ­
otrophic e ffe c t might indeed be physiologically important was supported 
by the work of Ketterer et a l , (1967) who showed that physiological 
doses of exogenous glucagon infused into the portal vein of dogs was 
s u ffic ie n t to stimulate insulin secretion.
Despite the vast amount of data, much of which is contradictory, which 
of the four main actions described above is the most important physio­
lo g ic a lly , is s t i l l  undetermined. I t  seems un like ly  that i t  is the same 
in every species.
1.7 Insulin and Glucagon in Glucose Homeostasis
The bihormonal model o f glucose homeostasis is that two mutually anta­
gonistic hormones, insulin and glucagon, each with th e ir  main effects  
upon the l iv e r ,  are secreted into the portal blood under various condi­
tions in order to maintain blood glucose levels w ithin closely defined 
lim its  under wide divergent conditions o f glucose supply and need (Unger 
& O rc i, 1981). This view is however d i f f ic u l t  to reconcile with evidence 
that glucagon is insulinotrophic and appears to play an essentia l, in te r ­
mediate role in the stimulation of insulin  secretion by certain  amino 
acids e .g . arginine and enteric stim uli released in response to the 
ingestion of certain nutrients (Samols et a l , 1972).
An a lternative  hypothesis was proposed in which pancreatic glucagon acts 
prim arily  as a potentiator and regulator of insu lin  secretion, but may 
also under conditions associated with increased sympathetic nervous act­
iv i ty ,  serve as an hyperglycaemic-gluconeogenic agent (Samols e t a l , 1972). 
The stimulation of insulin by glucagon, and its  negative feedback control 
by insulin provides a delicate mechanism fo r  achieving and maintaining 
homeostasis. Like a ll other servo-systems so fa r  studied in v iv o , i t  
can be overriden by stress which is here most c h a rac te ris tic a lly  repre­
sented by acute hypoglycaemia (a physiologically rare event) and by short­
term starvation. Under these circumstances there is increased sympathetico- 
nervous a c tiv ity  which, by enhancing glucagon secretion (Samols & Weir,
1979) a t the same time as i t  blocks its  insulinotrophic e ffe c t produces 
conditions that are ideal fo r increasing hepatic glycogenolysis and glu­
coneogenesis.
According to the bihormonal theory, insu lin  and glucagon secretions are 
under the primary and dominant control o f the ambient glucose concentra­
tions. That this is the case fo r  the B -cell is not seriously disputed. 
However, experiments with isolated is le ts  and perfused pancreas prepar­
ations suggest that the A -cell responds only to supra-physiological 
changes in perfusate glucose concentrations. This has prompted Bloom 
and Polak (1980) to suggest that the d irec t response o f the A -cell to 
glucose concentrations is in the nature of an emergency mechanism, and 
may therefore not be important in normal glucose homeostasis. In fa c t, 
under normal conditions, glucagon secretion is regulated by the para­
sympathetic innervation o f the is le ts  (Bloom, 1976) rather than by glu­
cose or other metabolite concentrations.
1-8 Somatostatin
Somatostatin is a 14-amino acid cyclic  polypeptide with an in tra-chain  
disulphide bridge. O rig ina lly  found in the hypothalamus, i t  is also pre­
sent in the brain, spinal cord, the gastro intestinal tra c t and the endo­
crine pancreas where i t  is localised in the D -cell s. Soon a fte r  its  
discovery, i t  was recognised th a t, in addition to its  a b il i ty  to in h ib it  
growth hormone secretion, somatostatin could also in h ib it  the secretion  
of many other polypeptide hormones including in su lin , glucagon, g as trin , 
secretin , VIP, m otilin  and GIP. I t  also reduces the rate of gastric  
emptying, gastric acid and pepsin secretion, pancreatic f lu id  and splanchn
blood flow (Vale e t a l , 1975; Gerich, 1977). Despite extensive invest­
igations by pharmacological methods, the physiological ro le o f somatostatin 
is s t i l l  poorly understood.
The ro le  of somatostatin in glucose homeostasis remains unclear. Infusions 
of somatostatin have variously been described as producing a lowering 
or raising of blood glucose concentrations depending upon the circumstances 
of th e ir  adm inistration. Whether somatostatin has any d irec t effects  on 
glucose homeostasis, or whether i t  acts in d ire c tly  via in h ib itio n  of insulin  
and glucagon remains to be determined. However, in several reports of 
patients with somatostatinomas (Wright e t a l , 1980; Krejs e t a l , 1979;
Ganda e t a l , 1977), only mild disorders o f carbohydrate metabolism were 
observed.
CHAPTER TWO
CHARACTERISATION OF A TRANSPLANTABLE 
RAT ISLET-CELL TUMOUR
Characterisation o f transplantable ra t is le t -c e ll  tumour
2.1 Introduction
Although hypoglycaemia occurring in treated diabetics is numerically 
the most common, endocrine tumours of the pancreas are c lin ic a lly  the 
most important cause o f spontaneous hypoglycaemia. Due to th e ir  
histological resemblance to is le ts  o f Langerhans, these tumours have 
been referred to as ' is le t -c e l l  tumours' irrespective o f th e ir  h is t­
ology or c e llu la r  origins i . e .  whether they arise by neoplastic  
transformation of pre-existing is le t -c e ll  o r, as seems more l ik e ly ,  
they arise by d iffe re n tia tio n  from ductular tissues (Bencosme 
1963; C reutzfeldt W., 1977).
The term 'insulinoma' is also widely used fo r tumours o f the pancreas 
that produce hypoglycaemia. This term is more appropriate as i t  is  
in lin e  with the widely adopted practice o f describing tumours by 
th e ir  main functional secretory product (C reu tzfe ld t, 1977; H olst, 
1979).
2.1.1 Incidence
Kalvie and White (1972) estimated the annual incidence o f diagnosed 
insulinoma as one case per 1 -  1.25 m illio n  persons; Frerichs and 
C reutzfeld t (1976) believe th is to be an overestimate. However, a 
higher incidence of about one case per 500,000 persons per year has 
also been reported in a study conducted by the R adcliffe  In firm ary , 
Oxford, over a period of 30 years, (reviewed by Marks & Samols, 1974).
The m ajority (85%) o f insulinomas are c la s s ifie d  as benign adenomata. 
Malignancy may be expected in about 10% of a ll  cases (Frerichs and 
C reutzfe ld t, 1976) with a spread of metastases prim arily  in to  the l iv e r
and the portal lymph nodes (Hanson, 1960). Only a small proportion 
(12.5%) of a ll malignant is le t -c e ll  tumours are insulinomas (C u b illa ,
1975). The m ajority are e ith e r non-endocrinologically ac tive , or 
produce the Z o llin g er-E lliso n , Watery diarrhoea, hypokalaemia and 
achlorhydria (WDHA), glucagonoma or carcinoid syndromes.
2 .1 .2  Structure and C ellu la r Oriqins
—  -  ---------
Insu lin  producing tumours orig inate in pancreatic tissue and are 
located within or adjacent to the gland. They are found evenly 
distributed throughout the pancreas as s o lita ry  or m ultip le  spherical 
to ovoid-shaped nodules, with diameters ranging from a few m i l l i ­
metres to several centrimetres (Laurent e t a l , 1971; Stefanini e t a l , 
1974).
The lig h t microscopic appearance of insulinomas has been extensively  
studied and they exh ib it no d is tin c t difference from other endocrine 
tumours (C reutzfeldt e t a l , 1973). The granular density o f normal 
B-cells is rarely  found in insulinoma ce lls  which suggests th a t the 
tumour ce lls  store less insu lin  than normal B -ce lls , and that the 
insu lin  concentration o f insulinoma tissue is lower than in normal 
is le t  tissue (Arnold et a l , 1972; C reutzfe ld t e t a l , 1973; C reutzfe ld t 
et a l , 1976). Furthermore, a variable number of tumour ce lls  contain 
few and often no beta granules, indicating a decreased storage capa­
c ity  (Frerichs & C reutzfe ld t; 1976). This defective storage capacity  
seems to be the major functional abnormality o f the insulinoma ce lls  
and is thought to be caused by defects in the in tra c e llu la r  in su lin  
transport and release processes (Frerichs and C reu tzfe ld t, 1976).
U ltrastructrual analysis of insulinomas shows a non-uniform c e llu la r  
composition. Besides B-cells with normal appearance of the secretory 
granules, ce lls  containing atypical granules identica l to those of 
the D-cells and agranular or nearly agranular ce lls  are found in 
varying proportions. Using elegant electron microscopic immuno- 
and histo-chemical studies, C reutzfeld t and co-workers (1973, 1976,
1977) have c lass ified  insulinomas in to  4 morphological catergories;
(a) ce lls  of Type I insulinomas contain large ly  typical B-granules
(b) Type I I  insulinomas contain ce lls  with typical as well as ce lls  
with atypical granules (c) Type I I I  insulinomas contain atypical gran­
ulated ce lls  only and (d) Type IV insulinomas which consist o f agranular 
ce lls : Types I ,  I I  and I I I  give a positive immunohistological reaction  
fo r in su lin . I t  has therefore been assumed th at Type IV insulinoma cells  
represent a special stage o f functional d ed iffe ren tia tio n  secondary to 
the morphological d iffe re n tia tio n  of precursor c e lls . These findings 
point to a common pred ifferentia ted  stem c e ll .
Further evidence fo r the undifferentiated precursor ce ll hypothesis 
comes from the presence of D^-like c e lls . The biosynthetic and functional 
properties of the ra re ly  occurring D-j-cells in normal is le t  are unknown. 
However the D^-like ce lls  are common to a ll  types of tumours, suggesting 
that th is  ce ll is an undifferentiated precursor or stem ce ll which may 
develop or p ro life ra te  in to  any of the pancreatic-gastrointestinal 
endocrine ce lls  (C reu tzfe ld t, 1975). D -j-like ce lls  are found in at 
least 42% of insulinomas, pointing to a common pred iffe ren tia ted  stem 
c e ll .  Furthermore, the immunohistological demonstration of m ultip le  
hormone producing tumours (pancreatic polyadenomatosis) and especially  
the demonstration of d iffe re n t hormone producing ce lls  w ithin one
(mostly malignant) tumour can only be explained by assuming an orig in  
from immature stem cells  (p red iffe ren tia ted  c e lls ) which gain 
functional specialisation during tumour growth (P ic te t and R utter, 
1972; C reutzfe ld t, 1975).
This theory of c e llu la r  origins of insulinomas supports the suggestion 
that insulinomas and diabetes m ellitus have a common pathogenesis. A 
closer than accidental re lationship  has been suggested by a number of 
authors despite the rare occurrence of insulinoma in patients with a 
previous history of diabetes (Re-Mine e t a l , 1960;
Dunn, 1971; Guinet e t a l , 1973; Marks & Samols, 1974; Sandler e t a l , 
1975; Atkinson et a l , 1978). The true incidence could be higher as 
an insu lin  producing tumour may be unrecognised in overt in su lin - 
treated diabetes, and may be suspected only in cases with adenomatosis 
or in cases with metastasising insulinomas (Frerichs & C reu tzfe ld t,
1976). Consistent with th e ir  generally malignant nature, insulinomas 
removed from diabetic subjects usually contain very l i t t l e  insu lin  
(Atkinson e t a l , 1978).
2 .1 .3  Hormonal Content
Rarely are tumours found that contain as much insu lin  as the equivalent 
amount of normal is le t  tissue. Despite the fac t that insulinomas 
appear h is to lo g ica lly  to consist almost e n tire ly  of is le t  tissue , 
th e ir  insu lin  content is extremely variable but generally much smaller 
(C reutzfe ld t e t a l , 1973; C reutzfeldt et a l , 1976; Floyd et a l , 1964).
A range from 5 to 40 per cent of the in s u lin -lik e  immunoreactive ( IR I) 
material found in insulinomas have been a ttribu ted  to p ro in su lin -like
components ( PLC) by d iffe re n t workers (Melani e t a l , 1970; Gordon et a l , 
1971; Lendall e t a l , 1972; Gutman et a l , 1973; Adcock et a l , 1975).
This is higher than extracts from normal and diabetic  human pancreas 
usually found to contain between 0.2 to 5 per cent PLC (C reutzfe ld t 
e t a l , 1973; Rastogi e t a l , 1973).
In tumours with typical Type I B-granules, the highest IRI concentra­
tion (mean 28 U/g) and the lowest percentage of PLC (mean 9.0%) was 
observed. In contrast, agranular Type IV tumours contained very low 
amounts of IRI (mean 0.5 U/g) but had a high proinsulin content 
(mean 18.8%). In Type I I  insulinomas, the PLC percentage was somewhat 
higher than in Type I with mean IRI of 28 U/g. Type I I I  tumours con­
ta in  on average 9 U/g IRI with the PLC a l i t t l e  lower than in the 
agranular tumours (C reutzfeld t et a l , 1973).
Although elevated fasting levels of plasma C-peptide have been observed, 
both high and low levels have been found in insulinomas (Ohneda e t a l , 
1979). Insulinomas have therefore been divided into 2 groups depending 
on th e ir  C-peptide leve ls . No correlation was found between C-peptide 
levels and malignancy. However, a relationship was suggested between 
C-peptide levels and the type of B-granules, with Types I and I I  
insulinomas having high leve ls , and Types I I I  and IV , low concentrations. 
Despite e ffo rts  to draw great significance from th is  (Ohneda e t a l ,
1979) these findings merely re fle c t the varying insu lin  content of the 
d iffe re n t tumour types - equimolar of each being formed as the resu lt 
of proinsulin cleavage.
Apart from in su lin , many insulinomas contain other pancreatic and 
ectopic hormones. There have been several reports concerning 
m ultip le hormone production by is le t -c e ll  tumours (Larsson et a l , 
1975; Arnold et a l , 1972; Heitz et a l , 1978;
Hayashi e t a l , 1977; Kahn et a l , 1977; Abe et a l , 1979; Fujiya e t a l , 
1979). The large range of hormones found in insulinomas include 
proinsulin , C-peptide, glucagon, somatostatin, pancreatic poly­
peptide (PP), gastrin , m o tilin , Vasoactive In tes tin a l Polypeptide 
(V IP ), C alcitonin, ACTH,^ -MSH and chorionic gonadotrophin (HCG). 
These are generally present in only in fin ites im al amounts but 
occasionally may be as abundant as insulin  i t s e l f .  However, even 
when moderately or markedly high, they only very rare ly  manifest 
themselves c lin ic a lly , symptoms being determined by the predominant 
hormone produced.
2 .1 .4  Pathology of Insulinomas
A decreased storage capacity for insulin  concomitant with an impaired 
a b il i ty  to suppress insulin secretion when c ircu la tin g  glucose con­
centration fa lls  below the stimulating threshold has become the 
concept of the basic functional disorder of the insulinoma ce ll 
(Frerichs & C reutzfe ld t, 1976). The regulation of insu lin  secretion 
is normally mediated by stimulatory and in h ib ito ry  signals depending 
on changes of glucose concentration and modulating effects of various 
hormonal and neural factors. Insulinomas produce hypoglycaemia as 
th e ir  major c lin ic a l manifestation because they secrete insu lin  in ­
appropriately rather than in large amounts. Insulin secretion is 
inappropriate to the stimulus; more insu lin  is released than is 
required and the resulting hypoglycaemia fa ils  to suppress the
secretion ra te .
Many mechanisms have been proposed to explain this inappropriate 
secretion of in su lin , although u ltrastructural findings and studies 
on proinsulin and insu lin  content of the tumour favours the hypo­
thesis that there is a loss of storage capacity combined with 
uncontrolled release due to a defect of in tra c e llu la r  insu lin  
transport and release processes (Frerichs & C reutzfe ld t, 1976).
Since the conversion of proinsulin to insulin  and C-peptide takes 
place w ithin the B-granules (Kemmler, 1975) an increased proinsulin  
content of the insulinoma cells  strongly suggests an impaired form­
ation of granules i .e .  capacity fo r storing in su lin . In addition, 
subcellular studies have shown that the very low density supernatant 
(S - 100 fraction ) of the tumour ce lls  contained s ig n ific a n tly  more 
IRI and PLC than the secretory fraction as compared to normal is le ts  
(C reutzfe ld t e t a l , 1973a). This suggests that an appreciable part 
of the IRI was present in a non-granular form. Insulinoma cells  
released IRI much fas ter and secreted a higher proportion of the 
available IR I. Impaired granule formation and function, and/or 
defect of in tra c e llu la r  insulin  transport and release processes 
would explain not only fasting hypoglycaemia due to inappropriate  
insu lin  release but also elevated c ircu la ting  PLC in the plasma of 
insulinoma patients.
2 .1 .5  Clin ic a l Symptoms
The c lin ic a l symptoms of acute or subacute developing hypoglycaemia 
or chronic progessive hypoglycaemia have been well reviewed (Breidahl 
e t a l , 1956; Rosner and Elstad, 1964; Laurent e t a l , 1971; Gressner 
e t a l , 1973; Marks & Samols, 1974; Marks & Rose, 1981). In general, 
the symptomatology of neuroglycopenia covers a wide spectrum of
deranged central nervous functions ranging from impairment or loss 
of co-ordination of various autonomic, sensory or motor a c tiv it ie s  
to changes in behavioural patterns, personality and in te lle c tu a l 
q u a litie s .
Symptoms have generally been present fo r about 6 months to 5 years, 
though the history may be as short as a few weeks, especially  in 
malignant cases, or as long as 30 years (Van Heerden e t a l , 1979; 
Buckle, 1964; Tomkins e t a l , 1967). The history is suggestive of 
'attacks' of subacute or, less commonly, of acute neuroglycopenia 
which increases in frequency and severity u n til they are occurring 
2 or 3 times a week, or even more often. In between attacks, 
in i t ia l l y  a t le a s t, the patient feels perfectly  w e ll. Symptoms are 
aggravated by abstinence from food. Other physical signs present 
at the time of an attack include nystagmus, which is often ro ta to ry , 
slurring d ys a rth ria , incoordination, extensor plantor responses 
and hemipares is .
2.1 .6  Diagnosis
The in term itten t and sporadic hypoglycaemic attacks may lead to 
erroneous diagnoses in the early stages. These include neurosis, 
dementia, brain tumour, epilepsy and alcoholic in toxication .
D efin itive  diagnosis takes place in three stages: the f i r s t  is 
suspicion and confirmation of hypoglycaemia as the cause of the 
patient's  symptoms (Whipple, 1938; Conn & S e ltze r, 1955); the second 
is the establishment of hyperinsulinism, i . e .  inappropriate insu lin  
secretion, as the cause of hypoglycaemia (Yalow  & Berson, 1965;
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Samols & Marks, 1966); the th ird  stage is the lo ca lisation  o f the 
les ion, which may be undertaken e ith er pre- or in tra -o p era tive ly  
(Turner e t a l , 1978; Madsen, 1966; Mi 11 an e t a l , 1979). Pre-operative 
loca lisation  of the lesion is s t i l l  extremely d i f f ic u l t , .
■ _ _ The demonstration of high
circu la tin g  levels of human chorionic gonadotrophin (Kahn et a l ,
1977) or its  subunits, is strong evidence o f malignancy, since they 
are not observed in patients with benign lesions.
Simultaneous estimation of 12 to 14 hour 'overnight' fasting blood 
glucose and insulin on 3 or more consecutive days w ill show increases 
in insulin-glucose ratios to establish the diagnosis o f organic hyper­
ins ulinaemi a in more than 90% of a ll insulinoma patients (Marks & Rose, 
1981). Suppression tests can be useful especially in d iffe re n tia l 
diagnosis. Probably the best is the Insu lin  Suppression Test, with 
the measurement of blood glucose and plasma C-peptide during hypo­
glycaemia induced with intravenous insu lin  (Turner & Heding, 1977; 
Rayfield e t a l , 1976; Service e t a l , 1977). Other tests include 
insulin estimation during intravenous infusion of alcohol a fte r  a 
36 hour fas t (Turner et a l , 1973) or specific  assay of human insu lin  
during hypoglycaemia induced by infusion of fish  insu lin  (Turner & 
H arris , 1974). Single estimations o f fasting proinsulins can also be 
diagnostic (Turner & Heding, 1977).
Stimulation tests rarely  provide clear diagnoses and glucagon, 
L-leucine, tolbutamide and calcium infusion tests have a ll been 
advocated at one time or another but are generally e ith e r superfluous
or have been superseded by suppression tests.
Although the commonest problem in d iffe re n tia l diagnosis is between 
insulinoma and reactive hypoglycaemia, the most d i f f ic u l t  ones are 
undoubtedly those of fa c titio u s  hypoglycaemia and nesidioblastosis in 
childhood, in which there may be fasting hypoglycaemia with inappro­
p ria te ly  high plasma insu lin  leve ls . These can generally be resolved 
by means of plasma C-peptide measurements made in blood specimens 
collected during the 'spontaneous' hypoglycaemic episodes.
2 .1 .7  Animal Model of Insulinoma
The low incidence of insulinoma and the d if f ic u lt ie s  in diagnosis and 
treatment, coupled with the ethical considerations of using such 
patients as research subjects have in it ia te d  the search fo r a suitable  
animal model. Insulinomas develop spontaneously or as a resu lt o f 
experimental induction in a number of animal species including the 
dog (Johnson, 1977; Meyer, 1977); cat (Lambard, 1953); mouse (Hueper, 
1936); cow (Torkania, 1961); hagfish (Falkmet e t a l , 1976) hamster 
(G r illo  e t a l , 1967; Luyclex & Lefebvre, 1976) and ra t (Schoental e t a l , 
1970; Rosen e t a l , 1961; Warren et a l , 1964; Chick et a l , 1977;
Kazumi e t a l , 1978). Of these,transplantable tumour lines have been 
developed in the hamster and ra t only, and these have been subjected 
to much investigation.
The spontaneous insulin -secreting tumour of hamsters has been extensively  
studied by a number of investigators. I t  behaves lik e  a mixed-hormone- 
secreting is le t -c e ll  carcinoma, and has been found to be a suitable  
animal model fo r studying is le t -c e ll  carcinomas by a number of workers 
(H eitz e t a l ,  1978; Belchetz et a l , 1973; Erlichman e t a l , 1979;
Shapiro e t a l , 1977; Shapiro et a l , 1975; Luyclex, 1976). This has been 
c rit ic is e d  by Chick and his colleagues on the grounds that the predom­
inant ce ll types in th is tumour remain unclear because the insu lin  content 
is extremely low, and lig h t microscopic sections fa ile d  to stain with 
appropriate aldehyde-type stains (Chick e t a l , 1977). This led to 
attempts to develop other animal models.
Insulin-containing is le t  ce ll tumours have been induced in non-genetically  
predisposed rats by whole body irrad ia tio n  of one of a p a ir o f parabiotic  
animals (Warren et a l , 1964). Amongst the many tumours produced in th is  
way, only one has so fa r  proved to be transplantable (Chick e t a l , 1977).
The orig inal tumour was removed from the pancreas o f the irrad ia ted  
partner of a pa ir of male parabiont, inbred albino NEDH ra ts , (New 
England Deaconess Hospital S tra in) 566 days a fte r  one partner received 
1000 rads of to ta l body X-ray irra d ia tio n . Insulinoma lines were 
developed with 100% success rate in the second generation; the tumours 
were propagated mainly by subcutaneous transplantation. C lin ic a lly , i t  
is an insulinoma with a high insulin content (61-452 U/g wet weight) but 
i t  also contains moderate amounts of somatostatin (20-40 jjg/g wet weight). 
H is to lo g ica lly , the tumour resembles an adenoma, but pathologically  i t  
behaves lik e  a slow-growing carcinoma with remarkably with tendency to 
metastasize.
Insulinomas have also been induced and maintained in w istar rats  
(Kazumi et a l , 1978) and Lewis rats (Chick et a l , 1980) using strep to - 
zotocin in combination with nicotinamide or pi col inamide. These tumour 
lines were developed because X-ray irrad iated  tumours must be maintained 
in the inbred NEDH rats which are not commerically ava ilab le . In te re s tin g ly , 
streptozotocin when administered alone produces B -cell necrosis and
diabetes and is therefore used therapeutically  in  the treatment of 
human insulinomas. These effects  are however blocked by nicotinamide 
and pi col inamide. Indeed, the administration of a combination of 
e ith e r drug with streptozotocin results in the formation of insulinomas 
rather than the induction of B -cell necrosis (Rakieten e t a l , 1971).
The tumour lines produced by chemical induction have not, however, 
achieved 100% success rates fo r transplantation; success rates o f 73% 
(Kazumi e t a l , 1978) and 54% (Chick et a l , 1980) have been reported. 
Another problem encountered with chemically induced insulinoma is  that 
the tumours are variab le , unlike those of X-ray irrad ia ted  lin es .
Kazumi and co-workers (1978) have c lass ified  two groups o f insulinoma 
on the basis of the blood glucose levels in the hosts a fte r  intravenous 
administration of glucose: "fast acting tumours" associated with low 
blood glucose values and "slow acting tumours" associated with high 
blood glucose leve ls . In contrast, the X-ray irrad ia ted  tumour lin e  
developed in inbred albino rats of the NEDH s tra in , as used in the 
present study, has consistent characteris tics .
The aim of the present study was the characterisation o f the trans­
plantable NEDH ra t insulinoma developed by Chick e t al (1977) and 
started at the Animal U n it, University o f Surrey by courtesy o f 
Professor N. Hales of Cambridge. Changes in glucose homeostasis during 
the p ro life ra tio n  of the insulinoma were studied. In addition , tissue  
d istrib u tio n  of in su lin , glucagon and somatostatin were analysed by 
radioimmunoassay, immuocytochemistry and High Pressure Liquid Chromato­
graphy. I t  is hoped that this investigation w ill va lidate  the use of 
NEDH insulinoma bearing rats as an animal model fo r the spontaneous 
lesions that occur in man.
2.2 Methodology
2.2.1 Breeding Programme o f NEDH Rats
As.far as i t  is known, the insulinoma produced by X-ray irra d ia tio n  
developed by Chick et al (1977) can only be maintained in the very 
inbred NEDH albino s tra in  of ra ts . Thus i t  was essential to maintain 
vigorous inbreeding of these rats by mating s ib lings. Each l i t t e r  was 
weaned as a u n it , and la te r  when a harem was needed only brothers and 
sisters were paired up.
Selection of the breeding stock was necessary, and th is  was done at the 
time of weaning. The c r ite r ia  used fo r the selection were even weight 
of l i t t e r ,  good coats and bright eyes. Several problems have been 
reported to resu lt from the inbreeding a t Cambridge, and these include 
a mild respiratory in fec tio n , glaucoma (eyes bulging), mal-occlusion 
of the teeth and balding l i t t e r s .  Apart from the occasional resp iratory  
in fec tio n , none of the other symptoms have been encountered in the
breeding programme at Surrey U niversity.
Transplant Programme
Pre-adult male ra ts , usually a minimum of about 60 days o ld , were used 
fo r transplants. The tumour is excised from the donor ra ts , f in e ly  
minced and sucked up into a syringe with a trochar. By means o f a small
incision in the recip ient ra t's  flan k , 0.1 ml of the minced tumour was
injected under the skin in about the scapular region. To prevent sepsis, 
diluted Wescodyne was used to clean the area of incis ion .
2 .2 .2  Autopsy
As part o f the characterisation programme, a study was carried out to 
determine the tissue d istrib u tio n  of in su lin , glucagon and somatostatin 
in control and insulinoma - bearing ra ts . Rats with the tumour were 
k ille d  and dissected 20 days a fte r  transplantation. A ll animals were
fed u n til the time of the autopsy. Before being k ille d  by cervical 
d islocation , the rats were weighed, bled and blood samples collected  
in heparinised tubes. Plasma was separated and stored at -20°C un til 
the time fo r glucose and insu lin  analyses.
A midline incision was made through the abdominal skin and muscle w a ll, 
cutting continued around both the ventral costal margines. The abdom­
inal viscerawereremoved and the in testines unravelled by breaking the 
mesenteries. The stomach was opened by cutting round the greater 
curvature and washed out in sa lin e . Three centrimetre lengths of the 
duodenum, jejunum, ileum and colon were excised and washed in sa line.
The pancreas was removed from ju s t below the spleen and under the 
stomach. The adrenal glands and kidneys were also removed.
The thorax was opened by cutting through the ribs to the manubrium, 
keeping to*the r ig h t o f the sternum. This was then removed and trimmed 
free of muscle and fa t .  The thoracic viscera were dissected and the 
thymus detached. The thyroids were removed from e ith e r side o f the 
trachea. Skin and muscle were removed from the neck o f the r a t ,  and 
the submaxi 11ary and sublingual sa livary  glands excised.
F ina lly  the head was detached between the f i r s t  and second c e r v i c a l  Ivertebrae 
The dorsal ha ir and skin were removed from underlying muscle and the 
occip ita l region. Bone forceps were used to dismantle the cranium, 
working away from the skull f lo o r by snipping the membrane and nerve 
attachments. The hypothalamus was removed by a scooping action using 
a microspatula. In the tumour ra ts , the subcutaneous tumour was.removed 
by cutting away the surrounding skin, and the whole tumour capsule.
All the tissues were weighed immediately upon removal, frozen in liqu id  
nitrogen and stored at -20°C.
Tissue Extraction
The tissues were thawed and fin e ly  minced using a microtome blade before 
being extracted in an acid-ethanol mixture (750 ml absolute alcohol,
250 ml d is t i l le d  water and 15 ml conc. HC1) ,  5 ml of acid ethanol was 
added per gram tissue. The material was then ultrasonicated at 4°C 
using a Dawe Soniprobe (Dawe Instruments U.K.) and allowed to stand 
overnight a t 4°C (Kenny, 1955). The extracts were then centrifuged  
a t 2000 rpm for 15 minutes, a fte r  which the supernatants were removed 
and stored at -20°C u n til radioimmunoassay analyses were performed.
2 .2 .3  Glucose Analysis
Plasma glucose was determined by an automated glucose oxidase procedure 
(Stevens, 1971) using a Beckman Glucose Analyser, Beckman L td ., 
Glenrothes, U.K.
The sample was injected into an aerated enzyme solution. The method 
is based on the fac t that in the presence of glucose oxidase, 
p  -  D - glucose from the sample combines with dissolved oxygen in the 
solution to give gluconic acid. Oxygen is consumed a t the same rate  
as gluconic acid formation. The enzyme reaction is carried out in a 
cup which contains an electrode that responds to changes in oxygen 
consumption which is d ire c tly  proportional to glucose concentration 
in the sample. The system is calibrated using Beckman aqueous glucose 
standard (8 .3  mmol/L).
2 .2 .4  Radioimmunoassay 
Introduction
Ever since the technique of radioimmunoassay ( RIA) was f i r s t  developed 
by Yalow and Berson (1959) fo r the measurement of plasma in su lin , i t  
has been widely used for the measurement of small quantities of c i r ­
culating hormones in the blood. In the present study, in su lin , glucagon 
and somatostatin were measured by RIA. These assays are b r ie f ly  des­
cribed in th is  section and data concerning th e ir  validation are pre­
sented.
2 .2 .4 .1  Rat Insulin Radioimmunoassay
In vivo experiments on conscious rats that require regular blood 
sampling normally involve ta i l  bleeding. However, comparatively small 
samples are obtained by th is  method. A highTy sensitive insu lin  assay 
modified to measure 20 jjl plasma samples was therefore needed. This 
was achieved by ( i )  using a small fin a l incubation volume (240 pi) and 
( i i )  introducing a pre-incubation step fo r the antibody-insulin reaction  
p rio r to the addition of labelled  insulin  i . e .  a "disequilibrium  assay".
Assay buffer
This was a 0.05M phosphate bu ffe r, pH 7.4 with 0.2% bovine serum
albumin (BSA, Sigma Chemical Co., St. Louis, U .S .A .). The assay buffer
125was used in the d ilu tio n  of standards, antiserum, I- in s u lin  and 
second antibodies.
Charcoal-stripped ra t serum
In su lin -fre e  ra t serum (20 j j l)  was added to the standard assay tubes.
This was prepared by pooling serum obtained from fasted rats by cardiac
puncture. A 20% N orit A charcoal (Hopkin and W illiam s, Chadwell 
Heath, Essex) was added and s tirred  fo r 24 hours. This mixture was 
then centrifuged and the supernatant f i l te re d  u n til a ll  the charcoal 
was removed. 0.5 ml aliquots were stored a t -20°C.
Standard
P urified  ra t insu lin  standard was purchased from the Novo Research 
In s t itu te , Copenhagen. The preparation had been purified  by gel 
f i l t r a t io n  to remove proinsulin and B-components. A 20 ng/ml standard 
was prepared with stock phosphate buffer. 1 ml aliquots were then 
lyophilised and subsequently stored at 4°C. 1.25 ml o f assay buffer
was added to each v ia l to obtain the top standard of 16 ng/ml. 20 .^1 
of standard was added to each tube.
Anti serum
A guinea pig a n ti-in s u lin  MF/GP/10 -  I I IA  obtained from Guildhay Antisera, 
Guildford was used throughout a t an in i t ia l  d ilu tio n  o f 1:9000. This 
was stored with 0.1% sodium azide at 4°C.
The anti serum was raised against porcine insu lin  (Novo Research 
In s t itu te , Copenhagen) conjugated with glutaraldehyde to egg albumin 
(BDH Chemicals, Poole, Dorset) and measures immunoreactive insulins  
( IR I)  (Shelagh Hampton, Guildhay Anti sera, Guildford, personal communi­
cation ).
Insulin Label 
125 I-bovine insulin was purchased from Amersham In tern a tio n a l, L i t t le
Chalfont, U.K. (1M38) and stored at 4°C. 50 y j  of a 1:20 in i t ia l  d i l -
125ution was added so that each assay tube contained 25 pg I- in s u lin .
Second Anti serum
A donkey anti-guinea pig HP/D/4/PR was obtained from Guildhay Anti sera, 
Guildford. 50 j A  of a 1:25 in i t ia l  d ilu tio n  was added to each assay 
tube. Normal guinea pig serum (25 ^ 1) was also added at an in i t ia l  
d ilu tion  of 1:200. The second anti serum and the normal guinea pig 
serum (NGPS) were d iluted in assay buffer with a 0.38% ethylene d ia- 
m inetetracetic acid (EDTA; BDH Chemicals L td ., Poole).
Polyethylene Glycol (PEG)
A 4% stock solution of PEG (BDH Chemicals L td ., Poole) was added in 
equal volumes to each assay tube to obtain a fin a l concentration of 
2% PEG. Second antiserum, NGPS and PEG were added a t the same time, 
incubated fo r 2 hours at 4°C and centrifuged a t 2500 rpm fo r 30 minutes.
Dextran-coated Charcoal
The second antibody-PEG separation system was compared with a charcoal 
separation method (Herbert .et a l , 1965; Albano e t a l , 1972). The 
charcoal suspension was prepared by mixing 2.5 g of N orit A charcoal 
(Hopkin & Williams, Chadwell Heath, Essex) and 0.25 g Dextran T-250 
(Pharmacia, G.B., L td .,)  with 100 ml of the assay buffer to form a 
2.5% stock solution. This was stored at 4°C. For use in the assay, 
the charcoal suspension (100y u l) was added to give a fin a l concentration 
of 0.7%. A fter addition of charcoal, the tubes were incubated a t 4°C 
fo r 10 minutes before centrifugation at 2500 rpm fo r 20 minutes.
Quality Controls
Rat serum from fed rats were pooled to obtain 2 quality  controls covering 
the top and bottom range of the assay. 0.1 ml aliquots were stored a t -20°
Results
Anti serum d ilu tio n  curves were carried out in a fin a l incubation volume 
of 240^/1. A constant amount of labelled insulin  (25 pg) was incubated 
fo r 24 hours at 4°C with double diluted concentrations o f a n ti-in s u lin  
MF/GP/10 -  I I IA  (5 0 ^ 1 ) . A charcoal separation was used. The concent­
ration of anti serum that gives about 50% binding of the label was deter­
mined to be the t i t r e ,  and th is was estimated to be 1:9000 (F ig . 1 ).
Comparison of Equilibrium and Disequilibrium Assay 
Using an antiserum t i t r e  of 1:9000, two standard curves were set up to 
compare the effects of disequilibrium assays (delay addition o f label 
insu lin ) on s e n s itiv ity . For the equilibrium assay, antiserum and 
label were added on the same day and separated with charcoal a fte r  a 
24 hour incubation at 4°C. For the disequilibrium  assay, anti serum and 
standards were allowed a 16 hour preincubation at 4°C. Labelled insu lin  
was then added and incubated fo r 24 hours at 4°C before charcoal separ­
ation . Greater s e n s itiv ity , defined as the precision a t zero standard 
(Ekins and Newman, 1970) was obtained with the disequilibrium  assay 
system (0 .3  ng/ml compared with 0.8 ng/ml for the equilibrium  assay) and 
th is was adopted for a ll future insulin assays (F ig . 2 ).
Comparison of two d iffe re n t separation systems
A comparison o f the two d iffe re n t separation systems tested in the assay 
is shown in Fig. 3. The sen s itiv ity  o f the standard curve obtained with 
charcoal was comparable to that obtained with second antibody and PEG, 
and was determined to be 0.3 ng/ml. The second antibody separation 
system was adopted for the assay.
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Precision and Reproducibility
The in tra -  and interassay reproducib ility  expressed as a co e ffic ien t  
of variation  for the two qu ality  control pools (high and low level 
pool) was 5.9% (n=14) and 6.6% (n=14) respectively.
Discussion
Rats and mice (Markussen, 1971) are the only mammals that has so fa r  
been shown to produce more than one in su lin , although m ultip le insulins  
appear to occur frequently among fishes (Yamamoto e t a l , 1960; Jorgensen, 
1960). When the amino acid sequence of ra t insu lin  was investigated, 
i t  was found that there were two types o f molecule, one having one 
residue and the other 2 residues o f Lysine (Smith, 1964; Smith, 1966; 
Clark and Steiner, 1969). The two types are present in about equal 
amounts. The physiological significance of th is  is not known. A nti- 
sera to insu lin  cross react equally well with both molecular forms.
A number of insu lin  radioimmunoassays have been reported in the l i t e r ­
ature since the f i r s t  report by Yalow and Berson (1959). A double­
antibody separation techniques was reported by Hales and Randle (1963) 
and a dextran/charcoal system by Herbert e t a l , (1965), Albano e t a l , 
(1972) and Buchanan and McCarroll (1971).
Using a disequilibrium  system, a sensitive and precise assay was 
developed for the measurement of ra t plasma in su lin . The l im it  of 
detection was determined to be around 0.3 ng/ml.
2 .2 .4 .2  Glucagon Radioimmunoassay
Unger and co-workers (1969) applied the principles of radioimmunoassay 
to the measurement of glucagon in blood very soon a fte r  Berson and 
Yalow (1959) f i r s t  introduced the technique fo r measuring plasma insu lin  
During the past 20 years, a great deal of work has been devoted to 
improving the glucagon radioimmunoassay ( Samols e t al
1966; Shima and Foa, 1968; Nonaka and Foa, 1969; Heding, 1971; Luyckx, 
1972; Alford et a l , 1977). A number of artefacts  and in te rfe rin g  
factors have been detected, the s e n s itiv ity  has been markedly improved, 
and important progress has been made in the area of s p e c ific ity .
The glucagon assay protocol used in th is study is essentia lly  that 
developed by Al Tamar (1978) and Tsiolakis (1979) in th is  laboratory, 
and is based on that of Buchanan and McCarroll (1971) and Buchanan e t al 
(1974). Further developments were carried out to improve assay sensit­
iv ity  with a new anti serum, and reducing the interference of plasma 
proteins by extraction with polyethylene glycol.
Assay buffer
A 0.04M stock phosphate bu ffer, pH 7.4 was prepared and stored fo r up 
to 2 months at 4°C. Double deionised water was used fo r preparing a ll  
the reagents. The assay buffer was made up fresh each time by adding 
2% of heat inactivated Horse Serum No. 5 (Wellcome Reagents L td ., 
Beckenham, Kent) and 12 mg/ml Benzamidine (Sigma) to the stock phos­
phate bu ffer. This assay bu ffer, besides being used in the assay tubes, 
is also used for d ilu tin g  the antiserum and la b e l. A 0.38% of disodium 
EDTA was further added fo r d ilu tin g  the second antibody.
Pooled Serum
Serum obtained from rats by cardiac puncture were pooled and heat 
treated fo r 30 minutes at 37°C. A fter allowing to cool a t room temper­
ature. The mixture was then aliquoted into 2 ml volumes and stored at 
-20°C.
A polyethylene glycol extract of the glucagon free serum was also pre­
pared. A 20% PEG solution was added to the pooled serum to a f in a l 
concentration of 10%. The mixture was then centrifuged fo r 10 minutes ~ 
at 3000 rpm and the supernatant aliquoted in to  2 ml volumes and stored 
at -20°C.
Standards
The WHO 1st International standard fo r Glucagon (porcine) fo r Bioassay 
(69 /194), obtained from the MRC National In s titu te  fo r Biological 
Standards and Control, London was used. Each ampoule contained 1.49 IU 
of porcine glucagon (N.B. Each Glucagon International Unit is approxi­
mately equal to 1 mg).
The contents of the ampoule were dissolved in acid ethanol (1 .5  ml con­
centrated HC1 : 75 ml absolute ethanol: 25 ml deionised water) to give 
a stock solution of 100yng/ml. This stock standard was aliquoted into  
0.5 ml volumes and stored at -20°C.
This stock was then d iluted with the same acid ethanol to give a D aily  
Working Standard (DWS) of l^g/ml which again was aliquoted and stored - 
at -20°C. I t  is stable in this way for up to 4 months. For use in the
assay, 10 ^ l1 of the DWS was added to 4 ml of the assay buffer to give 
a top glucagon standard of 2500 pg/ml. 100j a \  o f standards was added
to the assay standard tubes.
Anti serum
Two anti sera were used fo r radioimmunoassay in th is  study:-
( i )  MF/R/4 - LB -  a rabbit anti-pancreatic  glucagon anti serum 
directed against an immunodeterminant in the carboxyl-terminal 
region of the glucagon molecule (residues 24-29). This was 
obtained from Guildhay Anti sera, Guildford.
( i i )  GPC1/2 (25/11/76) -  a guinea pig antiserum which cross reacts 
strongly with pancreatic glucagon and immunoreactive glucagon 
from the gut. The antiserum is directed against the amino-terminal 
and central portion of the glucagon molecule (residues 2-23) and 
was used to measure "to ta l immunoreactive glucagon" (IRG). The 
anti serum was obtained by courtesy o f Dr. Peter F la t t  (1981).
I-125 -lab e lled  glucagon
This was prepared by the classical method of Hunter and Greenwood (1962) 
using a chloramine-T iodination, and an anion exchange chromatographic 
p u rifica tio n  with QAE Sephadex(jtfrgensen and Larsen, 1972). The eluate  
from the ion-exchange column was d ilu ted 1:1 with an acid-ethanol so l­
ution and stored at -20°C. S ta b ility  has been found to be around 4
weeks. 100^ 1 of d iluted label was added to the assay so that each tube
125contained approximately 15 pg I-glucagon.
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Second Antibody
A donkey a n ti-ra b b it, HP/D/41 - 11IB obtained from Guildhay Anti sera, 
Guildford,was used at an in i t ia l  d ilu tio n  of 1:30. A 100^,1 of a 
1:200  d ilu tio n  of normal rabb it serum was also added as c a rr ie r  protein.
Dextran-coated Charcoal
A 1% charcoal suspension was prepared by mixing 5 g o f charcoal (N orit 
A, Hopkin and Williams) and 0.5 g Dextran T-250 (Pharmacia) with 500 ml 
of stock phosphate bu ffer. This was prepared 24 hours before use, and 
stored at 4°C. For use in the assay, 100^1 o f the charcoal suspension 
was added to give a fin a l concentration of 0.15%. A fter addition of 
the charcoal, the tubes were allowed to stand a t 4°C fo r 10 minutes 
before centrifugation a t 2500 rpm fo r 20 minutes.
Quality Controls
Pooled ra t serum was d ilu ted with glucagon standards to give 2 pools of 
quality  controls covering the top and bottom range o f the assay. 0.5 ml 
aliquots were prepared and stored frozen a t -20°C u n til use.
Results
Anti serum t i t r e
Antibody d ilu tion  curves were formed by incubating a constant amount of 
label (15 pg) with double diluted concentrations of anti.serum fo r  
24 hours at 4°C. The t i t r e  was defined as the concentration o f a n ti­
body that gave a 50% binding of the la b e l. This was calculated to be 
1:15,000 fo r the C-terminal reacting rabbit anti serum, MF/R/4 -  LB and 
1:7000 fo r the N-terminal reacting guinea pig antiserum, GPC1/2 
(F ig . 4 ). I t  should be noted that antisera which react strongly with
bZ
(OOL x l/a)punoq uo6eDn[6-i
a heterogeneous group o f  gut-derived proteins c o lle c tive ly  called gut 
"glucagon-like immunoreativity" (GLI) (Heding, 1972) are termed 
N-terminal reactive.whereas those that react weakly with material from 
the gut are c lass ified  as C-terminal reactive anti sera (Assan and SI usher, 
1972; Buchanan, 1977; Conlon, 1980).
C ross-reactiv ity  Studies
The N-terminal reactive GPC1/2 anti serum did not show any cross-reaction  
with crude chol ecystokinin, gastrin pentapeptide or secretin (F la t t  & 
Swanston-Flatt, 1980). When tested against a gut extract prepared 
according to the method of Kenny (1955) and enriched with gut GLI (Novo), 
GPC1/2 displayed a strong cross-reaction with the ex tra c t, and 
yielded essentia lly  superimposable d ilu tio n  curves for porcine pancreatic 
glucagon and gut GLI (F la t t  & Swanston-Flatt, 1980). An estimate of 
antibody a f f in i ty  expressed as an index given by the equation (100 (Bq-B )/B o 
where Bq and B represent counts bound in the absence and presence of 
125 pg cold glucagon respectively (Hurn and Landon, 1971; Holst and 
Aasted, 1974) gave a ra tio  o f 1 .25, indicating an antiserum reacting  
equally well with glucagon and gut GLI (F la t t  and Swanston-Flatt, 1980).
This anti serum was used in the measurement of "total GLI" from tissue  
extracts.
Cross-reaction studies designed to evaluate the s p e c ific ity  of the 
C-terminal reactive rabbit antiserum, MF/R/4 - LB fa ile d  to show any 
interference from secretin  but gave a cross-reaction with porcine gut 
GLI of 1 % up to 8 ng/ml (Fig. 5 ). This is  in agreement with the apparent 
tendency of glucagon - albumin conjugates to y ie ld  a high proportion of
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Fig( 5 ) C ross-reactivity  of Secretin (a — a ), gut GLI ( • — •  ) and
pancreatic Glucagon(o— o) with a C-terminal reactive rabbit 
a n t i - g l u c a g o n ,M F /P /4 - L B .
antisera with restric ted  s p e c ific ity  in the rabbit as reported by 
Garand e t al (1976), Tager e t al (1977), F la tt  and Swanston-Flatt (1980). 
This anti serum was used in the measurement of "pancreatic glucagon".
Degradation of glucagon
I t  has been recognised fo r some time that labelled pancreatic glucagon 
was damaged during incubation with plasma (Linger e t a l , 1961) and la te r  
th is  "damage" was shown to be an enzymatic degradation o f the glucagon 
molecule, which could be reduced by addition of aprotinin (Trasylo l) a 
proteinase in h ib ito r (Eisentraut et a l , 1968). Since th e n ,; Trasylo l 
has been routinely used in glucagon radioimmunoassays.
In addition to Trasylol which is a polypeptide derived from beef parotid  
glands, other proteinase inh ib itors  available include a trypsin in h ib ito r  
derived from soyabeans, and several synthetic low-molecular-weight sub­
stances, such as mercaptoethanol and benzamidine (Foa et a l , 1977).
A major deterrent to the widespread use of Trasylol in the glucagon 
radioimmunoassay has been its  excessive cost. This has led other 
workers to search fo r a cheaper but ju s t as e ffec tive  substitu te.
Ensinck e t a l , (1974) have shown that an amide derivative o f benzene 
called benzamidine, which is a competitive in h ib ito r o f tryp s in , thrombin 
and plasmin was as e ffec tive  as Trasylol in the prevention o f glucagon 
degradation in human plasma at 1% the cost of tra s y lo l. With concent­
rations of benzamidine exceeding 0.05 M, in s ig n ifican t degradation of
125 oI-glucagon occurred in undiluted plasma up to 72 hours at 4 C. When
added to undiluted plasma in 0.05 M benzamidine, recovery of glucagon
was found to exceed 90%.
The claims of Ensinck et al (1974) were investigated and the e ffe c tiv e ­
ness of trasylo l and benzamidine as proteo lytic  inh ib ito rs  were com­
pared in a series of standard curves (F ig . 6 ) .  Trasylo l, benzamidine 
and control gave superimposable standard curves, although the control 
gave consistently lower binding. These results suggest that 0.05 M 
benzamidine was as e ffec tive  as 1250 KlU/ml Trasylol in the prevention 
o f glucagon degradation in the radioimmunoassay o f plasma glucagon. 
Furthermore, at that concentration, benzamidine did not in te rfe re  with 
the anti gen-anti body binding.
Benzamidine at a fin a l concentration of 20 mM has also been found to be 
a satis factory  replacement for Trasylol during the co llection  of blood 
and the storage of plasma glucagon samples at -20°C (Wojcikowski e t a l ,
1977).
Extraction
Many workers who perform glucagon radioimmunoassays, in addition to 
adding a proteolytic  in h ib ito r have found i t  necessary to carry out a 
plasma extraction procedure (Heding, 1971; Palmer e t a l , 1972; Alford  
e t a l , 1977; F la t t ,  1981). The reasons fo r this are as fo llow s:-
125(a) Incubation damage to 1-glucagon
125I t  has already been mentioned that when I-glucagon is incubated with 
plasma or serum, an enzymatic degradation takes place. This damage is 
higher in plasma than in buffer and varies from plasma to plasma. I t  
can be reduced, though not elim inated, by addition of t ra s y lo l, and 
therefore "damage controls" incubated without anti serum must be included
Fig . 6 Comparison o f Trasylol ( •,1250 KlU/ml) and 
Benzamidine (o,0.05M) as proteo lytic  inh ib itors  in the radio­
immunoassay of glucagon in plasma with MF/R4 LB. ( □  Control) 
Results are mean - SEM (n = 6 ) .
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in each assay in order to correct the values fo r damage. A true correction
125is d i f f ic u l t  because the damage of I-glucagon in the controls is
d iffe re n t to that of samples in the assay, where the glucagon antibodies
125protect a portion o f the I-glucagon from degradation. In order to 
elim inate th is difference, extraction procedures have been developed, 
which removes the plasma proteins, including the proteo lytic  enzymes.
(b) Degradation of endogenous glucagon during blood co llection  and 
storage
When blood was collected in tubes with or without the addition of
\
tra s y lo l, no difference in the plasma glucagon content could be shown 
(Hazzard e t a l , 1968; Elsentrant e t a l ,  1968). This is not to conclude 
that endogenous glucagon is not degraded during blood co llection  and 
storage, but only that no change can be detected in the to ta l GLI-content 
during blood co llection . Since the content of pancreatic glucagon in 
the plasma is probably of the order o f 100 pg/ml (Sokal and E zd in li,
1967; Aguilar-Parada e t a l ,  1969; F la t t ,  1981) or 260 pg/ml (Heding, 1971) 
a degradation of 30-50% would be very d i f f ic u lt  to observe due to lim its  
of detection in the assay. I t  is more than lik e ly  that some degradation 
does take place although i t  is not a t present detectable with current 
techniques. This is yet another reason fo r extracting the plasma glu­
cagon.
(c) Non-specific GLI of the plasma proteins
I t  has been demonstrated that a 1% gamma-globulin solution in h ib its  the 
binding o f labelled glucagon to some glucagon antibodies (Unger and 
Eisentraut, 1968). These non-specific GLI-effects makes the plasma
glucagon values appear a r t i f ic ia l l y  high and is possibly due to a 
reaction between the gamma-globulins and the antibodies. As th is  
reaction varies from anti serum to anti serum, the non-specific GLI e ffec t  
observed with d iffe re n t antisera varies , too. This e ffe c t can be elim ­
inated by removing the plasma proteins in an extraction procedure. 
F in a lly  as Heding (1971) has pointed out, differences have been found 
between glucagon determination performed d ire c tly  in plasma and a fte r  
extraction sometimes in the order of 0.5 ng/ml.
Two main techniques of extraction have been reported. The most elegant 
is that of Alford et al (1977) who have developed an assay whereby the 
glucagon content of each plasma sample is  measured against a standard 
curve made up in a aliquot of the same subjects plasma, made free o f  
glucagon by prio r extraction with a specific  glucagon immunoabsorbent 
consisting o f anti glucagon globulins coupled to cyanogen bromide a c t i­
vated Sepharose 4B beads. In th is  system a fasting pancreatic glucagon 
level o f 24 + 3 pg/ml was obtained. Although higher levels have been 
reported by others (Muller e t a l , 1970; Gerich e t a l , 1973; Heding e t a l , 
1972; Day e t a l , 1973; Henguin e t a l , 1974), th is  probably represents 
the true fasting level in normal subjects. The main disadvantage with 
th is  technique is the im practica lity  o f setting up individual standard 
curves with glucagon-free immunoabsorbed serum for each subject's  
samples. Furthermore, th is  is made more d i f f ic u l t  in the r a t ,  where 
to obtain s u ffic ie n t plasma to set up individual standard curves may 
require carrying out cardiac punctures before the commencement o f any 
animal experimentation. In addition , the problems of glucagon degrada­
tion and non-specific plasma protein interference are not completely 
overcome.
bU
By fa r the most popular extraction procedure is that introduced by 
Heding (1971) where plasma samples are extracted with a 61% (v /v ) 
fin a l concentration of ice-cold ethanol. The extracts can then be 
analysed using a single standard curve prepared in a reconstituted  
extract derived from a plasma pool previously stripped of glucagon 
using charcoal (Weir e t a l , 1973; Buchanan, 1977) or specific  immuno- 
absorbent (A lford e t a l , 1977). Recoveries greater than 80% have been 
reported fo r th is  procedure (Heding, 1971). The major disadvantage of 
the ethanol extraction technique however is the need to lyop h ilise  the 
extract to dryness under negative pressure in a dessicator or freeze- 
d r ie r , before reconstituting with assay b u ffe r. An a lte rn a tiv e  extraction  
procedure using polyethylene glycol (PEG) was subsequently investigated. 
This has the advantage of not requiring a lyo p h ilisa tio n  procedure.
Polyethylene Glycol Extraction
The properties of polyethylene glycol (PEG) in p rec ip ita ting  large  
molecular weight proteins were exploited in th is  extraction . PEG was 
added to the plasma samples in order to p rec ip ita te  proteo lytic  enzymes 
and high molecular weight plasma proteins th a t in te rfe re  non-specifica lly  
with the assay. The p rec ip ita te  was pelleted under centrifugation (3000 
rpm fo r 10 mins) and the supernatant, containing the low molecular weight 
proteins including hormones, assayed d ire c tly  (Con!on e t a l , 1981).
Recovery Experiments
Recovery studies were carried out with 3 d iffe re n t f in a l concentrations 
of PEG -  10%, 12% and 14%. The mean recovery of exogenous glucagon 
(2500, 1250, 625, 312 pg/ml) a fte r  extraction was 97%, 105% and 68% 
with 10%, 12% and 14% fin a l concentration of PEG respectively  
(Figs. 7 and 8 ) .
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Fig . 8 Recovery Studies with d iffe re n t fin a l concentrations o f polyethylene 
..glycol extraction (n=4)
Although Con!on et a l , (1981) use a 12% fin a l PEG concentration in 
th e ir  somatostatin extraction , we have found a 10% fin a l PEG concent­
r a t io n  to give better recoveries fo r glucagon.
Parallelism
Parallelism  between standard glucagon and 10% PEG extracted plasma 
samples was demonstrated by superim posibility o f plasma samples with 
standard curve using a lo g it /lo g  p lot (Rodbard and Lewald, 1970)
(F ig . 9 ).
Precision and Reproducibility
The intra-assay coeffic ien t of variation  a t a mean plasma level o f 
632 pg/ml was 7.3% (n=12). The inter-assay c o e ffic ie n t o f varia tion  
at a mean level of 600 pg/ml was 15.2% (n=10) and a t a mean level o f 
867 pg/ml was 10.3% (n=9).
S e n s itiv ity
The l im it  o f s e n s itiv ity  of the 10% PEG extracted plasma standard curve 
is 60 pg/ml, defined as the precision a t zero standard (Ekins and 
Newman, 1970). This is a s lig h t improvement compared with the unextracted 
plasma with a s e n s itiv ity  of 100 pg/ml (F ig . 10). The standard curve 
constructed with 10% PEG was superimposable with that o f the 10% PEG 
extracted plasma.
Discussion
Current radioimmunoassays fo r plasma pancreatic glucagon are s t i l l  
unreliable (Heding, 1971; Luyckx, 1972). A major source of e rro r is the 
quantita tive  interference by non-specific factors known to be present 
in the plasma (Heding 1971; Unger and E isentrant, 1958; Weir e t a l ,
1975). The reasons fo r these non-specific interference are not c le a r,
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but they have been shown to be important. Weir e t al (1975) have 
demonstrated that th is "interference factor" varies widely from sub­
je c t  to subject and may account fo r up to 100% of the "measured" 
basal glucagon concentration, employing the widely used anti serum 
of Dr. Unger's, 30K. The v a r ia b ility  of such interference in d iffe re n t  
assays probably accounts fo r the big discrepancies reported in the 
lite ra tu re  fo r fasting levels in diabetic subjects of pancreatic glu­
cagon, which has been quoted as low (Buchanan and McCarroll, 1972), 
normal (Weir et a l , 1975; Muller e t a l , 1970; Gerich e t a l , 1973;
Unger et a l , 1970) or raised (Aguilar-Parada e t a l , 1969; Heding and 
Rasmussen, 1972; Day and Anderson, 1973).
A radioimmunoassay was developed fo r glucagon that circumvents th is  
problem using an easy polyethylene glycol (PEG) extraction of plasma 
samples. PEG precip itates the large molecular weight plasma proteins 
as well as the glucagon-degrading enzymes, leaving the smaller molecular 
weight hormones in the supernatant. This was then measured against a 
standard curve made up in a PEG extracted glucagon-free plasma.
Degradation of endogenous glucagon during blood collection and storage 
can be reduced by a proteinase in h ib ito r , aprotin in (Trasylo l) 
(Eisenstrant e t a l , 1968). Benzamidine, a t 1/10 the cost of tra s y lo l,  
was found to be as e ffec tive  fo r this purpose.
F in a lly , there has recently been considerable controversy over a commonly 
acceptable terminology to describe the glucagon-like polypeptides 
(Conlon, 1980a; Murphy and Buchanan, 1980; Bloom 1980; Conlon, 1980b).
The Nomenclature Committee o f the In ternational Glucagon Symposium,
D allas, USA (Unger, 1976) has proposed that irrespective of th e ir  
tissue of o rig in , polypeptides which react with both C- and N-terminal 
specific  antibodies (Senyk e t a l , 1972; Assan and Shisher, 1972) are 
termed "immunoreactive glucagon, IRG" and polypeptides which react 
only with N-terminal specific  antibodies are termed "glucagon-like 
immunoreactivity, GLI". The approximate molecular weight of a component 
is given as a superscript e .g . "pancreatic glucagon" under th is  nomen­
clature becomes IR G ^ ^ , and "g licentin" becomes GLl"*2000.
Whilst acknowledging the need fo r a standardised nomenclature to c la r ify  
ex is tin g , the system proposed by the In ternational Glucagon Symposium 
(Unger 1976) does have its  p i t fa l ls .  To begin w ith , antibodies do not 
f a l l  neatly into the N- and C-terminal designation, and the degree of 
cro ss-reactiv ity  varies with d iffe re n t antisera. The suggested term­
inology is based on 2 antibodies which c o lle c tiv e ly  bind only a lim ited  
proportion of the to ta l glucagon structure. I t  could not describe 
fragments of glucagon or o f glucagon precursor(s) which bind to the 
C-terminal antibodies but not to the N-terminal antibodies. Also frag ­
ments of precursors or o f glucagon containing residues 1 to 12 o f the 
hormone are not detected by e ith e r antibody (Murphy and Buchanan, 1980).
The approximate molecular weights are derived from gel chromatography 
and are therefore by nature inaccurate (Bloom, 1980), Column peak position  
vary greatly with the physical conditions used, and are fu rther subdivisible  
i f  d iffe re n t and more powerful analytical techniques are used e .g . HPLC.
Only when these polypeptides have been sequenced w ill the precision and
c la r ity  which is being sought be a tta ined . The g licen tin  story 
il lu s tra te s  the need fo r caution on th is  point. In i t ia l l y  suggested 
by Sundby e t a l , (1976) to be a 100 amino acid polypeptide with a 
molecular weight of 12,000 on the basis of SDS-gel electrophoresis 
and amino acid analysis, g licen tin  has now been confirmed to be a 
molecule containing 69 amino acid residues with a molecular weight of 
8128 (Thim and Moody, 1981). This recent data w ill require a complete 
revision of the proposed terminology.
We are in agreement with Drs. Murphy and Buchanan (1980) th a t "rig id  
adherence to any proposed 'lin g u is t ic  uniform ity ' per se may not 
fa c i l i ta te  v e rs a til ity  and precision of expression and have adopted the 
terminology o f Moody and Heding where "glucagon-like imnunoreactivity" 
(GLI) is used for material other than glucagon (Sundby e t a l , 1976;
Thim and Moody, 1981; Heding 1971) and glucagon-like polypeptides of 
gut orig in  are called gut G LI's. Proglucagon (P a tze lt e t a l , 1979) is  
the name used fo r g lic e n tin , the glucagon precursor, follow ing the 
insu lin /pro insulin  nomenclature. Proglucagon is  a 69 amino acid pre­
cursor that is broken down into glucagon (33-61) and 2 GLI fragments 
(1-33) and (62 -69 ), (Thim and Moody, 1981).
2 .2 .4 .3  Somatostatin Radioimmunoassay
Several radioimmunoassays fo r somatostatin have been previously described 
(Arimura e t a l , 1975; Kronhiem e t a l , 1976; Epelbaum e t a l , 1977;
McIntosh e t a l , 1978; Patel and R eichlin , 1978; Penman e t a l , 1979).
Many d if f ic u lt ie s  have been encountered during attempts to measure c i r ­
culating somatostatin due to interference by substances in the plasma, 
including binding proteins, or to enzymic degradation. However, with
d iffe re n t extraction procedures, several groups have recently reported 
plasma somatostatin levels in man (Pimstone e t a l , 1976; Kronheim e t a l , 
1978; Penman e t a l , 1979; Conlon e t a l , 1981).
The assay used in th is study is essentia lly  that described by Penman 
et a l , (1979). Antiserum and somatostatin tracer were kindly supplied 
by Professor Lesley Rees, C lin ica l Endocrinology Department,
St. Bartholomew's Hospital, London, EC1. The assay was o r ig in a lly  
optimised to assay plasma somatostatin levels in man. For the purpose 
of th is study, the assay was adapted to measure somatostatin in ra t  
tissue extracts. These modifications w ill be described b r ie f ly .
Assay Buffer
A stock 0.05 M phosphate b u ffe r, pH 7.4 was prepared using double glass 
d is t i l le d  water. 0.02% (w/v) sodium azide and 0.25% EDTA were added, 
and the stock buffer solution stored a t 4°C. The assay buffer was pre­
pared by supplementing the stock phosphate buffer with 0.2% BSA (Sigma).
Standards
Synthetic cyclic-som atostatin was obtained from Bachem In c ., (C a lifo rn ia , 
USA). A stock solution of 20 mg/ml in 0.01 M HC1 was made and 50 pi 
aliquots stored at -70°C. This stock solution was diluted with the stock 
phosphate buffer to give a "Daily Working Standard" of 100 ng/ml. This 
was further aliquoted in 60 pi samples and stored at -70°C. For use in 
the assay, the d a ily  working standard was d iluted 1:40 with assay bu ffer  
to give a top standard of 2.5 ng/ml of somatostatin.
Anti serum
A rabbit a n ti-c y c lic  somatostatin, R9, was kindly donated by 
Prof. L. H. Rees from St. Bartholomew's H ospital, London EC1. The 
antiserum showed no cross-reaction with a large range of the hypothal­
amic, p itu ita ry  or gastro intestinal proteins or peptides tested 
(Penman e t a l , 1979).
Labelled Somatostatin
This was also a generous g i f t  donated by Prof. L. H. Rees from 
St. Bartholomew's Hospital, London EC!. Somatostatin has neither a 
tyrosine nor a h istid in e  residue. I t  was therefore necessary to use 
a tyrosinated analogue fo r iodination. A lactoperoxidase-iodinated  
preparation of ^Tyr-somatostatin purified  on ODS S ilic a  (Penman e t a l , 
1979) was used throughout th is  study. The tracer was stored at -70°C.
Second Antibody
A donkey a n ti-ra b b it antiserum, HP/D/41 - 11IB obtained from Guildhay 
Antisera (Guildford) was used at an in i t ia l  d ilu tio n  o f 1:30. A 1:200 
d ilu tio n  of normal rabbit serum was also added as c a rr ie r  protein .
Polyethylene Glycol (PEG)
A 4% PEG solution (BDH Chemicals, Poole, Dorset, England) was added to 
achieve a fin a l concentration of 2 % .  Second antibody, normal rabbit 
serum and PEG were added a t the same time, l e f t  at 4°C fo r 2 hours before 
centrifugation a t 2500 rpm fo r 30 min.
Dextran-coated charcoal
A 1% stock charcoal suspension was prepared by mixing 1 g charcoal
(N o rit A, Hopkin and Williams) and 0.1 g dextran T-250 (Pharmacia Fine 
Chemicals Uppsala, Sweden) suspended in 100 mis assay buffer. The 
charcoal suspension was added to give a fin a l concentration of 0.15%, 
allowed to stand at 4°C fo r 10 minutes before centrifugation at 2500 rpm 
fo r 20 minutes.
Quality Controls
Quality controls were prepared by d ilu tin g  the Bachem Standard to con­
centrations of 2 ng/ml, 1.0 ng/ml and 0.5 ng/ml in the acid-ethanol 
mixture used for extracting peptide hormones from tissues d iluted 1:10  
with assay buffer i . e .  750 ml absolute alcohol, 250 ml double glass 
d is t i l le d  water and 15 ml cone, HC1 d ilu ted  1:10 with assay bu ffer.
Results
Antibody t i t r e
The t i t r e ,  defined as 50% binding of the la b e l, was determined to be 
1:30,000 (F ig . 11). This was in agreement with information received 
from St. Bartholomew's Hospital (Dr. P. Wu, personal communication).
Comparison of Equilibrium and Disequilibrium Assay 
Using an anti serum t i t r e  of 1:30,000, standard curves were set up to 
compare the effects of equilibrium and disequilibrium  assays on sen­
s i t iv i t y .  Two disequilibrium curves were performed -  one with a 24 hr 
pre-incubation, the second with 48 hrs. This was then followed by a 
24 hr incubation a fte r  addition of tracer somatostatin. The equilibrium  
assay was carried out by incubating label and anti serum fo r 24 hrs. A 
highly sensitive standard curve ( 0.02  ng/ml) was obtained with the
F
ig
.II
 
An
ti 
se
ru
m 
D
ilu
tio
n 
Cu
rv
e 
fo
r 
R9 
an
ti-
so
m
at
os
ta
tin
/ 1
s-<D
CO•n4->C<C
EO
4->
=3
P
fed
vD
1i i
O
00
o
VO
o o
CXI
(001 x i / a ) Pun°q u s o q . e u i o s - ^ 1  - 1 <a I I  hcl
Ty
r-
so
m
at
os
ta
tin
 
bo
un
d
72
3.0
2.0
1 .0
inC\J 0
1.2 2.80.4 2.0sp6s
Somatostatin ng/ml
F ig .12 Comparison of an equilibrium  ( • - • )  and disequilibrium  (o-o) 
Somatostatin assay.
disequilibrium  assay. However, the equilibrium  assay gave adequate 
s e n s itiv ity  (0.04 ng/ml) fo r the purpose o f this study (Fig. 12) and 
th is was adopted throughout.
Comparison of two separation systems
Two separation systems were assessed - one using dextran-coated charcoal, 
the other using Second Antibody and polyethylene glycol (F ig . 13).
Assay s e n s itiv ity  was comparable in both systems, (0.04 ng/m l), and the 
charcoal system was adopted for the assay.
Precision and Reproducibility
The in tra - and interassay reproducib ility  expressed as a co e ffic ie n t o f 
variation for the qu ality  control pools was 7% (n=9) and 15% (n=10) 
respectively.
Discussion
We have been able to adapt the highly sensitive human plasma somatostatin 
assay (Penman et a l , 1979) fo r the determination of somatostatin and 
SLI levels in ra t issue extracts. Using a highly purified  tracer pre­
paration and a specific antiserum, R9, an equilibrium assay was validated  
with a l im it  of s e n s itiv ity  of 60 pg/ml.
Recently, the iso lation and structure of a larger form of immunoreactive 
somatostatin, S28, have been reported by several workers. This octacosa- 
peptide has been isolated from porcine upper small in testine  (Pradayrol 
et a l , 1980), porcine hypothalamus (Schally e t a l , 1980) and ra t hypo­
thalamus (Wu et a l , 1982). I t  has been shown to possess high somatotrophin
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somatostatin radioimmunoassay.
(growth hormone) and prolactin re lease-in h ib iting  a c tiv ity  in v itro  
(Schally e t a l , 1980) and as e ffec tive  as S14 in in h ib itin g  the gastric  
and pancreatic exocrine and endocrine responses to cephalic vagal stim­
ulation (Konturek e t a l , 1982). This octacosa-peptide is most lik e ly  
to be a precursor (pro-hormone) of somatostatin-14. The antibody, R9, 
used in th is study reacts on an equimolar basis with S28 and S I4 
(Wu et a l , 1982).
2 .2 .5  High Pressure Liquid Chromatography (HPLC)
High Pressure Liquid Chromatography (HPLC) is now used extensively  
both in research and c lin ic a l chemistry laboratories . (See reviews by 
Dixon e t a l , 1976; Lim, 1979; Scott, 1972). Dense column packings give 
high resolution, high pressure metering systems maintain reproducible 
solvent flow, and on-line detectors monitor the elution o f solutes and 
measure them, usually non-destructively so that they can be collected  
fo r fu rther investigations. The technique is v e rs a tile , rapid and 
reproducible; and the inherent need in gas-liquid chromatography (GLC) 
of transformation into a v o la tile  derivative without decomposition is 
replaced by s o lu b ility  in a liqu id  mobile phase. These characteristics  
explain its  growing applications in d iffe re n t f ie ld s .
Whilst the HPLC analyses of drugs, nucleic acids, nucleotides, porphyrins, 
b ile  pigments, steroids and catecholamines are now routinely carried out, 
the application of HPLC to polypeptide hormones is s t i l l  in i t  develop­
ment stage. This has been lim ited by the in s ta b ility  of the ion-exchange 
and molecular-sieve-gel support materials under pressure (
Monch & Dehnen, 1978). Recently however, HPLC methods capable of
resolving a wide range of polypeptides and some proteins have been 
described, (O'Hare & Nice, 1979; Nice & O'Hare, 1979; Nice e t a l , 1979; 
Frei e t a l , 1976; Radhakrishnan et a l , 1977; Monch & Dehnen, 1977).
This is based on the use of reversed-phase packings, pioneered in this  
role by R iv ier (1976) , and depends on the hydrophobic interactions
(Molnar & Horvath, 1977) and a gradient elution system (Monch & Dehnen, 
1978) to achieve separations.
Under optimal conditions, a large number of polypeptides can be simul­
taneously resolved with retention of biological a c tiv ity  by larger  
molecules such as ACTH-j^g (O'Hare & Nice, 1979). S im ilar methods have 
also been used in the iso la tion  of some smaller peptides (Ling e t a l , 
1976; Dunlap e t a l , 1978), the analysis o f polypep­
tide hormone degradation in vivo (Bennett e t a l , 1977; McMartin &[Purdonl 
1978), and in v itro  (Seidah et a l , 1979), peptide mapping o f protein  
digests (McMillan et a l , 1979) p u rifica tio n  of
synthesised polypeptides ( Hancock e t a l , 1976; Larsen e t a l ,
1978; Knox & Szokan, 1979) and analysis of pharmaceutical peptide pre­
parations (Krumen & F re i, 1977).
Small peptides are easily  separable by reverse-phase chromatography 
using e ith er aceto n itrile -w ater or methanol-water as the eluents (Hansen 
e t a l , 1977; Hancock et a l , 1976), while polypeptides usually require  
the presence of a buffer or surfactant fo r satis factory  resolution  
(Krumen & F re i, 1977; Molnar & Horvath, 1977). Monch and Dehnen (1977,
1978) developed a gradient system for the separation of polypeptides and
proteins of molecular weight 450,000 on an ODS column using 0.05 M 
KH2P04 -2-methoxyethanol (95 .5 , pH 2) as the elution mixtures. The 
separation of eight proteins, including in su lin , were demonstrated.
New polar bonded phases, the glycophases, which have a combination of 
high permeability and mechanical r ig id ity  have been developed and 
shown to be useful fo r the separation of high molecular weight proteins 
(Regrier & Noel, 1976; Chaing et a l , 1976).
More recently , HPLC has also been applied to the gut hormones including  
gastrin 17 & 34, Bombesin 14 (Dimaline & Reeve, 1982), plasma CCK 4 ,
8 , 12, 33 & 39 (Maton et a l , 1982), Oxyntomodulin (B a ta ille  e t a l , 1981) 
and somatostatin 14 & 28 (Wu et a l , 1982; Pradayrol e t a l , 1980;
Schally e t a l , 1980).
The HPLC technique coupled to radioimmunoassay, was applied to extracts  
from the ra t is le t -c e ll  tumour in an attempt to iso la te  and id e n tify  the 
molecular species o f in su lin , glucagon and somatostatin. The HPLC work 
was carried out in collaboration with Dr. C. K. Lim at the Division of 
C lin ica l Chemistry, C lin ica l Research Centre, Harrow, Middlesex.
Materials and Methods
An HPLC system consists of a reservoir (or reservoirs fo r  gradient e lu tion ) 
a f i l t e r ,  a high pressure pump, a column with an in jection  u n it through 
which samples are injected into the top of the column, and a suitable  
detector. For the present study, fractions were collected fo r  RIA 
analyses.
High-resolution chromatography of samples and standards was carried  
out on a 250 mm x 5 mm I.D . stainless-steel column slurry-packed in 
the laboratory with Hypersil-ODS (oc tadecyls ily l) spherical porous 
(100ft) microparticulate (5 jjm) chemically-bonded s i l ic a  packings 
(Shandon Southern, Runcorn, Great B r i ta in ) .  The characteristics of 
these materials have been described by Knox and Pryde (1975). The 
chromatograph used was a Varian 500 (Varian, Walnut Creek, C a lifo rn ia ,
USA), with a programmable gradient module, operated at constant pressure 
(92 atmospheres) and a constant flow of 1 ml/min. Samples were loaded 
via a septum!ess valve f i t te d  with a 1 ml in jection loop. The lin ear  
gradient used was established from two solvents (A and B). Solvent A 
consisted of 0.1 M phosphate buffer, pH 2 .5 , and Solvent B of A ce to n itr i le .  
The in i t i a l  concentration of the gradient was 80% of Solvent A with 20% 
of Solvent B; the fina l concentration was 50% of each solvent. Eluted 
compounds were detected by sequential UV-absorbance at 215 nm (Varian 
Californ ia) and radioimmunoassay. Detection lim its  of th is  HPLC system 
for polypeptides was around 40 ng (Dr. Lim, personal communication).
2 .2 .6  Immunocytochemistry 
Introduction
Immunocytochemical methods with th e ir  a b i l i t y  to stain a wide range of  
ce llu la r  substances including hormones, oncofetal antigens and globulins 
in fixed tissue sections, are proving to be an important tool in research 
and histopathology. The localisation of such substances may be o f value 
in diagnosis (Heyderman e t  a l , 1979; Huang, 1975; Blenkinsopp & Haffenden, 
1977), in suggesting a possible primary s ite  fo r  tumour presenting with 
metastatic disease, in prognosis, and in suggesting the most suitable  
circulating marker to use for individual patient monitoring (Heyderman, 
1979a).
By fa r  the technique of choice a t the present time is the immunoperoxi- 
dase technique due to the permanence of the reaction product together 
with the f a c i l i t y  for simultaneous pathological diagnosis (De Lei 1is 
et a l , 1979). This technique is based on the concept of localis ing  
the very stable enzyme, horseraddish peroxidase to the s ite  of antigen- 
antibody reaction, and the v isualisation of these sites through the 
peroxidase acting on a suitable substrate, the most widely used being 
diami nobenzidine. In the presence of peroxidase and hydrogen peroxide, 
the diami nobenzidine is polymerised to form an insoluble brown polymer 
which is deposited at the s ite  of antigen-antibody reaction.
Various modifications of th is  technique have been reported in the l i t e r ­
ature, and these include the:
( i )  D irect Method
( i i )  Ind irect (sandwich) method (Nakane & Kawaio, 1974)
( i i i )  PAP (unlabelled antibody) method (Sternberger e t a l , 1970)
( iv )  Enzyme bridge ( t r ip le  sandwich) method (Mason e t a l , 1969)
(v) Labelled antigen method (Mason & Sammons, 1979)
( v i i )  Alkaline Phosphatase methods (Mason & Sammons, 1978)
For a review and re la t iv e  merit of these methods see Heyderman (1979b). 
Methodology
For this study, the In d irec t Method as schematized in Fig. 14 was used. 
The f i r s t  antibody which is not labelled with enzyme, is directed against 
the endogenous antigen. The second antibody, which is directed against
the immunoglobulin of the species in which the f i r s t  antibody is raised 
is conjugated to peroxidase (Nakane & Kawaio, 1974). Excellent results 
in terms of sens it iv ity  and s p e c if ic ity  have been reported using the 
Indirect Method compared with the other methods (Heyderman, 1979b; 
Heyderman & N ev ille , 1977).
Insoluble brown polymer
t
DAB
t
RPO
Sheep 
A nti-rabbitZMZ
Rabbi t  
Anti-Anti gen X
Antigen X
Fig (14) Schematic representation of the Indirect (Sandwich) Method 
of Immunoperoxidase staining.
DAB = Diami nobenzidine 
HRPO = Horseraddish peroxidase
Preparation of tissue sections:
Normal wistar albino ra t pancreas, normal NEDH ra t  pancreas, NEDH 
insulinomas and insulinoma ra t 's  own pancreas were fixed in Bouin's 
solution overnight, and fixed in d e fin ite ly  in 75% alcohol u n ti l  they 
were embedded in paraffin wax. Glycerin albumin (Raymond Lamb, U.K.) 
was used as adhesive to minimise l i f t in g  and subsequent loss of tissue
sections. The slides were dried slowly in a 56°C oven overnight.
Anti sera:
a) Primary anti sera: The following primary anti sera were obtained 
from Guildhay, Biochemistry Department, Surrey University.
Rabbit anti-porcine glucagon (MF/R/4-LB)
Guinea pig anti-porcine insulin (MF/GP/4-IIIA)
Rabbit anti-bovine pancreatic polypeptide (GR/39-PD)
Rabbit anti-synthetic cyclic somatostatin (GR/57-PB)
b) Secondary anti sera: The following secondary anti sera conjugates 
were used.
Peroxidase conjugated goat an ti-ra b b it  IgG (Dr. Heyderman, St. Thomas' 
Hospital, London)
Peroxidase conjugated goat anti-guinea pig IgG (Miles Laboratories, U.K.) 
Immunoperoxidase Staining (Heyderman, 1979b):
1) The slides were prepared for staining by dewaxing through 3 changes 
of xylene and 3 changes of alcohol to tap water.
2) Acid haematin was bleached with 6.0% H2O2 in d is t i l le d  water for  
5 minutes and subsequently washed in 3 changes of tap water.
3) Endogenous peroxidase was inhibited with solution of 2.5% periodic  
acid in d is t i l le d  water (5 minutes) and again washed in 3 changes of 
tap water.
4) Aldehyde groups were blocked with 0.02% potassium borohydride in 
d is t i l le d  water (2 minutes) and washed with 2 changes of tap water and 
one of phosphate buffered saline (PBS), pH 7 .2 , containing 0.02% sodium 
azide.
5) After drying with b lotting paper, the slides were incubated for
s t30 minutes in a moist chamber with 100 jj! of the 1 antibody diluted
in 1 % ovalbumin PBS. The slides were then washed with PBS.
6 ) The next step involved a 15 minute agitation in a PBS bath con­
taining a few drops of detergent (1 % BRIJ 96 , Sigma)
7) The slides were then dried with b lotting paper and incubated for
n  j
30 minutes in a moist chamber with 100 jjl of the 2 antibody ( in d ire c t
conjugate) diluted in 1% ovalbumin in PBS. At the end of the incubation,
the slides were washed with PBS.
8 ) A 15 minute agitation in a PBS bath containing a few drops of 1%
BRIJ 96detergent, was carried out.
9) The slides were then incubated in diaminobenzidine (DAB), (10 mg
DAB freshly dissolved in 10 mis 0.03% H^ O^  in PBS). DAB is thought to
be carcinogenic and should therefore be handled in a fume cupboard. At 
the end of 5 minutes, the slides were washed with tap water.
10) Counterstaining in Mayer's haemal urn (4 minutes) was carried out, 
rinsed in tap water, blue in lithium carbonate (1 minute), f in a l rinse
in running tap water and prepared for mounting in XAM (GURR) or Permount 
(Fisher).
Absorption Controls by A f f in ity  Chromatography
Heyderman (1979b) has argued strongly for appropriate controls to be 
carried out with immunocytochemical techniques in order to confirm the 
spec if ic ity  of the staining. The abolition of positive staining a f te r  
absorption of the antibody with the antigen under test is the most use­
ful s p e c if ic ity  control. The inadequacy of other types of controls have 
also been discussed (Heyderman, 1976b).
With this in view, we sought to prepare absorption controls of the 
s tvarious 1 anti sera by a f f in i t y  chromatography with A ff ige l-10  
(Bio-Rad Labs.).
Materials and Methods
All equipment and reagents were l e f t  overnight at 4°C and the entire  
procedure carried out in the cold room. The required volume of 
A ffige l-10  (Bio-Rad Labs., Richmond, C a lifo rn ia , USA) gel was trans­
ferred to a buchner funnel and washed with 3 bed volumes of cold iso­
propanol (reagent grade) followed by 3 bed volumes of cold deionised 
water. The wash was fa c i l i ta te d  by applying a vacuum, care being taken 
not to allow the gel bed to go dry. For optimum coupling of ligands 
i t  is recommended that this washing procedure should be completed and 
the gel combined with the ligand solution within 20 minutes. Substan­
t ia l  loss of N-hydroxysuccinimide groups from the gel can occur upon 
prolonged washing of the gel with aqueous buffers, or storage of the 
washed gel cake at room temperature prio r to combination with ligand  
solution.
The moist gel cake was then transferred to a test-tube , and the cold 
ligand solution added. A minimum volume of 0.5 ml of ligand per m i l l i ­
l i t r e  of gel is recommended. For in su lin , 3 mg of peptide was dissolved 
in 1.5 mis of 0.1 M NaHCOg, pH 8.0 and this was added to 3 mis o f A ffige l  
The tube was agitated to ensure a uniform suspension is formed.
Gentle agitation of the gel slurry was continued for 4 hours at 4°C on 
a rocker. Unreacted sites were then blocked by adding 0.1 ml 1 M glycine
pH 8.0 per m i l l i l i t r e  of gel. Rocking was continued for a further  
hour to allow completion of the blocking reaction. The gel was then 
transferred to a column (0.5 x 15 cm) and washed with 0.1 M NaHCOg, 
pH 8.0 until the gel is free of reactants as detected by ODggQ. The 
column was subsequently washed with PBS, pH 7.2 containing 0.02% 
sodium azide and is now ready for loading. When not in use, i t  was 
stored at 4°C.
50 jjI of the anti serum was loaded onto the column a f te r  a stable base 
l ine  had been established by running PBS through the column. The c lip  
was closed, and binding of anti serum to the A ff ig e l- l in k ed  antigen 
allowed to take place for 30 minutes. The column was then eluted with 
PBS. This is the absorption control fraction (Peak A) with the a n t i-  
serum stripped of i ts  a c t iv i ty ,  Fig. (15).
To obtain the a f f in i ty -p u r i f ie d  immunoglobulins(Ig)the column was eluted 
with 3 M Guanidine HC1, pH 3.0 (10 ml wash) and O.IMNH^OH, pH 10.5 
(10 mis wash). A PBS wash was carried out in between these elutions.
The Guanidine and NH^ OH eluted fractions were dialysed against PBS for  
2 hours at room temperature to prevent degradation of the Ig 's  by the 
guanidine and NH^ OH, and to clean up the fractions for immunoperoxidase 
staining. These dialysed fractions were then re-loaded onto the column 
and eluted with 10 mis NH^ OH followed by a PBS wash. These NH^ OH 
fractions were again dialysed before testing fo r immunoperoxidase staining.
Results and Discussion
No immunoperoxidase staining was found with the insulin absorption con­
tro l fraction (Peak A) at a 1:2 d ilu tion  in 2% ovalbumin. This would
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suggest that the Guildhay MF/GP/4-IIIA a n ti- in s u lin  was directed spec­
i f i c a l l y  against insu lin . However, attempts at e luting o f f  the a f f in i t y -  
bound insulin Ig 's  using 3 M Guanidine HC1, pH 3 .0 , and 0.1 M NH^OH, 
pH 10.5, were unsuccessful as indicated by negative immunoperoxidase 
staining. Further attempts at eluting o f f  the purified  insulin Ig 's  
using Glycine-HCl, pH 2.0; 3.5 M potassium thiocynate (KSCN), pH 7.6;  
and 2%  Human Serum Albumin (HSA) pH 2 .0 , were also unsuccessful. The 
reasons for this are unclear but may be related to the fact that the 
insulin antibodies were raised in guinea-pigs and had a high av id ity .  
Similar problems have also been encountered by other workers (Heyderman, 
personal communication).
A f f in i ty  purified glucagon Ig 's  (MF/R/4-LB) have however been success­
fu l ly  prepared for use in this study. A s im ilar a f f in i t y  chromatography 
column was prepared for glucagon on A ff ig e l-1 0 , and the column eluted 
with PBS to obtain the negative absorption control. To obtain the 
purified Ig 's ,  the column was eluted with 200 ml of 2% HSA,pH to 2.5  
with 1 M HC1 into a beaker with a magnetic s t i r r e r ,  containing 50 ml 
1 M Tris-HCl, pH 7 .6 . Damage to the immunoglobulins due to the acid 
is reduced by bringing the pH back to clear physiological immediately. 
Dialysis was then carried out against 4 changes of PBS. A fter freeze- 
drying and reconstituting with PBS, the presence of a f f in i ty  purified  
glucagon Ig 's were demonstrated by radioimmunoassay and immunocytochemistry.
Negative absorption controls have s im ila r ly  been obtained for somatostatin 
antibodies (GR/57-PB), although a f f in i t y  purified somatostatin Ig 's  have 
not been prepared.
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Positive Controls
I t  is useful to have a " library" of normal and neoplastic tissues to 
use as both positive and negative controls, and to establish differences 
in anti sera by v irtue of differences in staining. Once the presence of 
an antigen in a tissue had been established using appropriate absorption 
controls, a section of the known prositive tissue was included in each 
batch of slides to ensure that absence of positive staining was not due 
to fau lty  technique. The following positive controls were used: Human 
nesidioblastosis, glucagonoma and somatostatinoma.
2.3 Results
Body weight and food consumption
The insulinoma rats consumed s ig n if ic a n tly  more food than the controls 
from day 15 post-transplant onwards. However, no s ign if ican t weight 
difference was found between them throughout the period of study (Fig 16), 
although tota l weight gain was s ig n if ic an tly  greater in the insulinoma 
bearing rats (Table 1).
Plasma glucose, insulin and glucagon levels
No s ign ificant difference between the plasma glucose concentrations of 
insulinoma and control rats were observed until day 10 post-transplant. 
Glucose levels were s ig n if ican tly  lower (p<0 .001) in the insulinoma 
rats 10, 17, 20 and 22-24 days post-transplant (Fig 1 6 ) .  This decrease 
was accompanied by an increase in plasma insulin concentration of 165% 
on day 17 ( p < 0 .01) and 973% on days 22-24 (p< 0 .001)(Fig 16). No sig­
n if ican t changes were detected in the plasma glucagon levels in both 
groups over the period of study (Fig 16a)-
plasma glucose and insulin of recipient rats ( • )  and control ra ts (o ) .  
Mean values + S.E.M.(n=9)- T
35(1
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F ig . l6 (continued)
Effect of transplantable insulinoma on plasma 
glucagon in recipient rats ( • )  and control ra ts (o ) .  
Results are Mean + SEM(n=9)
Survival Time 
since
transplant
(Days)
Tumour
weiqht
(g)
Gain
in
body
wt(o)
Plasma 
insulin  
(ng/ml)
Plasma
glucose
(mmol/L)
Molar 
insulin:  
glucose 
r a t io (x l0 )
Insulinoma 24 2.1 84 36* 0.84 0.72*
rats + 1 + 0.4 t  6 + 2 .8 +0.05 + 0.07
Control
rats
- - 67.7 
+ 4.2
2.7 
+ 0.2
5.0
+0.3
0.06
+0.003
t-values,p <0.05 < 0.001 < 0.001 < 0.001
Table 1 Characteristics of control and insulinoma-bearing r a ts ,22-24 days 
a fte r  transplantation. Values are Mean + SEM(n=9). *  indicates 
positive correlation (p< 0.05) with tumour weight.
Survival Time and Tumour Weight
The average survival time was 24 + 1 days (range 22-28 days) with a 
mean tumour weight of 2.1 + 0.4 g. No correlation was found between 
tumour size and survival time, although positive correlations were 
found between tumour size and the f in a l plasma insulin concentration 
and the insulin-glucose molar ra tio  (Table 1).
Tissue distribution of in su lin , glucagon and somatostatin 
Analysis of the acid-ethanol extract of the various tissues for immuno- 
re a c t iv ity  insulin ( IR I ) ,  glucagon-like immunoreactivity (GLI) and 
somatostatin-like immunoreactivity (SLI) were carried out and th e ir  
results summarised in Tables, 2, 3, 4.
Tumour extracts were shown to contain large amounts of IR I ,  124 + 21 U/g 
tissue, whereas IRI was undetectable in the stomach, duodenum, jejunum, 
ileum, colon, kidney and hypothalamus (Table 2 ) .  A mean insulin con­
centration of 1.6 U/g tissue was found in the pancreas of control rats. 
In the insulinoma bearing ra ts , this was found to be 20-fold lower,
0.08 U/g tissue (p< 0.001). Parallelism between the tumour extract and 
ra t  insulin standard was also demonstrated (Fig 17).
Glucagon-like immunoreactivities (GLI1s) were undetectable in extracts 
from tumour, stomach, kidney and hypothalamus using the N-terminal 
reacting antiserum, GPC1/2 for "Total GLI1s (Table 3 ). The absence of 
GLI in the tumour extract was further confirmed using the C-terminal 
reactive antiserum, MF/R/4-LB for "Pancreatic glucagon". High levels 
of GLI were found in the ileum of both control and insulinoma ra ts ,
Immunoreactive in s u lin ( IR I)  
Units/g tissue
Control Rats 
Mean + SEM
Insulinoma Rats 
Mean + SEM
Significance 
t-value j
Tumour 124 + 21
I
iti
Pancreas 1.6 + 0.4 • 0.08 + 0.02
1
p<o. ooi i
i
Stomach n.d.
■
n.d. 1
Duodenum n.d. n.d.
Jejunum n.d. n.d.
Ileum n.d. ■ n.d.
Colon n.d. n.d.
Ki dney n.d. n.d.
Hypothalamus n.d. n.d.
Table 2 Tissue distribution of Immunoreactive in su lin ( IR I)  in
control and insulinoma rats . Results are Mean + SEM(n=12).
n.d.= not detectable^ Less than 0.04 Units/g tissue)
+1.0 r
j( Less than 0.04 nits/g tissue
+0.5
-0 .5
543I 2
Log (Insu lin  concentration)
F ig .17 Demonstration of parallelism of insulinoma extract(o) and ra t  insulin  
standard(«),using lo g it / lo g  p lo t. Z=B/B where B=% bound corrected for  
non-specific binding. Values on x-axis apply to the standard only.
Glucagon-like immunoreactivity 
ng/g tissue
Control Rats 
Mean + SEM
Insulinoma Rats 
Mean + SEM
Significance
t-value
Tumour - n.d.
Pancreas 5030 +1100 1000 + 320 p<0.05
Stomach n.d. n.d.
Duodenum 31 + 10 24 + 6 N.S.
i
Ileum 420 + 106 471 + 207 N.S.
Kidney n.d. n.d.
Hypothalamus n.d. n.d.
Table 3 Tissue distribution of Glucagon-like immunoreactivities
(GLI) in control and insulinoma rats. Results are Mean + SEM 
(n=12). n.d.= not detectable ; N.S.= not s ign if ican t.
(n.d.= not detectable. Less than 0.3 ng/g tissue)
mean values of 420 and 471 ng/g tissue respectively. Like insu lin ,  
pancreatic glucagon concentration was found to be s ign if ican tly  lower 
in the insulinoma rats (mean = 1.0  |ig/g tissue) than in control rats 
(mean = 5.0 jjg/g t issue).
The presence of somatostatin-like immunoreactivity (SLI) in the tumour 
extract was demonstrated (5.2 + 0.6 ng/g tissue). No s ign ificant d i f f ­
erence in the SLI concentrations of the stomach, duodenum, jejunum, 
colon, kidney and hypothalamus were found between the two groups(Table 4 ) .  
Parallelism between the tumour extract and synthetic cyclic somatostatin-14 
standard was also demonstrated (Fig 18 ) .
Immunocytochemical Staining
The results of the immunoperoxidase staining are summarised in Table 5, 
and shown in Figs. 19, 20, 21, 22.
Host Control Positive
Tumour Pancreas Pancreas Control
Insulin + + + +
Glucagon - + + +
Somatostatin + + + +
Table 5 Summary of the immunoperoxidase staining for in su lin , glucagon 
and somatostatin (+ = positive stain; -  = negative s ta in ) .
The presence of insulin and somatostatin, and the absence of glucagon 
in the tumour were confirmed by the Indirect (sandwich) immunoperoxidase 
technique (Fig. 19). Uneven staining, characteristic  of tumours, was 
observed. This was due to the presence of cells at various stages of
Somatostatin-like immunoreactivity 
ng/g tissue
Control Rats Insulinoma Rats Significance
Mean + SEM Mean + SEM . t-value
Tumour - 5.2 + 0.6
Pancreas 20.0 + 5 8.4 + 1.7 p<0.01
Stomach 36 + 6 3 7 + 7 . 0 NS
Duodenum 10.5 + 1.7 9.4 + 1.6 NS
Jejunum 6.5 + 1 8.1 + 1 .0 NS
Colon 9.8 + 1.5 . 13 + 2.7 NS
Ki dney 0 .8  + 0 .2 0.9 + 0 .1 NS
Hypothalamus 194 + 20 217 + 32 NS
Table 4 Tissue distribution of Somatostatin-like immunoreactivity(SLI) 
in control and insulinoma rats. Results are Mean + SEM(n=12). 
NS= not s ign ificant.
+1
0
M
2
I 2 3 4
Log (Somatostatin concentration)
F ig .18 Demonstration of parallelism of is le t  ce ll tumour 
extract (o  ) and somatostatin standard ( •  ) using 
lo g it / lo g  p lot. Z=B^ BQ where B- %  bound corrected for  
non-specific binding. The values on the x-axis apply to 
the standard only.
F ig .1 9 a  Rat t r a n s p l a n t a b l e  in s u l in o m a .  S ta ined  p o s i t i v e  f o r  
i n s u l i n . ( x l 00 m a g n i f i c a t i o n )
F ig .19b  Rat t r a n s p l a n t a b l e  in s u l in o m a .  S ta ined  neg a t i ve  f o r  
p a n c r e a t i c  g lucago n . ( x l 00 m a g n i f i c a t i o n )
yo
F ig .1 9 c  Rat t r a n s p l a n t a b l e  in s u l in o m a .  S ta ined  p o s i t i v e  f o r  
s o m a t o s t a t i n . ( x l 00 m a g n i f i c a t i o n )
F ig .20a  Host  pancreas o f  i n s u l i n o m a - b e a r in g  r a t s .  S ta ined  
p o s i t i v e  f o r  i n s u l i n . ( x l 00 m a g n i f i c a t i o n )
F ig .20b  Host  pancreas o f  i n s u l i n o m a - b e a r in g  r a t s .  S ta ined
p o s i t i v e  f o r  p a n c re a t i c  g l u c a g o n . ( x l 00 m a g n i f i c a t i o n )
F ig .20c  Host pancreas o f  i n s u l i n o m a - b e a r in g  r a t . S t a i n e d  p o s i t i v e  
f o r  s o m a to s ta t i n . ( x lO O  m a g n i f i c a t i o n )
Fig .21a  Con tro l  NEDH r a t  pancreas.  S ta ined  p o s i t i v e  f o r  i n s u l i n .  
(xlOO m a g n i f i c a t i o n )
F i g .21b Con tro l  NEDH r a t  pancreas.  S ta in ed  p o s i t i v e  f o r  
p a n c re a t i c  g lucago n . ( x l 00 m a g n i f i c a t i o n )
J J
t
Fi g.21c Con t ro l  NEDH r a t  pancreas.  S ta in e d  p o s i t i v e  f o r  
s o m a to s ta t i n . ( x lO O  m a g n i f i c a t i o n )
F ig .22a  Human n e s i d i o b l a s t o s i s .  P o s i t i v e  c o n t r o l  f o r  i n s u l i n .  
(xlOO m a g n i f i c a t i o n )
100
F ig .22b  Human glucagonoma. P o s i t i v e  c o n t r o l  f o r  g lucagon.  
(xlOO m a g n i f i c a t i o n )
F ig .22c  Human som a to s ta t ino m a . P o s i t i v e  c o n t r o l  f o r  
s o m a to s ta t i n . ( x 4 0 0  m a g n i f i c a t i o n )
necrosis, or mitotic division. Pancreases of normal NEDH rats when 
stained showed that B-cells were located mainly in the centre of the 
is le ts ,  whilst A and D-cells occurred mainly in the periphery (Fig. 21). 
Pancreases of insulinoma bearing rats (host pancreases) showed the 
presence of B, A and D-cells . The sizes of these is le ts  ranged from 
the very large to very small, and without accurate measurements of the 
i s le t  surface areas, no firm conclusions about is le t  atrophy can be 
made. However atrophy is suggested by the s ign if ican t decrease in the
?
number of is le ts  observed in the host pancreases (mean = 32 islets/100mm )
2compared with a mean of 70 islet/100mm in control pancreases. In 
addition, is le ts  of host pancreases, which are normally compact, ovoid 
bodies, were found to be vacuolated (Fig. 20).
Results of the positive controls for in su lin , glucagon and somatostatin 
are shown in Fig. 22. Positive stainings for insulin were indicated in 
the human nesidioblastosis. The characteristic  ribbon-like strands of 
cells and dense vacuolation were observed in these is le ts .  A human 
glucagonoma and a human somatostatinoma were stained positive ly  for glu­
cagon and somatostatin respectively.
HPLC and RIA Analyses
Chromatographic separation of three standards were performed -  Rat 
insulin (Novo Research In s t i tu te ,  Copenhagen), synthetic cyclic somat­
ostatin -! 4 (Bachem In c . ,  C a lifo rn ia , USA), and porcine glucagon (MRC, 
National In s t i tu te  for Biological Standards and Controls, London)
(Figs. 23, 24, 25). Two main peaks were observed for the Rat insulin  
standard (50 ng) with retention times (R^  ) of 12.5 and 17.5 mins (Fig. 23).
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Area of peak B (R^ .= 17.5 min) was approximately 50% that of Peak A.
A single peak was found for the synthetic cyclic somatostatin (50 ng) 
with a retention time of 21 min (Fig. 24). The MRC procine glucagon on 
HPLC gave a rather broad peak with a large shoulder (R^= 8 min) and a 
second small broad peak with a retention time of 9 min (Fig. 25).
Porcine glucagon from Sigma Chemical Co., (St. Louis, USA) contained 
even more contaminants as indicated by the 5 peaks on HPLC analyses 
(Results not shown). These profiles  were a l l  confirmed by radioimmuno­
assay.
HPLC p ro f i le  of the insulinoma extract consisted of numerous small peaks 
with a major component between R^ = 19-22 min (Fig. 26). Radioimmuno­
assays of these fractions confirmed the absence of glucagon in the tumour, 
but showed the presence of a single somatostatin peak with a retention 
time of 21 min (Fig 27), corresponding to that of the synthetic cyclic  
somatostatin-14 standard. No other molecular forms of somatostatin were 
found.
The two ra t insulin peaks, with expected retention times of 12.5 and 
17.5 mins, were not observed in the insulinoma extract a f te r  RIA analysis 
of the HPLC fractions. Instead the IRI components were located between 
R ^ =  19-30 min. Seven peaks can be d iffe ren tia ted  with R^ . of 19.5, 21,
23, 24, 25.5, 27 and 28.5 min (Fig. 28). In the absence e ither of a ra t  
proinsulin assay or ra t  proinsulin standards, i t  has not been possible 
to elucidate the nature of each peak. In terestingly  the major IRI peak 
with a R^  of 21 min coincides with the somatostatin peak.
Further attempts at separating the IRI components of the ra t  insulinoma
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were carried out on gel f i l t r a t io n  column chromatography. Acid-ethanol 
extract of the tumour was applied to a 1.5 cm x 4.2 cm Bio Gel P-30 column 
(Bio-Rad Labs., California) and eluted with 1 M acetic acid pH 2 .5 ,  
Rubenstein et a l , 1977; Melani e t  a l , 1970; Perez-Castillo & Blazquez,
1980). 1 ml fractions were collected and aliquots assayed in an insulin
radioimmunoassay and measured against a ra t  insulin standard. The void 
volume was determined by the elution position of blue dextran 2000
(Sigma Chemical Co., St. Louis, USA) and the column calibrated with
125 125I- in s u lin  and I-glucagon. Several peaks with insulin immunoreact-
125iv i ty  were obtained (Fig. 29). A peak eluting with the I - in s u lin  
marker suggests the presence of an IRI component comparable in molecular 
weight to normal insulin . The exact id en tit ies  of the early eluting  
peaks are not known, but probably represents pro insu lin -like  components
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2 .4  Discussion
Although sign ificant advances have been made during the past decade 
in the diagnosis, treatment and management of patients with is le t  
B-cell tumours (Frerichs & Creutzfe ldt, 1976; Marks & Rose, 1981), 
much remains to be learnt about the basic nature of the defect and the 
general effects of insulin-secreting tumours (insulinomas) on metabolism. 
To answer these questions, attention has been given to the development 
of an animal model suitable for more detailed and thorough investigation  
(Baba e t a l , 1979; Creutzfeldt e t a l , 1980). Various approaches have 
been used for tumour induction ranging from the administration o f chem­
icals to the exposure to ionising radiations. Despite the low success 
rate , various is le t  cell tumours with widely d iffe ren t characteristics  
have been induced (Baba et a l , 1979; Creutzfeldt et a l , 1980). However, 
few of them have been found to be suitable for propagation by serial 
transplantation (Check et a l , 1980).
The insulinoma line  used in the present study was induced by x-ray  
irrad ia tion  (Chick et a l , 1977) and is s e r ia l ly  transplantable. Since 
i ts  development i t  has been,used as a convenient a lternative  source of 
tissues to normal is le ts  of Langerhans for studies on the metabolism of 
the pancreatic B-cell (Duguid et a l , 1976; Gazdar et a l , 1980; Eisenbarth 
et a l , 1981; Sopwith et a l , 1981).
Characteristics of tumour pro life ra tion
Small fragments of mature tumour from donor insulinoma-bearing rats when 
implanted subcutaneously into the subscapular region of pre-adult, male 
NEDH rats resulted in hyperphagia, increased weight gain,progressive 
hyper-insulinaemia and death from hypoglycaemia a fte r  22-28 days. The
survival time was markedly shorter than that reported by Chick et a l ,
(1977) who found that rats receiving 7th generation tumours became 
moribund between 2 to 4 months. This possibly reflects  a trend towards 
enhanced tumour growth rate and/or increased functional a c t iv ity  of the 
tumour B-cells . Tumours became palpable by 11-16 days and attained a 
f ina l mean weight of approximately 2.1 g.
In terestingly , the development o f hypoglycaemia (Day 10) preceded 
tumour pa lpab ility  (mean = Day 13), hyperphagia (Day 15) and the esta­
blishment of hyperinsulinaemia (Day 17). I t  seems l ik e ly  that the insu l­
inomas were secreting insulin at this early stage in amounts s u ff ic ien t  
to cause hypoglycaemia. Whether hypoglycaemia is the cause of increased 
food consumption is debatable. Feelings of hunger are provoked by 
insulin induced hypoglycaemia, both in normal and diabetic patients 
(Marks & Rose, 1981). Indeed, enhancement of appetite by hypoglycaemia 
has been used to explain the increase in weight which many maturity on­
set diabetics experience shortly before the appearance of overt signs 
of diabetes mellitus.
Plasma immunoreactive insulin ( IR I)  levels rose sharply a f te r  17 days 
and a 10-fold increase in mean c irculating concentrations (36.0 + 9.3 ng/ml) 
was attained by 22-24 days compared with control levels of 3.7 + 0.67 ng/ml. 
Mean glucose levels at this time was 7 times lower (0.84 + 0.05 mmol/L) 
than normal (5.51 + 0 . 1  mmol/L). Chick e t a l , (1977) reported plasma 
glucose and insulin concentrations of 3.5 + 0.4 mmol/L and 6.5 + 1.4 ng/ml 
respectively, prior to death in th e ir  animals; this corresponds to only 
two fold changes in the normal c ircu lating concentrations of both glucose 
and insulin.
Insulin-glucose molar ratios in peripheral blood plasma of insulinoma 
and control rats were 0.72 x 10 ® and 0.06 x 10”  ^ respectively. These 
values re f le c t  the hyperinsulinaemia and hypoglycaemia in the tumour- 
bearing animals.
The theory that glucagon is a counter-regulatory hormone to insulin in 
maintaining glucose homeostasis is widely accepted and has been summarised 
by Unger & Orci (1981). According to this theory, the primary role of 
glucagon is to "reverse" the hypoglycaemia e ffe c t  of insulin by stimu­
lating glycogenolysis and gluconeogenesis. The ambient glucose concen­
tration  is thought to be the dominant factor in the control of insulin  
and glucagon synthesis (Unger & Orci, 1976). The view is however d i f f ­
ic u l t  to reconcile with the data presented here. Plasma glucagon levels  
were not raised despite progressive and severe hyperinsulinaemia and 
hypoglycaemia. That hypoglycaemia is a powerful in h ib ito r  of endogenous 
insulin secretion is now beyond dispute (Samols, 1965; Shima et a l , 1978). 
But i t  is only a mild to moderate stimulator of pancreatic glucagon stim­
ulation. Hypoglycaemia seldom produces more than a 2-3 fold rise in 
plasma glucagon levels compared to the 50-fold rise in plasma growth 
hormone and adrenaline that i t  stimulates. In the insulinoma-bearing 
ra ts , hypoglycaemia does not stimulate glucagon secretion in the pre­
sence of high c irculating insulin leve ls , suggesting that glucose con­
centration is not the only factor involved in the regulation of gluc­
agon secretion.
Tissue content of insu lin , glucagon and somatostatin
I t  is interesting that although plasma glucagon levels in the insulinoma
rats were sim ilar to control leve ls , pancreatic extracts from insulinoma
rats contained s ig n if ican tly  less glucagon (mean = 1.0 jjg/g tissue) 
than; extracts from controls (mean = 5.0 jjg/g tissue). This 80% decrease 
in glucagon content and the 50% reduction in the total number of is le ts  
suggest a reduction in the number of A-cells in the host pancreatic 
islets.These data are consistent with the concept of a negative feed­
back control by insulin on glucagon secretion (Samols et a l , 1972;
Marks, 1980); whilst glucagon stimulates insulin secretion by the B -ce lls ,  
insulin i t s e l f  inh ib its  glucagon secretion by the A -cells . The reduction 
in the pancreatic glucagon content associated with hyperinsulinaemia 
provides further evidence for th is .  I t  appears that the reduced number 
of A-cells are nevertheless capable of maintaining glucagon levels within  
the normal range.
In agreement with the original report by Chick e t a l , (1977) the present 
study has confirmed the presence of insulin and somatostatin but no 
detectable glucagon in the insulinoma by both radioimmunoassay and immuno- 
cytochemical stainings. Analysis of the acid-ethanol extracts of the 
tumour revealed high IRI content, 124 + 21 U/g tissue, comparable to 
that reported by Chick et a l , (1971) of 223 + 66 U/g tissue. No meta- 
stases were detected in any of the 8 tissues investigated.
However, the immunoreactive somatostatin content of the tumour 
(5 .2  + 0.6 ng/g) was s ign if ican tly  lower than that reported by Chick et a l , 
(1977) (25.9 + 4.2 }jg/g). This discrepancy can be explained e ither  by 
transformation of the insulinoma, or as appears more l ik e ly  by technical 
differences. Comparison of the published levels of somatostatin found 
in various ra t tissues, reveals some discrepancies. Mean concentrations 
of 340 ng/g tissue (Vale e t a l , 1976), 142 ng/g tissue (Arimura e t a l ,
1975) and 170 ng/g tissue (Patel & Reichlin, 1978) have been reported
for  ra t pancreatic extracts, whereas in the present study, a mean con­
centration of only 20 ng/g tissue was obtained. This is however,comp­
arable to that of 33 ng/g tissue reported by McIntosh e t a l , (1978). 
Sim ilarly  extracts of the stomach and duodenum gave values comparable 
to those reported by McIntosh e t a l , (1978) which are themselves 10-fold  
lower than those reported by Patel and Reichlin (1978), Arimura et a l ,
(1975)and Kronheim et a l , (1976). These d isparities  are l ik e ly  to be 
due to differences in extraction techniques, antibody characteristics  
and assay procedures. Furthermore, in the absence of an international 
standard for somatostatin, care is needed when comparing published results .
As well as glucagon, the pancreases of tumour-bearing rats also contained 
lower concentrations of insulin and somatostatin than those of normal 
rats. Although s ign ificant atrophy of the host's is le ts ,  including a 
reduction in the number and size of the B-cells has previously been 
reported (Appel et a l , 1979; Chick et a l , 1977), s im ilar observations 
have not yet been reported for A and D-cells . Atrophy of is le t  B-cells  
and the decreased number of cytoplasmic aldehydefuchsin-staining are 
features previously described in is le ts  of rats treated for prolonged 
periods of time with large quantities of exogenous insulin (Latta &
Harvey, 1942; Logothetopoulos et a l , 1964; Horowitz et a l , 1975)
Feedback of insulin on i ts  own secretion is s t i l l  a matter of disagree­
ment. Autoregulation of insulin secretion was o r ig in a lly  proposed by 
Frerichs et a l , (1965) and more recently by Ammon & Verspohl (1976) 
but the concept has been c r it ic ised  by Grodsky et a l , (1973) and Schatz
(1976). S im ilarly , negative feedback control by insulin on D-cells is
s t i l l  controversial. Hyperinsulinaemia was associated with decreased 
levels of plasma somatostatin in studies with rats and mice (Patel et a l , 
1978a). Weir et a l , (1979) however fa i le d  to lower somatostatin levels 
by exogenous insulin using an isolated perfused canine pancreas. The 
present study suggests that in the pathological situation produced by 
an insulinoma in the r a t ,  hyperinsulinaemia is associated with a reduction 
in the pancreatic content of insu lin , glucagon and somatostatin, and may 
be involved in the suppression of the B, A and D-cells resulting in 
th e ir  atrophy. I t  is conceivable that the release of somatostatin from 
the small number of D-cells within the tumour may also contribute to the 
suppression of the host pancreatic is le t  c e lls .  However the small amount 
of somatostatin (mean = 5 ng/g) compared with that of insulin (mean = 5 mg/g) 
in the tumour would suggest that i ts  suppression of i s le t  cells  is r e la t ­
ive ly  small.
The presence of B and D-cells but no A-cells in the ra t  insulinoma, as 
confirmed by radioimmunoassay and immunocytochemical stainings, suggest 
that i t  might be a suitable model for studying the paracrine in te r ­
relationships of B and D-cells in an A-cell free environment. No A-cell 
free model has so fa r  been reported, since no method has yet been found 
of selectively  destroying the A -ce lls . The absence of chemical agents 
capable of selectively blocking is le t  ce ll functions or, except in the 
case of B -ce lls , selectively  destroying them has meant that i t  has so 
fa r  been v ir tu a l ly  impossible to study B-cell function in isolation from 
A -cells . The tumour, i f  shown to be suitab le , would provide B and D-cells  
in greater quantity than is obtainable by isolating is le ts .
HPLC
HPLC analysis of tumour extracts followed by radioimmunoassay for soma­
to s ta t in - l ik e  immunoreactivity (SLI) showed the presence of a single 
molecular species corresponding to S-14. No larger forms were detected, 
and this was conformed by Dr. P. Wu (St. Bartholomew's Hospital, London, 
personal communication). Molecular heterogeneity has previously been 
reported in a human pancreatic somatostatin (Larsson et a l , 1977).
Although gel chromatography of the insulinoma extract revealed an insulin
125component eluting with the I - in s u lin  marker with an approximate mole­
cular weight of around 6,000, normal ra t  insulins were not detected by 
HPLC at the elution positions of the ra t  insulin markers. Instead, 
tumour IRI components eluted as a broad band between 19-30 min retention  
time. The reason for this anomaly is not c lear at the present time.
One possible explanation is that the tumour may contain variant forms 
of insu lin . Gel f i l t r a t io n  studies would indicate that the tumour 
insulins have molecular weights s im ilar to normal insulins. However 
HPLC analysis, which separates peptides according to both th e ir  mole­
cular weights and charges, suggests that the overall charge of the tumour 
insulins may be d if fe ren t from normal insulins. The divergence between 
the gel f i l t r a t io n  and HPLC profiles could then be accounted for by 
changes in the amino acid sequence and/or composition which a l te r  the 
overall change of the tumour insulin molecules without s ig n if ica n tly  
changing th e ir  molecular weights.
Variant forms of insulin have previously been reported. Some rare forms 
of diabetes have been shown to be due to the production of abnormal 
insulins possibly due to mutated pre-proinsulin genes. In one such case,
described by Tager et a l , (1979), the patient's  insulin was a mixture 
of normal hormone and an abnormal variant containing a Leu for Phe 
replacement at position 24 of the B chain. Because the Phe codon in 
this position of the pre-proinsulin gene is TTC (Bell et a l , 1980;
Bell e t a l , 1979; Sures et a l , 1980; U llr ich  e t  a l , 1980), a single 
nucleotide substitution leading to a Leu codon CTC or TTR (where R is 
A or G) must have occurred (Tager et a l , 1979).
Further studies are needed to e ither prove or disprove the presence of 
abnormal insulins in the tumour. HPLC and radioimmunoassay analyses 
of the insulin fractions obtained from gel chromatography w il l  help to 
c la r i fy  this question. In addition, s u ff ic ie n t amounts of tumour 
insulins could be isolated for amino acid sequencing.
Immunologically, the tumour insulins are s im ilar to normal ra t  insulins  
as demonstrated by parallelism between insulinoma extracts and ra t  
insulin standards. In addition, some or a l l  of the tumour IRI are bio­
log ica lly  active as evidenced by th e ir  a b i l i t y  to precipitate  hypogly- 
caemic episodes when the animals were stimulated with insulinotrophic  
agents (see next chapter) and, in preliminary experiments, to reverse 
the severe diabetes in NEDH rats experimentally induced by streptozotocin  
However the ir  individual biological potencies have not been evaluated.
Gel f i l t r a t io n  p ro fi le  showed the presence of several p ro insu lin -like  
components (PLC) in the ra t  insulinoma extract. In the absence of the 
appropriate purified ra t  PLC markers, i t  has not been possible to iden­
t i f y  these tumour PLC's.
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In addition to pre-proinsulin, proinsulins, insulins and th e ir  corres­
ponding C-peptides (Clark & Steiner, 1969; Chan et a l , 1976; Lomedico 
et a l , 1976; Tager & Steiner, 1972; Sundby & Markussen, 1972), several 
intermediate forms of PLC have also been id en tif ied  in ra t  is le ts  (Clark 
& Steiner, 1969; Tager et a l , 1973). These are partly  cleaved forms of 
ra t  proinsulin which have 2 chains, as in insu lin , but s t i l l  retain the 
connecting peptides, or fragments there o f ,  attached to the A or B chains.
Proinsulin intermediates have also been reported in human insulinomas 
(Rubenstein et a l , 1977). Lazarus et a l , (1972) have described the pre­
sence of a proinsulin intermediate in the serum of a patient with is le t  
cell carcinoma. Polyacrylamide gel electrophoresis showed three peaks; 
two of which had m obilities corresponding to insulin and proinsulin, 
while the th ird  peak ran in an intermediate position. Gordon et a l ,
(1971) have also described a pro insulin-like  component that eluted ahead 
of the proinsulin marker on a Sephadex G-50 column in a patient with an 
is le t  cell carcinoma. This PLC was determined to be 3 times as biolog­
ic a l ly  active as porcine proinsulin. The presence of a high-molecular- 
weight immunoreactive component in an acid-ethanol extract of an insulinoma 
was reported by Melani et a l , (1970a). This m aterial, which eluted in 
the void volume of the Bio Gel P-30 column, comprised 10% of the tota l 
IR I.  A PLC with a molecular weight o f . 24,000 was also found in the serum 
of a patient with an is le t  cell tumour by Nunes-Corra et a l , (1974).
Whether a l l  or some of these pro insu lin -like  components are present in 
the ra t insulinoma cannot be determined from the present study. Further 
work involving HPLC analysis of PLC fractions from gel chromatography 
w il l  add to our understanding of these components. And f in a l ly ,  amino 
acid sequence analysis can be performed on the purified PLC material to 
provide details of the ir  structure.
CHAPTER 3
METABOLIC STUDIES ON A TRANSPLANTABLE 
RAT INSULINOMA
Chapter 3 Metabolic Studies on a transplantable rat insulinoma
3.1 Introduction
The most characteristic  defect o f insulin secretion found in insulinomas 
is the in a b i l i ty  of the B-cells to suppress insulin release in response 
to hypoglycaemia (Yalow & Berson, 1965; Samols & Marks, 1966; Marks &
Rose, 1981). In normal subjects, the inh ib itory  e ffec t of hypoglycaemia 
on insulin secretion ensures that inh ib ition  of hepatic glucose release 
by insulin is decreased with progressive hypoglycaemia. This regulatory 
mechanism is absent in the insulinoma cell which continues to secrete 
insulin even in the face of quite marked hypoglycaemia, with the result  
that inh ib ition  of hepatic glucose release is sustained. Failure of the 
l iv e r  to replace glucose consumed by obligatory g lucose-utiliz ing tissues, 
leads to a reduction in the size of the glucose pool, and hence, severe 
hypoglycaemia.
Glucose u t i l iz a t io n  by peripheral tissue has been reported to be reduced 
in insulinoma patients (Scandellari e t a l , 1980) although basal metabolic 
rates were found to be normal. This reduced glucose u t i l iz a t io n  is mainly 
due to tissues adapting to the reduction in glucose pool. I f  carbohydrate 
a v a i la b i l i ty  was in fact augmented by a glucose infusion in these p a t i ­
ents, the rate of glucose disappearance from the blood is generally in ­
creased. The reduced glucose u t i l iz a t io n  coupled with a normal basal 
metabolic rate shows that hypoglycaemia, when i t  is established, is kept 
up by the in a b i l i ty  of the l iv e r  to produce su ff ic ien t glucose, rather  
than being a result of an excessive glucose uptake by the tissues.
Circulating insulin levels in insulinoma patients are seldom s u ff ic ie n t ly  
high to completely depress lipo lys is  in adipose tissue (Grunt e t a l , 1970),
with the result that plasma ketone levels are generally normal (Federspil 
et a l , 1978; Scandellari e t a l , 1980). I t  is these ketones that presum­
ably provide s u ff ic ien t fuel to the brain to prevent the body malfunction­
ing even in the presence of quite severe hypoglycaemia, (Marks & Rose,
1981).
3.1.1 Insulin Secretogogues
Although there are occasional insulinomas that are glucose responsive, 
most benign and malignant human insulinomas do not secrete insulin in 
response to intravenous glucose (Powers, 1969; Steinke et a l , 1963;
Adcock et a l , 1975; Lins & Efendic, 1979). The hamster insulinoma has 
e ither  sluggish or absent insulin secretion in response to a glucose 
load (Lins & Efendic, 1979; Shapiro et a l , 1977). The reason for this  
in sen s it iv ity  to the insulinotrophic e ffec t  of glucose is not clear at 
this time. I t  has been shown not to be related to defects e ither in 
glucose transport into the cell or i ts  phosphorytation, but may be due 
to the in a b i l i ty  of glucose to induce calcium flux  into the cells  (Shapiro 
et a l ,  1977).
The importance of calcium in the coupling of stimulus-recognition to the 
discharge of insulin from the pancreatic B-cell is now well established 
(Heilman et a l , 1979; Malaisse e t a l , 1977). In tra c e llu la r  calcium ions 
act as a tr igger for the exocytotic process o f secretory granule release 
from the B-cell by activating a membrane-oriented microtubular- 
microfilamentous system coupled to the granules (Devis et a l , 1975; 1977; 
Heilman et a l , 1977). Calcium se n s it iv ity  of human insulinomas has been 
proposed for i ts  diagnosis (Frerichs & Creutzfe ldt, 1980). Membrane 
depolarising agents such as potassium ions and ouabain also promote calcium
uptake and insulin release in hamster insulinoma (Shapiro e t a l , 1977), 
suggesting calcium dependence in the tumour c e l ls ,  s im ilar to that in 
the is le t  B-cells .
Most insulinomas respond normally to other insulinotrophic stimuli 
including glucagon (Marrack et a l , 1961; Marks & Samols, 1968) t o l ­
butamide (Marrack et a l , 1961; Frawley & Pensuwan, 1968) dibutyl cyclic  
AMP (Shapiro e t a l , 1977) and theophylline (Sopwith et a l , 1981) and 
L-leucine (Marrack et a l , 1960; Frawley & Pensuwan, 1968). In te res t­
ingly , the insulinotrophic response to arginine, normally a much more 
potent stimulus to insulin secretion than L-leucine, is not exaggerated 
in human insulinomas (Fajans et a l , 1967; Fallucca et a l , 1976).
Although intravenous glucose is often a poor stimulus of insulin secre­
tion in patients with insulinoma, oral glucose may however be e ffec t iv e ,  
suggesting that in this pathological condition the capacity to respond 
to insulinotrophic gut factors is maintained. Human insulinomas seem 
to respond to a variety  of gut hormones including secretin, pentagastrin 
and pancreozymin (CCK-PZ) (Fallucca et a l , 1976).
A minority of patients with surgically proven insulinomas, both benign 
and malignant, f a i l  to respond to any of the stimuli to insulin secretion, 
although they do exhibit inappropriate insulin secretion (Erwald et a l , 
1972; Dewilde et a l , 1975).
3 .1 .2 . Insulin Inhibitors
Most inhib itors of normal pancreatic B-cell have been found to be e ffec tive  
in suppressing insulin secretion from insulinomas. Hence, insulin release
from tumour cells in response to leucine plus theophylline is inhibited  
by antagonists of c e llu la r  oxidative phosphorylation such as cyanide, 
2,4-dinitrophenol and antimycin A (Sopwith et a l , 1981) as in normal 
i s le t  tissue (Coore & Randle, 1964; Milner & Hales, 1969). This suggests 
that the mechanism of insulin release in tumours as in is le ts  is energy 
requiring.
The dependence of insulinomas on calcium is indicated by th e ir  reduced 
responsiveness on lowering the external concentration of calcium ions 
(Sopwith e t aT, 1981; Heilman et a l , 1979). The involvement of calcium 
in induced insulin release was confirmed by the inhib itory action of vera­
pamil (Shapiro e t a l , 1977; Sopwith et a l , 1981) whose blockade of trans­
membrane calcium ion movements (Naylor & Szeto, 1972; Malaisse et a l ,
1977) and inh ib ition  of is le t  insulin secretion (Devis e t  a l , 1975) are
well established. In addition, the response of the tumour was inhibited
2+ 2+ by elevating the external concentration of Mg or by adding Co or
La^+ ions (Sopwith et a l ,  1981). These same manipulations of is le t  tissue
2+perturbs membrane e lec trica l a c t iv ity  and Ca handling, and inhib its  
insulin secretion (Heilman et a l , 1979; Malaisse et a l , 1976; Henquin & 
Lambert, 1975; Preissler & Meissner, 1978).
Calmodulin is a widely distributed calcium binding protein that may med­
ia te  the e ffec t of changes in in tra c e llu la r  calcium ion concentration 
(Cheung, 1980; Means & Dedman, 1980). This protein has recently been 
id en tif ied  in ra t is le ts  (Sugden et a l , 1979; Valverde e t a l , 1979) and 
the calmodulin in h ib ito r  tr ifluoperazine (Levin et a l , 1977) found to 
in h ib it  insulin secretion (Sugden et a l , 1979). A s im ilar action of 
trifjluoperazine on insulin release induced from the tumour has also been
demonstrated (Sopwith et a l , 1981).
Antagonists of microtubules such as vinblastine and colchicine, which 
in h ib it  insulin release in normal pancreatic is le ts  (Malaisse et a l ,
1971; Devis e t a l , 1974; Somers et a l , 1974) also in h ib it  insulin release 
in insulinomas (Sopwith et a l ,  1981).
The two main naturally  occurring catecholamines, adrenaline and noradren­
aline increase blood glucose by a dual action: they increase glucose 
inflow from the l iv e r  by activating glycogenolysis and decrease glucose 
outflow into the tissues. The la t te r  action is quantita tively  the more 
important and is la rge ly , i f  not e n t ire ly ,  due to inh ib ition  of insulin  
secretion by an -adrenergic mechanism (Porte, 1967; Marks & Rose, 1981). 
Catecholamines and monoamine precursors also in h ib it  insulin secretion 
from tumour cells (Sopwith et a l , 1981; Feldman e t a l , 1981). S im ilarly  
the inhib itory action of the yd-adrenergic blocker, propranolol has 
been demonstrated in normal is le ts  (Furman & Tayo, 1973) and in in su lin ­
omas (Blum et a l , 1975; Neri e t a l , 1969).
The inhib itory e ffec t of somatostatin on insulin secretion has been 
described (Koerker e t a l , 1974) although its  mechanism of action is 
unknown. In the insulinoma c e lls ,  somatostatin inhib its  basal and glu­
cagon or 8-Bromo-cAMP-stimulated insulin release without s ig n if ica n tly  
lowering c e llu la r  cAMP in glucagon-stimulated cells  (Shubart e t a l , 1977; 
Sopwith et a l , 1981).
Our present understanding suggests that insulin secretion by is le t  ce ll 
tumours occurs by an exocytotic process which requires c e l lu la r  energy, 
movement of calcium ions and the in te g r ity  of the microtubular system,
and in which calmodulin and cyclic nucleotides partic ipate . Inhib ition  
of insulin secretion by various antagonists further argues for the fun- 
tional in teg rity  of the plasma membrane and receptors, especially the 
adrenergic ones. The insulinoma may thus possess a stimulus and in h ib it io n -  
secretion coupling mechanism very s im ilar to that of pancreatic tissue. 
Indeed, insulinoma cell suspensions have been used as a large-scale model 
of the insulin secretory process (Duguid et a l , 1976; Gazdar et a l , 1980; 
Eisenbarth et a l , 1981; Sopwith et a l , 1981).
3 .1.3 Therapy and Management
Surgical removal of the insulinoma is the f i r s t  and obvious choice of 
treatment. The risk of fa ta l complications increases with the extent 
of the operative procedure, being highest following tota l or subtotal 
pancreactomy and lowest with enucleation or distal resection. The 
major problem is therefore localisation of the insulinoma. Various tech­
niques have been suggested with variable results (Frerichs & C reutzfe ld t, 
1976; Turner et a l ,  1978).
However i f  the tumour cannot be localised, or is found to be malignant 
with secondary metastases, p a ll ia t iv e  treatment such as diazoxide, dip- 
henylhydantoin, chlorpromazine, mannoheptulose, propranolol, and monoa­
mine precursors (Frerichs & Track, 1974; Blum et a l , 1975; Feldman, 1981)
may be useful. A recent development has been the use of the long-acting
1 ? 4 5 1? lft ft somatostatin analogue Des AA ’ * * * ’ D Try somatostatin, which sup­
presses secretion of pancreatic endocrine tumours for up to 24 hours 
(Long et a l , 1979). Furthermore, in patients with metastasising B-cell 
carcinoma, antitumour therapy with streptozotocin (Carter &' Broder, 1974)
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has to be considered, possibly a f te r  p a l l ia t iv e  surgery has minimised 
the tumour mass. Streptozotocin induces biochemical regression in some 
patients and doubles survival time in responders. In patients who do 
not respond to streptozotocin, i t  may be possible to control the hypo­
glycaemia with L-asparaginase (Sadoff, 1973).
In this present study, we investigated the metabolic and functional pro­
perties of the transplantable ra t  insulinoma in response to a variety  
of stimuli and inhibitors of insulin secretion. Attempts at treating  
the insulinoma using surgical resection and anti-cancer agents were also 
studied. F in a lly , further information about the tumour was obtained by 
investigating the diurnal changes of food consumption, plasma glucose and 
insulin concentrations.
3.2 Methodology
Rats were restrained in specially designed adjustable ra t  restrainers
(Tan & Bishop, University of Surrey Design) and bled from the t a i l .  All
/
agents tested were administered as a single intraperitoneal ( ip )  in jec tion .  
Blood was collected into polyethylene microfuge tubes that had been pre­
coated with heparin (500 U/ml). Plasma was separated by centrifugation  
for 10 seconds at approximately 9000 g using a microfuge (Type B, Beckman 
L td ., High Wycombe)and stored at -20°C until glucose and insulin  analyses 
were performed.
3.3 Results
3.3.1 Effects of insulin secretogogues
(a) Effect of glucose
Glucose tolerance tests (GTT's) were performed on insulinoma and control 
rats at 3 and 17 days post-transplantation. D-glucose (2 g/kg body weight)
were administered as a single intraperitoneal in jection .
Glucose tolerance in insulinoma rats was normal 3 days a fte r  transplan- 
ta tion (F ig . 30a). However, an abnormal response was found on day 17 
post-transplantation (Fig. 30c). Plasma glucose concentration of 
insulinoma rats were s ig n if ic an tly  lower (p < 0 .0 1 )  prior to glucose 
administration. The 30 min rise in glucose concentration was less than 
that observed in the controls (p< 0 .001). A s ign if ican t increase in 
plasma insulin concentration was observed 30 min a f te r  glucose admini­
stration (p < 0 .0 5 ) .  However, plasma insulin  of the insulinoma rats 
continued to increase and was markedly higher (p < 0 .0 1 )  than the prestim­
ulatory value. Plasma glucose and insulin levels were s ig n if ic an tly  
d iffe ren t from controls at a l l  three time points.
By day 20 post-transplant, insulinoma bearing rats were severely hypo- 
glycaemic and hyperinsulinaemic. The plasma glucose and insulin responses 
to GTT were disturbed (Fig. 30b). Glucose concentrations were s ig n i f i ­
cantly depressed a t time 0 (p< 0.001) and remained low throughout the 
tes t; the glucose response curve was f la ttened . Plasma insulin levels  
were s ign if ican tly  higher than controls (p< 0.001) p rio r to GTT.
Glucose fa i le d  to stimulate a plasma insulin response. In fac t plasma 
insulin levels were depressed 30 min a f te r  GTT (p<.0.001) but had risen 
to prestimulatory levels by 60 min.
(b) Effect of L-Arginine
The e ffec t of arginine on plasma glucose, insulin  and glucagon was studied 
in control and insulinoma bearing ra ts . All animals received an in t ra ­
peritoneal in jection of L-arginine monochiorhydrate (1 .5 g/kg body weight; 
Sigma Chemical Co., St. Louis, USA).
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Arginine administration day 3 post-transplantation resulted in a sign­
i f ic a n t  increase in plasma glucose and insulin levels in both controls 
and insulinoma rats (Fig. 31a). No s ign if icant differences were observed 
between test and control groups. S ignificant changes were detected on 
day 20 post-transplantation (Fig. 31b). Glucose response in the insul­
inoma rats was maintained although glucose concentrations were s ig n i f i ­
cantly lower than controls at time zero (p 4  0.001) 30 min (p 40 .05) and 
60 min (p < 0 .0 1 ) .  However arginine fa i le d  to stimulate a s ign ificant  
insulin response in the insulinoma rats as i t  did in the controls. The 
tumour rats were hyperinsulinaemic throughout the duration of the exper­
iment.
Plasma glucagon measurements showed that although basal levels were 
s im ilar , arginine fa iled  to stimulate a glucagon response in the insu l­
inoma rats as was observed in control rats (Fig. 32).
(c) Effect of Glucagon
Glucagon (1.5 mg/kg body weight; Eli L i l ly  & Co., USA) was administered 
to control and insulinoma rats day 20 a f te r  transplantation.
A s ign ificant rise in plasma glucose concentrations occurred in the con­
tro l rats in response to glucagon stimulation (p 4 0 .0 0 1 ).  No change in 
plasma glucose concentrations was observed however in the insulinoma rats 
(Fig. 33). Glucagon evoked an exaggerated plasma insulin response (p< 0.001) 
in the test animals despite markedly elevated basal levels . Glucagon 
stimulated a s ign ificant plasma insulin response in the control animals
(p < 0 .0 0 1 ) .
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(d) Effect of Glibenclamide
The effects of the sulphonyl urea, glibenclamide (Hoechst, Milton Keynes, 
U.K.) was studied by in tra  peritoneal administration (0.3 mg/kg body 
weight) into 20 day post-transplant tumour and control rats.
G1ibenclamide stimulated a s ign ificant increase in plasma insulin in 
controls (p < 0 .02 ) and a consequent decrease in plasma glucose concen­
tration  (p<0.001) (Fig. 34). No changes in e ither  plasma insulin or 
glucose were observed in the insulinoma group.
3 .3 .2  Effects of Insulin Inhibitors
(a) Effect of Insulin
Insulin suppression tests were performed on control and tumour rats on 
days 3 and 20 post-transplantation. Intraperitoneal injections of 
Actrapid porcine insulin (0.25 U/kg body weight in saline) (Novo Industri 
A/S, Denmark) were administered.
Insulin sens it iv ity  in the tumour rats was normal on day 3 (Fig. 35a).
A small but s ign ificant ( p < 0.001) decrease in plasma glucose was observed 
at 60 minutes for both test and control animals. With the severe hyper­
insul inaemia and hypoglycaemia insulin se n s it iv ity  was impaired on day 20 
(Fig. 35b). No plasma glucose changes were observed in the insulinoma 
rats.
(b) Effect of Adrenaline
The response of the insulinoma to adrenergic inh ib ition  was studied using 
Adrenaline b ita r tra te  (1 mg/kg body weight, Sigma Chemical Co., St. Louis, 
USA).
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On day 3 post-transplantation, no s ign if icant differences between tumour 
and control responses were found (Fig. 36a). Inh ib ition of insulin  
release and an increase in plasma glucose concentration occurred in both 
groups. Despite severe hypoglycaemia and hyperinsulinaemia on day 20, 
the a b i l i ty  of adrenaline to suppress plasma insulin and raise plasma 
glucose concentrations was retained (Fig. 36b).
(c) Effect of Propranolol
The effects of the -blocker, propranolol hydrochloride (30 mg/kg body 
weight; IC I,  U.K.) on plasma insulin and glucose were investigated on 
day 20 post-transplantation.
The a b i l i ty  of propranolol to in h ib it  insulin secretion and raise plasma 
glucose concentrations was retained despite s ig n if ica n tly  lower plasma 
glucose concentrations ( p < 0 .0 1 ) and markedly higher plasma insulin  
levels (p < 0 .01 ) at zero time (Fig. 37).
3 .3 .3  Surgical Resection
The treatment of insulinoma by surgical resection was investigated, and 
plasma glucose and insulin responses studied at various times a f te r  
excision of the tumours.
Rats were anaesthetised with sodium pentobarbitone (50 mg/kg body weight, 
ip) and an incision was made into the skin on the side of the tumour. 
Tumours were located subcutaneously on the la te ra l margin of the upper 
abdomen. Although the same amount o f minced tumour (0.1 ml) was implanted 
21 days previously to a l l  ra ts , the size of the resulting tumour varied 
considerably. Adhesions between the tumour capsule and the surrounding
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subcutaneous tissue were separated by blunt dissection taking care to 
l igature and transect large blood vessels. The smaller tumours were 
vacularised by numerous small vessels from the surrounding subcutaneous 
tissue. These vessels were cut and sealed by gentle pressure. Larger 
tumours were additionally  vascularised by several well defined arteries  
and veins connected to e ith er  the local cutaneous or muscular vasculature. 
The tumours were removed with th e ir  capsules in ta c t ,  and the wounds closed.
A total of 12 insulinoma-bearing rats were used in the experiment to ­
gether with 9 sham-operated controls. Blood samples were taken before 
and at frequent intervals until 12 days a f te r  resection. The rats were 
observed for a total period of 60 days to check for the recurrence of 
hypoglycaemia.
In contrast to inevitable m ortality by 28 days, surgical resection at  
day 21 resulted in a prompt and marked reversal of the metabolic abnor­
malities (Figs. 38 & 39). Plasma insulin concentrations f e l l  rapidly to 
the range of anaesthetised controls within 10 minutes (Fig. 38), corres­
ponding to an estimated insulin h a l f - l i f e  of approximately 3.5 minutes. 
Despite this rapid reduction, hypoglycaemia persisted until 60 minutes 
(Fig. 39), followed thereafter by hyperglycaemia of 1 days duration.
This was followed by a small but s ign ificant rebound between days 3 and 
6. Both plasma insulin and glucose were normalised by 12 days post­
resection, but tumour recurrence was observed in a ll  rats with resection 
giving a 20-60 day prolongation of l i f e .
Glucose tolerance (2 g/kg, ip) and arginine stimulation (1.5 g/kg, ip) 
tests were performed 1 and 12 days post-resection. On day 1 post­
resection, glucose tolerance in test animals was reasonably normalised 
(Fig. 40a). Test pancreases responded normally to the glucose load with
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s ig n if ican tly  increases in insulin concentration at 30 mins (p < 0 .0 0 1 ) .  
Plasma glucose levels were also elevated at this time (p ^ 0 .0 5 '.) .  How­
ever, at 60 mins, when control levels had fa l le n ,  glucose levels in test  
rats remained s ig n if ic a n tly  raised (p < 0 .0 5 ) .  Unlike the glucose response 
argihine stimulation was impaired in the test animals (Fig. 41a).
Arginine fa ile d  to evoke e ither an insulin or a glucose response in the 
resected animals.
On day 12 post-resection insulin release in response to a glucose load 
was lost although plasma glucose concentrations were elevated (p-dO.Ol) 
(Fig. 40b). S im ilarly  the insulin response to arginine stimulation was 
abolished (Fig. 41b), and no s ign ificant rise in plasma glucose was 
observed in test animals. These characteristics resemble those animals 
17 days a f te r  transplantation,' and may be due to the beginning of tumour 
recurrence in the resected animals.
3 .3 .4  Effects of Cytotoxic Drugs
The short term effects of methotrexate, alloxan and streptozotocin in 
insulinoma-bearing rats were studied. The dosage schedule consisted of 
two doses administered on consecutive days. The amount of drug given 
on the second day was h a lf  the concentration of the in i t i a l  dose. All 
drugs were administered in traperitoneally  into 21 day post-transplanted  
rats.
The anti-cancer drug, methotrexate (10 mg/kg; Lederle Lab. Division,
New York, USA) did not s ign if icantly  a l te r  plasma glucose or insulin  
concentrations 4 hours a f te r  administration on Day 1 (Fig. 42). Plasma 
insulin concentrations were however s ig n if ica n tly  lower by the second
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F ig .42 Effects of Methotrexate(10mg/kg,ip) on plasma glucose 
and insulin in insulinoma rats . Mean + SEM(6). 
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(p< 0.001) and th ird  day (p<0.02), although plasma glucose remained 
unchanged. Inspite of a second dose o f methotrexate (5 mg/kg) on day 
2, plasma insulin levels continued to rise* and was s ig n if ic a n tly  higher 
than day 2 levels by the 4th (p < 0 .0 5 )  and 5th day (p < 0 .0 5 ) .  These 
changes were accompanied by progressively severe hypoglycaemia. Mean 
survival time a fte r  treatment was 7.8 + 2.8 (6) days with a range of 
2-17 days. The large range demonstrates the varied responses of the 
tumour rats to methotrexate treatment.
Glucose tolerance was tested in the insulinoma rats 5 days a f te r  metho­
trexate treatment (Fig. 45). Glucose fa i le d  to stimulate insu lin  sec­
retion beyond high prestimulatory levels . However, plasma glucose con­
centrations were s ig n if ican tly  raised by 30 and 60 minutes ( p < 0.001).
The B-cytotoxic agent, alloxan (200 mg/kg; Sigma Chemical Co., St. Louis, 
USA) fa ile d  to a ffec t plasma glucose concentrations over 5 days, although 
plasma insulin concentrations were s ig n if ic an tly  decreased by 2 hours 
( p< 0 .0 5 )  and 4 hours (p < 0 .0 2 )  of the f i r s t  day, and by day 2 (pCO.Ol) 
(Fig. 43). Progressive hyperinsulinaemia was observed from day 3-5 , but 
these levels were not s ig n if ican tly  higher than values on day 2.
Glucose tolerance in the alloxan treated insulinoma rats was s im ilar  to 
that of the methotrexate treated animals. Glucose administration resulted 
in a s ign ificant increase in plasma glucose concentrations (p < 0 .0 0 1 )  
but fa i le d  to stimulate insulin secretion (Fig. 45). Mean survival time 
a fte r  treatment was 8.2 + 0.8 (6) days with a range of 5-11 days.
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In contrast to the actions of methotrexate and alloxan, streptozocin 
(100 mg/kg; Sigma Chemical Co., St. Louis, USA) reduced plasma insulin  
within 60 mins (p < 0 .0 2 )  and concentrations continued to f a l l  leading 
to overt hypoinsulinaemia by day 5 (Fig. 44). Consistent with this  
action, plasma glucose was increased s ig n if ica n tly  by 24 hours (p < 0 .0 5 )  
with the la te r  development of marked hyperglycaemia. Four deaths were 
recorded by day 5, and the mean survival time a f te r  treatment was 
3.8 + 0.7 (6) days with a range of 1-6 days. Glucose tolerance on 
day 5 in the diabetic animals was severly impaired (Fig. 45). No changes 
in e ither plasma glucose or insulin concentrations were observed.
3.3 .5  Diurnal variations of glucose homeostasis
To obtain further information on the functional properties of the ra t  
insulinoma, diurnal changes o f food consumption, glucose and insulin  
concentrations were examined at 3-hourly in tervals  for 24 hours in 20 
days post-transplanted rats .
Control rats exhibited d is t in c t  diurnal changes in the parameters studied. 
Two phases of increased food consumption were observed -  the f i r s t  occurring 
at the s ta r t  of the dark period between 1700 hours to 2300 hours, the 
second between 0200 hours and 0500 hours. Corresponding to these time 
periods, plasma glucose and insulin concentrations were also raised 
(Fig. 46).
In contrast, insulinoma-bearing rats displayed no diurnal changes other 
than a small reduction in food consumption at 0500 hours and 1100 hours 
(Fig. 47). Plasma glucose and insulin concentrations were s ig n if ic a n t ly  
diffe rent from control values at a l l  times, as was food consumption between
Fo
od
 
In
ta
ke
 
Pl
as
ma
 
In
su
lin
 
Pl
as
ma
 
G
lu
co
se
 
(g
/a
ni
m
al
/3
h)
 
(n
g/
m
l)
(m
m
ol
/I)
6
4
2
*
* *
0800 1400 2000 0200
Time (24-h clock)
F ig .46 Diurnal variations in food consumption and plasma concentrations of 
glucose and insulin in control NEDH rats. Values are Mean + SEM of 6 
observations. (*=p<?0.05, **p<0.01 compared with values at 0800h)
0800
Fo
od
 
In
ta
ke
 
Pl
as
ma
 
In
su
lin
 
Pl
as
ma
 
G
lu
co
se
 
(g
/a
ni
m
al
/3
h)
 
(n
g/
m
l) 
(m
m
ol
/l)
I DM-
4r
OL
10
6
6r
OL
£
£
£
0800
F ig .47
1400 2000
Time (24-h clock)
0200 0800
Diurnal variations in food consumption and plasma concentrations of 
glucose and insulin in insulinoma rats. Values are Mean + SEM of 6 
observations.(*=p<0.05 compared with values at 2000h)
155
2300 hours and 1700 hours. The mean 24 hour plasma concentrations of 
glucose and insu lin , insulin-glucose ra tio  and food consumption in 
insulinoma and control rats are summarised in Table 6_. The insulinoma 
rats are ch arac ter is tica lly  hyperphagic, hypoglycaemic, and hyperinsulin- 
aemi c .
Control Tumour P
Plasma glucose 5.57 + 0.2 1.56 + 0.05 <0.001
(mmol/L)
Plasma insulin 2.89 + 0.26 10.12 + 0.5 <0.001
(ng/ml)
Insulin-glucose ra tio  0.5 + 0.06 6.6 + 0.4 <0.001
(ng/ml/mmol/L)
Food consumption 1.38 + 0.21 3.13 + 0.16 <0.001
(g/animal/3 h r .)
Table 6 24 hour mean plasma concentrations of glucose and in su lin ,
insulin-glucose ra tio  and food consumption in control and 
insulinoma rats . Values are mean + SEM calculated from data 
presented in Fig. 46&47.A11 parameters measured were s ig n if ic a n tly  
d iffe re n t from control values.
Interruption of continual nutrient intake by the withdrawal of food 
exacerbated the hypoglycaemia of the tumour-bearing rats resulting in 
death by 6 hours (Fig. 48). In teresting ly , instead of remaining hyper- 
insulinaemic due to inappropriate insulin secretion, plasma insulin  con­
centrations f e l l  s ig n if ican tly  by 6 hours (p < 0 .001 ).
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3.4 Discussion
The characteristics and functional properties of human insulinomas have 
been described in deta il (Frerichs & Creutzfeldt, 1976; Marks & Rose, 
1981). Using these known characteristics, the s u i ta b i l i ty  of the trans­
plantable ra t  insulinoma as an animal model was assessed.
Insulin secretogogues
Plasma glucose and insulin responses to intraperitoneal glucose were 
unchanged 3 days a f te r  transplantation. However, with progressive hyper- 
insulinaemia and hypoglycaemia, glucose sen s it iv ity  was lost by days 17 
and 20. Plasma glucose concentrations remained low a f te r  glucose admin­
is tra tion  on these days, suggesting a greater disappearance rate of glu­
cose from the glucose pool into the tissues. This would indicate that  
the plasma h a l f - l i f e  of glucose was probably reduced in these hypogly- 
caemic animals. This is in accordance with results by Scandellari e t  a l , 
(1980) who have shown that glucose infusion in hyperinsulinaemic patients  
resulted in an increased rate of glucose disappearance from the blood.
Hyperinsulinaemia and an exaggerated plasma insulin response to glucose 
was observed on day 17. This responsiveness was lost however by day 20 
when a s ign ificant inh ib ition  of plasma insulin from high pre-stimulating  
levels was observed. The reasons for these abnormal plasma insulin  pro­
f i le s  during GTT are not known. Similar inhibitions of plasma insulin  
during oral glucose tolerance tests have also been reported by Mirouze 
et a l , (1980). In sen s it iv ity  of the transplantable ra t  insulinoma to 
acute stimulation of glucose may be an in tr in s ic  characteristic  of the 
tumour (Shapiro et a l , 1977; Sopwith et a l , 1981), or may re f le c t  the 
hypoglycaemic situation analogous to gross starvation (Malaisse e t  a l , 
1967; Buchanan et a l , 1969).
At 20 days, glucagon evoked a marked plasma insulin response with no 
change in plasma glucose concentrations. In contrast, arginine which 
is both an insulinotrophic and glucagonotrophic agent, raised plasma 
glucose but fa i le d  to stimulate insulin above high basal concentrations. 
This divergence may be related to the tumour defect or to the apparent 
lack of A-cells within the tumour coupled with the atrophy of the pan­
creatic A -ce lls . The fa i lu re  of arginine to stimulate glucagon secretion 
from A-cells of the pancreas in the insulinoma rats would tend to support 
the la t te r  explanation. I f ,  as has been suggested by Tsiolakis (1979) 
and Tan & Marks (1981) (see Chapter 4) that the insulinotrophic action 
of arginine is mediated by A -ce lls ,. fa i lu re  to stimulate glucagon secre­
tion because of the absence of A-cells in the tumour and the atrophy of 
A-cells in the host pancreas, would explain the absence of the insulin  
response to arginine. These observations were further confirmed in acute 
in v itro  experiments using isolated cell suspensions, and w i l l  be d is­
cussed in Chapter 4. They provide further evidence fo r  the role of glu­
cagon in insulin secretion.
In addition, the theory of glucagon as a counter-regulatory hormone to 
insulin is d i f f i c u l t  to reconcile with these observations. Glucagon 
rather than stimulating hepatic glycogenolysis and gluconeogenesis to 
"reverse" the hypoglycaemia was found to stimulate a marked insulin  
release leading to severe and fa ta l hypoglycaemia. The a b i l i t y  o f glu­
cagon to stimulate insulin secretion has also been reported fo r  human 
insulinoma (Marks & Samols, 1968; Marrack e t a l , 1961) and the transplant­
able hamster insulinoma (Shapiro et al 1977; Shubart et a l , 1977). At 
least under these pathological conditions, glucagon instead of a l le v ia t in g
the hypoglycaemia, severely aggravated i t  by stimulating a marked insulin  
secretion in these rats.
The sulphonyl urea, glibenclamide fa iled  to stimulate insulin  secretion 
in the insulinoma rats. This could be related to the tumour defect, the 
prevailing hypoglycaemia, or as with arginine, be due to the apparent 
in a b i l i ty  o f the rats to secrete glucagon. Current evidence suggests 
that glibenclamide stimulate insulin release through a d irec t e f fec t  on 
the B-cells (Heilman & Ta ljeda l, 1975) rather than via the A -ce lls . This 
would indicate that the in se n s it iv ity  to glibenclamide is not due to the 
absence of A-cells in the tumour. In addition, glibenclamide has been 
reported not to stimulate glucagon secretion in studies with perfused 
pancreases (Laube et a l , 1971; Samols et a l , 1971). Failure of gliben­
clamide to stimulate insulin secretion could be explained by the low blood 
glucose levels. Glibenclamide has been reported to potentiate glucose- 
induced insulin secretion (Heilman & Ta ljeda l, 1975), and i ts  action could 
be dependent on the prevailing glucose concentrations. In v itro  experi­
ments are necessary to substantiate or repudiate this suggestion.
Insulin Inhibitors
With progressive hyperinsulinaemia and hypoglycaemia, insulin  s e n s it iv ity  
became impaired by 20 days a fte r  transplantation. The mechanism of this  
is not known but may be due to the "resistance" of tissues to insu lin  
because of the persistent hyperinsulinism. Whether exogenously admini­
stered insulin has a negative feedback on insulin secretion from the 
insulinoma could not be answered in the absence of an assay for ra t  
C-peptide.
The a b i l i t y  of adrenaline and propranolol to suppress plasma insulin and 
raise plasma glucose concentrations was retained 20 days a f te r  trans­
plantation. Their a b i l i t y  to raise blood glucose can be explained by 
the c irculatory catecholamines increasing glucose inflow due to activation  
of hepatic glycogenolysis, and decreasing glucose outflow due to inhib­
it io n  of insulin secretion. Adrenaline inh ib its  insulin secretion by 
activating the o<-receptors. Stimulation of insulin secretion by glu­
cagon, and inh ib ition  by adrenaline further implies adenosine 3 1:5 1 
cyclic monophosphate modulation of insulin release by the insulinoma 
(Sutherland e t a l , 1965). The ^ -b lo c k e r ,  propranolol acts by blocking 
the stimulation of insulin release via y6-receptor activation , and 
enhancing the inh ib itory  action of c ircu lating  catecholamines via the 
oC -adrenergic mechanism. Whether isoproterenol, a jb -adrenergic stim­
ulant (Porte 1967a) stimulates insulin release from the ra t  insulinoma 
remains to be tested. These results would suggest that some glycogen 
store was s t i l l  availab le , probably in the l iv e r ,  which cannot be mob­
i l is e d  in the presence of persistent hyperinsulinaemia. Adrenaline has 
also been shown to in h ib it  insulin secretion from the ra t  insulinoma in 
in v itro  experiments (Sopwith e t a l , 1981).
Although the inh ib itory  e ffec t  of catecholamines on insulin secretion 
from the pancreas is well established, th e ir  effects on human insulinomas 
have been varied depending on the experimental design. Shen (1975) 
found that an acute infusion of propranolol and adrenaline inhib ited  
insulin secretion in 5 out of 7 patients with insulinoma. Lins and 
Efendic (1979) noted that an adrenaline infusion inhibited glucose- 
stimulated insulin secretion in patients with glucose responsive in su lin ­
omas, but did not in h ib it  glucagon-stimulated insulin secretion.
Scandellari e t a l , (1978) found that chronic propranolol administration 
ameliorated the hypoglycaemia of patients with insulinomas and decreased 
th e ir  insulin response to a challenge with glucose, tolbutamide or glucagon.
Feldman & Lebovitz (1972) and Wilson et a l , (1974) have suggested that 
monoamines such as adrenaline, being polar compounds, do not penetrate 
cell membranes as e ffec t iv e ly  as th e ir  non-polar monoamine precursors. 
5-hydroxytryptophan (5-HTP), L-3,4-dihydroxyphenylalanine (L-DOPA) and 
DL-threo-dihydroxyphenylsenine (DOPS) are readily taken up by hamster 
pancreatic is le ts  and insulinoma, and are converted in tra c e l lu la r ly  to 
serotonin, dopamine and noradrenaline where they in h ib it  insulin secre­
tion . Future studies to investigate the effects of these monoamine 
precursors on the transplantable ra t  insulinoma could be of considerable 
in teres t.
Surgical Resection
Surgical removal of the insulinoma resulted in a prompt and marked 
reversal of the metabolic abnormalities. Plasma insulin concentrations 
f e l l  rapidly to control levels within 10 minutes, corresponding to an 
estimated insulin h a l f - l i f e  o f approximately 3.5 minutes. However, 
despite this rapid reduction, hypoglycaemia persisted until 60 minutes.
The reason for this is probably due to the small hyperinsulinaemic 
rebound occurring 20 minutes a f te r  resection and persisting for over 
60 minutes. The source of insulin fo r  this small rebound is persumably 
the host animal's pancreas, although the reason for i ts  occurrence is  
not known.
Following this rebound, severe but temporary hypoglycaemia of 1 day's 
duration occurred. As with human insulinomas, hyperglycaemia appears 
to be an inevitab le consequence of the surgical r e l ie f  of hyperinsulinism. 
In man i t  lasts from a few days to as long as two weeks, and blood glucose' 
concentration may be high and glycosuria pronounced. The cause of the 
hyperglycaemic rebound is not known. Although previously attributed  
to hypoinsulinaemia from pressurized is le t  atrophy caused by prolonged 
hypoglycaemia, this is now disputed (Chu & Goodner, 1968) since, post- 
operatively , endogenous plasma insulin levels are commonly normal or 
high (Klink et a l , 1967; Kerner et a l , 1980) although in other patients 
they may drop to low or very low levels within minutes of tumour removal, 
(Boucher et a l , 1970). The present study shows that over the period 
of the hyperglycaemic rebound, plasma insulin levels remained between 
normal and s lig h t ly  higher than control range. This would argue against 
hypoinsulinaemia being the cause of the hyperglycaemic rebound. The 
period of hyperglycaemia that follows resection of the tumours is  
consistent with the concept of beta cell function suppression, and both 
are observed a f te r  prolonged periods of insulin administration in rats 
(Turner & Johnson, 1973; Horwitz e t a l , 1975).
Glucose tolerance had normalised by day 1 a fte r  resection of tumour, 
and insulin response to glucose was restored. This suggests that  
despite the decrease in number, the pancreatic is le t  B-cells remain 
responsive to glucose. In addition, i t  provides further evidence that 
the impaired insulin response to glucose in the insulinoma rats prior  
to resection, may be an in tr in s ic  feature of the tumour defect. Con­
s istent with the hyperglycaemic rebound observed over this period, 
plasma glucose levels remained high throughout the course of the glucose 
tolerance test.
Unlike the glucose response, arginine stimulation was impaired, 
fa i l in g  to evoke either an insulin or glucose response in the resected 
animals. These observations are s im ilar to those of the insulinoma 
ra ts , 20 days a fte r  transplantation, and may indicate that the impaired 
insulin response to arginine is not d irec tly  related to the tumour 
defect. These results are however consistent with the suggestion that 
the insulinotrophic action of arginine is mediated via the A-cells  
(Tan & Marks, 1981). In agreement with observations in 20-day post­
transplanted ra ts , the glucagon response to arginine in the resected 
animals is probably impaired due to the suppression and atrophy of the 
is le t  A -cells . Direct plasma glucagon measurements a f te r  arginine stim­
ulation , and the demonstration of the insulinotrophic action of glucagon 
in the resected animals are needed to provide further evidence for this  
hypothesis.
By 12 days post-resection, glucose and insulin responses to both arginine 
and glucose stimulation were impaired. This could be due to the early  
stages of tumour recurrence in the resected animals because th e ir  
pattern of plasma glucose and insulin resembles that of animals 17 days 
a fte r  transplantation. Characteristic of malignant insulinomas, tumour 
recurrence was observed in a l l  rats with resection giving a 20-60 day 
prolongation of l i f e .
I t  is apparent that insulin-induced hypoglycaemia has a marked e ffec t  
on insulin secretion by the pancreatic beta cell during the recovery 
from hypoglycaemia (Horwitz et a l , 1975; Service et a l , 1977; F r ie r  
et a l , 1980; F r ie r  et a l , 1981). However, the pattern of insulin
secretion in response to glucose following recovery from acute 
insulin-induced hypoglycaemia appears to be d if fe re n t  from that 
induced by prolonged hyperinsulinism as in the case of the ra t  insulinoma. 
In one such study (F r ie r  et a l , 1981), acute hypoglycaemia was associated 
with an abnormal pattern of insulin secretion, characterised by an 
in i t i a l  impairment in insulin secretion and la te  hyperinsulinaemia.
The authors suggest that this abnormal function of the pancreatic B-cell 
is unlikely to be caused e ither by an abnormal entero-insular axis or 
an elevation of plasma catecholamine levels. Instead they suggest that 
the e ffec t  of hypoglycaemia on insulin secretion may be caused by glu- 
copenia of the pancreatic beta c e lls . Whether these conclusions are 
applicable to the transplantable ra t  insulinoma remains to be v e r if ie d .
The status of the entero-insular axis and plasma catecholamine levels  
may be important factors in the development of hypoglycaemia in the 
insulinoma rats.
Effects of cytotoxic drugs
Surgical resection of the insulinoma causes a rapid reversal of the 
hyperinsulinaemia with a 20-60 day prolongation of l i f e .  However, in 
view of the inevitable tumour recurrence, the present study examines 
the short term effects of methotrexate (10 mg/kg), alloxan (200 mg/kg) 
and streptozotocin (100 mg/kg) in 21 day post-transplanted ra ts .
Methotrexate, one of the f i r s t  anti-neoplastic agents, is now widely 
used in the treatment of acute leukemia, non-Hodgkin's lymphoma, 
choriocarcinoma, and breast and pulmonary carcinoma (Bleyer, 1978).
I t  is a potent in h ib ito r  of the enzyme dihydrofolate reductase respon­
sible for converting fo l ic  acid to reduced fo late  cofactors. Reduced 
folates are required for the metabolic transfer of 1-carbon units
especially important in the biosynthesis of thymidylic acid and purine 
precursors necessary fo r both DNA and RNA synthesis. In man, metho­
trexate appears to in h ib it  DNA synthesis to a greater extent than RNA 
synthesis, suggesting that in h ib ition  of thymidylate synthesis is the 
most important mechanism of methotrexate cytotoxic ity  (Hofflerend & Tripp,
1972). Its  pharmacokinetic properties and to x ic ity  have been reviewed 
by Bleyer (1978) and Bender et a l ,  (1978).
Despite a temporal in h ib itio n  of plasma insu lin  secretion on the second 
and th ird  day a fte r  treatment, methotrexate fa ile d  to permanently reverse 
the hyperinsulinaemia and hypoglycaemia. These results show that the 
tumour was unresponsive to the administered dose of methotrexate.
Whether the insulinoma w ill respond to higher doses remains to be 
investigated.
The B-cytotoxic agents, alloxan and streptozotocin are known to produce 
permanent diabetes by destruction of the is le t  B-cells in several species 
including the r a t ,  mouse, dog and monkey (see review by Dulin & Soret, 
1977). However, in the insulinoma-bearing ra ts , alloxan fa ile d  to 
permanently lower plasma insu lin  concentration. In contrast, strepto­
zotocin reduced plasma insu lin  w ithin 60 minutes resulting in overt 
hypoinsulinaemia and marked hyperglycaemia by day 3. These observations 
show that the insulinoma is unresponsive to the administered dose of 
alloxan but is acutely sensitive to streptozotocin. Whether i t  responds 
to higher doses of alloxan remains to be tested.
The divergence between the effectiveness of alloxan and streptozotocin  
emphasizes the d iffe re n t characteristics of the pancreatic and tumour 
B -ce lls , and may suggest possible tumour defects in the ce ll membrane.
Although both streptozotocin and alloxan produce experimental diabetes 
niellitus and share certain common pathways, available evidence suggests 
that they damage the B-cell through two d iffe re n t mechanisms. In ra t  
pancreatic is le ts , they both cause DNA strand fragmentation which 
stimulates nuclear poly (ADP-ribose) synthetase, thereby depleting  
in tra c e llu la r  NAD and in h ib itin g  proinsulin synthesis (Yamamoto e t a l , 
1981). However, the mechanism by which alloxan destroys the B-cells  
is apparently an ex trac e llu la r one, since the alloxan remains extra­
c e llu la r  (Cooperstein & Lazarow, 1964; Watkins e t a l , 1964), whereas 
streptozotocin probably acts in tra c e llu la r ly .
Further evidence that alloxan acts a t the membrane level and probably 
a t the glucose receptor s ite  include the observation that glucose can 
protect against the diabetogenic e ffects  of alloxan (Zawalick & B eid ler,
1973) and alloxan blocks glucose-stimulated insu lin  release (Tomita 
e t a l ,  1974). Furthermore the oc-anomer of glucose is  a more potent
in h ib ito r of alloxan to x ic ity  than the /$-anomer while there is  no
/
preferentia l metabolism of these anomers (Rossini et a l , 1975). In 
addition, the non-metabolizable sugars, 2-deoxyglucose and 3-0-methyl 
glucose in h ib it  the diabetogenic action of alloxan but are not metabo­
lised (Rossini e t a l , 1975). Failure of alloxan to in h ib it  insu lin  
release from the tumour B-cells might therefore indicate membrane 
changes in these c e lls . Further studies are needed to elucidate the 
precise nature of these changes.
Diurnal Variations of Glucose Homeostasis
Diurnal variations of glucose homeostasis have been observed in several 
species including mice (Nowell, 1970; Gagliardino and Hernandez, 1972; 
Bailey e t a l , 1975), rats (B ellinger e t a l , 1975) and humans (C arro ll
& N estel, 1973; Bowen & Reeves, 1967). Results from the present study 
demonstrate that diurnal variations o f glucose homeostasis are also 
present in the NEDH stra in  of ra ts . Food consumption and plasma 
concentrations of glucose and insu lin  exh ib it diurnal patterns in the 
control ra ts . In contrast, there were no s ig n ifican t diurnal changes 
in the insulinoma-bearing ra ts . These observations demonstrate that 
the transplantable insulinoma not only causes hypoglycaemia and hyper- 
insulinaemia but also results in hyperphagia and defective diurnal 
changes of food consumption, plasma glucose and plasma insu lin  concen­
tra tio n s .
The mechanisms whereby these diurnal changes are abolished are not known 
but may be consistently explained by the persistent hyperinsulinism. 
Inappropriate insulin  secretion by the tumour leads to persistent 
hyperinsulinaemia and a loss of the diurnal insu lin  pattern. This 
results in plasma glucose concentrations being consistently depressed, 
and its  diurnal pattern abolished. Whether i t  is the hypoglycaemia or 
the hyperinsulinaemia or an in teraction  of these and other metabolic 
factors that causes the hyperphagia is not known, since the mechanism 
of appetite control is  s t i l l  a matter of controversy.
The regulation of carbohydrate metabolism involves a complex in teraction  
of neural, hormonal and metabolic facto rs , many of which are known to 
possess a circadian p erio d ic ity , fo r example: in tes tin a l glucose absorption 
(Furuya & Yagari, 1974), the hepatic handling of glucose (Nowell, 1970; 
McVerry & Kim, 1972), insulin  s e n s itiv ity  (Nowell, 1970; Gibson & J a rre tt ,  
1972) and the c ircu la ting  levels o f several other hormones th a t influence  
carbohydrate metabolism (B ellinger e t a l , 1975; Ganguli & Forrester, 1972). 
Neural mechanisms, both inherent and in response to the hormonal and
metabolic environment might also modulate diurnal changes in carbohydrate 
metabolism. For example, food intake (Mayer, 1970), the secretion of 
various hormones (C a tt, 1970) and hepatic metabolism (Shimazu & Amakawa, 
1968) are affected in th is manner. Further information is required 
in order to understand the regulation of diurnal variations of carbo­
hydrate metabolism in conditions of both normal and compromised carbo­
hydrate balance.
Short term fasting exacerbated the hypoglycaemia of the insulinoma rats  
resulting in death by 6 hours. Contrary to expectation, plasma insu lin  
concentrations fe l l  s ig n ific a n tly  by that time. The reason fo r these 
observations could be due to the fac t that insu lin  secretion is an 
energy-requiring process. The severe hypoglycaemia could mean that 
glucose would be unavailable for this process resulting in a f a l l  in 
the plasma insu lin  concentrations.
CHAPTER 4
INTRA-ISLET RELATIONSHIPS BETWEEN B- AND A-CELLS
4.1 In tro d u c tio n
I t  is now established that the normal human and canine pancreatic is le ts  
contain A, B, D and PP ce lls  which secrete respectively glucagon, in s u lin , 
somatostatin and pancreatic polypeptide. Since Samols e t a l , (1965) f i r s t  
demonstrated that glucagon stimulated insu lin  release, and conversely, 
that insu lin  suppressed glucagon secretion (Samols e t a l , 1969; 1970), 
there have been numerous suggestions as to the paracrine in ter-re la tio n sh ip s  
between the various is le t  ce ll types (Marks, 1970; Samols e t a l , 1972; 
Wojcikowski e t a l , 1977; Unger & O rc i, 1977; Schatz & K u llik , 1980;
Itoh e t a l , 1980; Tanigawa e t a l , 1981; Taniguchi e t a l , 1980). By 
v irtue  o f the anatomical juxtaposition of the A, B, D and PP ce lls  
(Orci & Unger, 1975), and the existence of both t ig h t and gap junctions 
(Orci e t a l , 1973; Orci et a l , 1975a), i t  seemed reasonable to assume 
that some mechanism exists whereby the pancreatic hormones suppress or 
stimulate each others secretion. I t  would appear that the is le t  is an 
extraord inarily  complex micro-organ, with a highly sophisticated neural 
and vascular system and a multitude o f ways fo r the endocrine ce lls  to 
in te rac t with each other.
Though understanding of the possible paracrine in ter-re la tio n sh ip s  in  
the is le t  ce lls  has increased considerably in recent years, th is  has 
been based mainly on pharmacological experiements. The follow ing Table 7, 
summaries the current status of the work:
B A D pp
Insulin 4 r » 4 r > —^
Glucagon t ?
Somatostatin 4- ?
Pancreatic Polypeptide 7 ? ? 7
/T‘ = stimulatory —> = no discernible e ffe c t
^  = in h ib ito ry  ? = not known
Table 7 Current understanding of the in ter-re la tio n sh ip s  between the 
is le t  c e lls .
4 .1 .1  In s u l in
Exogenous insu lin  have been shown to in h ib it glucagon secretion in vivo 
and in v itro  (Samols et a l , 1970; 1972; Samols & Harrison 1976; Weir 
e t a l , 1976). Suppression o f c ircu la tin g  glucagon by 20-30% is read ily  
achieved with exogenous insu lin  during euglycemia maintained with a 
glucose clamp in man (Service e t a l , 1978; Asplin et a l , 1981). The 
concentrations of insu lin  (<v25mU/ml) necessary in v itro  fo r A -cell 
suppression are very high (Ostenson, 1979) perhaps because the A -cells  
are normally accustomed to being surrounded by such high insu lin  levels  
(Samols & Harrison, 1976; Weir e t a l , 1976).
The feedback of insu lin  on its  own secretion is s t i l l  a matter o f d is­
agreement. An autoregulation o f insu lin  secretion has been proposed by 
Ammon and Verspohl (1976) although the concept has been c r it ic iz e d  by 
Grodsky e t a l , (1973). I t  has also been suggested that exogenous 
C-peptide inh ib ited  insu lin  secretion in the isolated perfused ra t  
pancreas (Wojcikowski e t a l , 1977).
There is some controversy over the e ffe c t of insu lin  on D -cell s. In 
chronic studies with rats and mice, hypoinsulinaemia is associated with 
high plasma levels and hyperinsulinaemia is associated with reduced levels  
of somatostatin (Patel e t a l , 1978). Suppression of somatostatin sec­
retion by insu lin  has also been demonstrated by Gerber e t a l , (1981) 
and R ouiller e t a l , (1981) but was not confirmed by Patton e t a l , (1977) 
and Weir e t a l , (1979).
Exogenous insu lin  had no e ffe c t on pancreatic polypeptide secretion  
(Weir e t a l , 1979) by an isolated perfused canine pancreas with a glucose
containing perfusate. Hypoglycaemia however, is  a potent stimulus of 
pancreatic polypeptide secretion in vivo (Floyd et a l , 1976).
4 .1 .2  Glucagon
Although the insulinotrophic e ffe c t o f glucagon has been demonstrated 
as long ago as 1965 (Samols e t a l , 1965), there is  s t i l l  no proof that 
this is physiologically important. Conversely, i t  has not been esta­
blished that stim ulation of the B -cell can occur in an A -cell free  
environment, since no method has yet been found of se lec tive ly  destroying 
the A -ce lls . I f  the insulinotrophic ro le of glucagon can be substanti­
ated as physiologically important, our current understanding of gluc­
agon as a counter-regulatory hormone in glucose homeostasis as summarised 
by Unger & Orci (1981), w ill need to be revised.
Exogenous glucagon has also been shown to stimulate somatostatin release 
by the D -cells (Patton e t a l , 1976, 1977; Weir e t a l , 1979). In the 
isolated canine pancreas the insulin  and somatostatin stim ulatory  
responses are dose dependent, and occur in a biphasic pattern (Weir e t a l , 
1979). A raised glucose concentration c learly  potentiates glucagon's 
stim ulation of the B -c e ll, but not of the D -cell (Weir e t a l , 1979).
A negative feedback of glucagon on its  own secretion has not been reported.
4 .1 .3  Somatostatin
The major portion of pancreatic is le t  somatostatin appears to be iden tica l 
to hypothalamic somatostatin-14. Somatostatin is a potent in h ib ito r  of 
insulin  and glucagon secretion in vivo (A lberti e t a l , 1973; Koerker e t a l ,
1974) and in v itro  (Iversen, 1974; Efendic e t a l , 1974; Johnson e t a l ,
1975; Gerich et a l , 1975) in concentrations as low as 10 pg/ml
(Samols & Harrison, 1976a; Kawai & R o u ille r, 1981; Zyznar e t a l ,
1981).
Somatostatin is probably equipotent as an in h ib ito r of A- compared with 
B-cell secretion, with weaker effects  on the PP ce ll (Hermansen & Schwartz
1979), although some studies have suggested that somatostatin se lec tive ly  
in h ib its  insu lin  (Efendic e t a l , 1975; Raptis e t a l , 1977), while others 
found a suppressive preference fo r glucagon (Gerich et a l , 1975; Samols 
and Harrison, 1976). Secretion of insu lin  and glucagon by v ir tu a lly  a ll  
known stimulants can be inhib ited by appropriate concentrations of soma­
to s ta tin  (Gerich, 1981).
Although there is evidence that the pancreas contains several molecular 
species of somatostatin (Patel & R eichlin , 1978) most of these have not 
been adequately characterised. However, the presence of somatostatin-28 
(S-28) as a minor component (Benoit e t a l , 1980) is in te re s tin g , because 
i t  is about 10-100 times more potent than S-14 as an in h ib ito r  of the 
arginine-stim ulated A -cell i . e .  S-28 should se lec tive ly  in h ib it  the A -cell 
However, of scores of synthetic somatostatin analogs tested, the se lect­
iv ity  o f suppression fo r e ith e r the B- or A -cell has, at best, been 
re la tiv e  (Adrian e t a l , 1981).
The e ffe c t of somatostatin on the secretory function of D -cell and 
PP ce lls  is not known. There is also recent evidence to suggest a pro­
found disturbance of D-cells in diabetes (Orci e t a l , 1976; Patel e t a l , 
1977; Patel et a l , 1980). In in su lin -d e fic ie n t diabetes produced in rats  
by streptozotocin, there is a marked increase in pancreatic somatostatin 
concentration due to a hyperplasia of the D-cells accompanied by a para­
l le l  increase in gastric  somatostatin (Patel e t a l ,  1978).
4 .1 .4  Pancreatic Polypeptide
There lare finsu ffic ien t data a t the present time regarding the effects of 
pancreatic polypeptide on the other is le t  ce ll types to draw firm  con­
clusions, although in prelim inary reports Samols & Harrison, (1976), Ipp 
et a l , (1978) and Adrian et a l , (1978), suggested that pancreatic poly­
peptide has no e ffe c t on A -, B- or D -ce lls .
4 .1 .5  Other potential is le t  modulators
The ce lls  of the is le ts  are part of a larger "gastroenteropancreatic"
(GEP) system, and in addition to the four major ce ll types, ra rer D-j 
and P c e lls  (Solcia e t a l , 1978), whose secretions are not known, have 
been detected in the human pancreas. There are also reports of immuno- 
re a c tiv ity  in A -ce lls , or unidentified c e lls , fo r gastric in h ib ito ry  
polypeptide (Smith e t a l , 1977), cholecystokinin, (Grube e t a l , 1978), 
beta-endorphin (Grube e t a l , 1978a) secretin (Rufener e t a l , 1976), 
corticotrophin (Larsson, 1977) and g licen tin  (Moody e t a l , 1978). Vas­
oactive in tes tin a l peptide but not somatostatin (Larsson, 1980) is pre­
sent in is le t  nerves. The pancreatic is le t  ce lls  of many species con­
tain  dopamine and/or serotonin (Lundquist, 1971; Feldman, 1979) and 
k a llik re in  has been demonstrated in human B-cells (Olemoiyoi e t a l , 1979). 
All of the above in t r a - is le t  putative chemical messengers have been shown 
to influence the secretion o f insulin  and most have been described as 
stimulating or in h ib itin g  glucagon and somatostatin secretion. Their 
role in is le t  physiology has not been characterised.
4 .1 .6
Paracrine In te r-re la tio n s  Demonstrated by Neutralisation with Anti sera 
A major reason fo r the confusion over paracrine in ter-re la tio n sh ip s  bet­
ween the various is le t  ce lls  has been the absence of chemical agents cap­
able of se lectively  blocking is le t  ce ll functions o r, except in the case
of B -ce lls , se lective ly  destroying them. Hence for example, i t  has 
been v ir tu a lly  impossible to study B-cell function in iso lation  from 
A -ce lls . An a ttra c tiv e  approach to this problem is the use of antibodies 
specific  to the secretory products of each of the is le t  ce ll types in 
an attempt to neutralise th e ir  effects and/or block th e ir  secretion.
The in jection  of insulin  antibodies has been shown by previous in ve s ti­
gators (Moloney and Coval, 1955; Armin et a l , 1966) to produce marked 
and transient hyperglycaemia proportional in in tensity  and duration to 
the quantity of anti serum administered. Attempts have also been made 
to produce an analogous condition of glucagon deficiency by the in jection  
of glucagon antibodies (Grey et a l , 1970; Barling & Beloff-Chain, 1973; 
Epand and Douglas, 1973; Holst e t a l , 1978; Kumar e t a l , 1978). These 
have variously been described as producing a mild to moderate lowering 
of the blood glucose concentration or, more commonly, as having no sign­
if ic a n t  e ffe c t. In fasting genetically  hyperinsulinaemic (ob/ob) mice, 
ontheother hand, glucagon antibodies do produce a f a l l  in blood glucose 
concentration (F la tt  e t a l , 1979).
There have been several studies in which large amounts of somatostatin 
antiserum have been injected into rats and dogs intravenously 
(Schusdziarra e t a l , 1978; Tannenbaum et a l , 1978). In several o f these, 
no changes in the concentration of c ircu lating  insulin and glucagon were 
observed and blood glucose levels were unchanged, but in another there 
was an increase in plasma insulin concentration (Schusdziarra e t a l , 
(1980).
Another approach has been to incubate isolated is le ts  with antisera.
This has been reported fo r somatostatin antisera (Taniguchi e t a l , 1977; 
Barden e t a l , 1977; Itoh e t a l , 1980; Schatz & K u llick , 1980; Tanigawa 
et a l , 1981), and have yielded s im ila rly  conflic ting  resu lts . Barden 
et a l , (1977) reported that anti somatostatin increased glucagon but not 
insulin release from ra t is le ts  incubated in the presence of 5.5 mM 
glucose. In contrast, Taniguchi et a l , (1980) reported that preincubatt 
of ra t is le ts  with anti somatostatin enhanced insulin release when the 
is le ts  were subsequently incubated in the presence of 3.3 and 8.3 mM 
glucose, but not when incubated with 16.7 mM glucose.
A th ird  approach has been the infusion o f anti serum into isolated per­
fused pancreases. Several reports where somatostatin anti sera have been 
infused into perfused ra t and canine pancreas have yielded uniformly 
negative results (Anmura et a l , 1978; Sorenson e t a l , 1980). Neutra­
lis a tio n  of somatostatin fa ile d  to raise insu lin  and glucagon concen­
tra tio n s .
The studies mentioned above are subject to several c ritic ism s . The 
variable e ffects  of anti serum administration could be due to a t least 
4 d iffe re n t factors:
1) Incomplete neutralisation of the c ircu la tin g  hormone -  Antibodies 
when administered should have a high a f f in i ty  to ensure complete 
n eutra lisa tio n , and a high binding capacity a t 37°C, to avoid 
infusing excessively large volumes (Barling & B eloff-C hain, 1973; 
Heding, 1972). In some of the studies mentioned, binding chara­
c te ris tic s  of the anti sera used were not described, w h ils t other 
employed anti sera of low binding capacities. In view of the large
quantities needed fo r such studies, i t  is understandable that 
workers have tended to use poorer quality  antiserum. However, 
th is has led in some cases to infusing excessively large volumes, 
of anti serum in an attempt to ensure complete neutra lisation  of 
the hormone. The characteristics of the d iffe re n t anti sera used 
could account fo r some of the discrepancies.
Lack of s p e c ific ity  -  The monospecificity of the anti serum is  
c r i t ic a l ly  important because the presence o f cross-contaminants 
with other pancreatic hormones might a ffe c t the is le t  ce ll d ire c tly . 
Such antibodies would, in a d d itio n / in te rfe re  with the radioimmuno­
assay of other hormones in the serum and in v itro  incubation medium. 
This is p artic u la rly  important in the case of insu lin  and glucagon 
antibodies. Purified preparations of insu lin  used fo r antiserum 
production may contain small amounts of glucagon and pancreatic 
polypeptide, and glucagon preparations are often contaminated with 
in su lin . This problem would obviously be solved by monoclonal 
antibodies. But in the absence of such monoclonal antibodies, con­
ventional antibodies must be care fu lly  characterised and th e ir  mono­
sp e c ific ity  checked by radioimmunoassay and i f  necessary, by a f f in i ty  
chromatography. I t  is  also important to demonstrate that the hormone 
to be measured can indeed be recovered in the presence o f antibodies
to the other is le t  hormones.
Presence of contaminants - The m ajority of studies mentioned admin­
is te r  neat anti serum into animals. However, the potential influences 
due to contaminants or to the serum constituents themselves can best 
be avoided or minimised by using purified  immunoglobulins.
Experimental design -  Studies with infusion of somatostatin antisera  
appear to be based on the assumption that the secretion o f in su lin
and glucagon in the unstimulated state is  ac tive ly  in h ib ited  by
somatostatin secretion. Hence the removal of this in h ib itio n  by 
somatostatin antiserum would be expected to resu lt in a rapid release 
of insulin  and glucagon. This assumption may not be true. Rather, 
i t  is more probable that the role of somatostatin in the in h ib itio n  
of insu lin  and glucagon secretions only comes into e ffe c t during 
B- and A-cell stim ulation. I f  th is  is the case, neutra lisation  of 
somatostatin by anti serum in the unstimulated state would not resu lt  
in increased insu lin  and glucagon release. To demonstrate the in tra ­
is le t  somatostatin in h ib itio n  of insu lin  and glucagon secretions, 
experiments should be designed whereby in su lin , glucagon and somato­
s ta tin  are simultaneously stimulated and attempts made to abolish 
the in h ib itin g  effects with somatostatin anti serum.
In this study the role of glucagon in insu lin  release was investigated  
by incubating isolated is le ts  in v itro  with glucagon antiserum. The 
role of glucagon in glucose homeostatis w ill  also be studied in v ivo . 
Fina lly  using ce ll suspensions prepared from the ra t insulinoma as an 
A-cell free model, the insu lin  response to glucose, arginine and glucagon 
stimulation w ill fu rth er contribute to our understanding of the in te r ­
relationship between the B- and A -ce lls .
4.2 Methodology
4.2.1 Characterisation of glucagon anti serum
A C-terminal reacting glucagon anti serum, MF/Y6 was obtained from Guildhay 
Anti sera, Guildford, U .K ., with a t i t r e  of 1:180,000 (T s io lak is , 1979).
The anti serum was produced in h a lf-lo p  rabbits immunised with a g lu ta ra l-  
dehyde conjugation of glucagon to egg albumin and em ulsification in Freund' 
complete adjuvant. , A pool of anti serum from rabbit Y6 was analysed fo r  
s p e c ific ity , av id ity  and binding capacity.
Results
Cross re a c tiv ity  studies fa ile d  to reveal any interference from in su lin
(Nova Research In s t itu te , Copenhagen), gastrin (MRC, National In s titu te
for Biological Standards and Controls, London) secretin ( Karolinska
In s titu te , Stockholm), gastric in h ib ito ry  polypeptide (Dr. John Brown,
University of B ritish  Columbia, Vancouver) and vasoactive in tes tin a l
polypeptide (Karolinska In s titu te , Stockholm) as shown in Fig. 49.
Further evidence fo r the monospecificity of the anti serum and the absence
of insu lin  antibodies in MF/Y6 antiglucagon is shown in Fig. 50. Although
125the insu lin  antiserum, MF/GP/4 bound to I- in s u lin , no binding was 
observed fo r both glucagon antisera, MF/Y6 and MF/R/4-LB. Recoveries 
of exogenous porcine insu lin  added to plasma samples containing an 
immunoglobulin ( Ig ) fraction  of the glucagon antiserum, MF/Y6 (1:20) 
were carried out (F ig . 51). The results indicate that the recovery of 
in su lin , as measured by radioimmunoassay, is possible in the presence 
of anti-glucagon Ig , MF/Y6. A ff in ity  chromatography o f the anti serum 
has also been performed according to deta ils  described in section 2 .2 .3 .
The a f f in i ty  p u rified  antibodies were found to be specific  fo r  glucagon 
as determined by immunocytochemistry.
The pool o f glucagon antisera, MF/Y6 was incubated with increasing
125amounts o f unlabelled glucagon and 15 pg I-glucagon tracer in a 
volume of 0.45 ml. Free and bound hormone were separated by double 
antibody p rec ip ita tio n . From the binding data, a Scatchard p lo t was 
constructed (F ig . 52).
The non-linear shape o f the Scatchard p lo t indicated the presence of
two classes of glucagon binding s ite s . The higher a f f in i ty  class of
antibodies was found to have an equilibrium  constant o f 2.9 x 1 0 ^  litre s /m o l
and a binding capacity of 6030 nm ol/I. The a f f in ity  class of antibodies
9had an equilibrium  constant of 3.7 x 10 litres /m o l and a binding 
capacity of 20.16 mmol/L.
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Preparation o f  an ti-g lucagon  serum Ig  f ra c t io n  and concentra tion  o f
glucagon antibodies
The glucagon antibodies used in this study were added as Ig fraction  
prepared in the following way: two volumes of saturated ammonium sulphate 
were added drop by drop to one volume of anti-glucagon serum with con­
tinuous s t ir r in g  using a magnetic s t ir r e r .  The mixture was then c e n tr i­
fuged fo r 20 minutes. Part of the supernatant was kept fo r detection  
of any antibodies that were not precipitated and the rest was discarded. 
The precip itated Ig was dissolved with the in i t ia l  volume of sa lin e , 
placed in a d ia lysis  sac and dialysed against a t least 5 changes of 
0.9% NaCl a t 4°C. I t  was then stored and kept frozen at -20°C.
Recovery of glucagon antibodies in the Ig preparation 
The glucagon antibodies recovered in the ammonium sulphate precip itated  
globulin were assessed by constructing anti serum d ilu tio n  and displace­
ment curves. These curves were found to be almost superimposable with 
those obtained fo r the neat antiserum, (F ig . 53 and Fig. 54) indicating  
complete recovery of glucagon antibodies in the Ig preparation. More­
over, incubation o f seria l d ilutions of the supernatant obtained a fte r
125the ammonium sulphate precip ita tion  with I-glucagon did not show any 
detectable antibodies and simply paralleled dilutions of the supernatant 
obtained from s im ila rly  precipitated non-immune serum.
Discussion
As the variable e ffe c t of glucagon antibodies administration in previous 
studies could be the resu lt o f incomplete neutralisation o f c ircu la tin g  
glucagon, an attempt to demonstrate by immunochemical methods i f  the 
administration of potent glucagon anti sera to rats w ill lead to an 
extensive neutralisation of endogenous glucagon was considered to be
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necessary. In th is study, a pool of antiglucagon serum raised in rabbits  
was used with a binding capacity, av id ity  and t i t r e  more potent then the 
antisera used in previous studies (Grey et a l , 1970; Barling & Beloff-Chai 
1973; Dunbar e t a l , 1978) and s im ilar to the characteristics o f the 
anti serum used by Holst e t a l , (1978).
Indications that an extensive binding and neutra lisation of endogenous 
glucagon occurs a fte r  the administration of antibodies are as follows:
(a) the binding capacity and av id ity  o f the dose of antibodies in jected  
(0 .5  ml per 200 g ra t) in a ll experiments done appears to be adequate 
The to ta l binding capacity of the antibodies used, calculated as
the sum of both binding s ite  capacities, was about 13 nmol which 
is capable of neutralising some 12 times the to ta l content of glu­
cagon in the ra t pancreas, estimated by Barling & Beloff-Chain,
(1973) to be 1.08 nmol. Even i f  only the high a f f in i t y ,  low cap­
ac ity  class of antibodies is taken in to account, the binding cap­
ac ity  calculated to be 3 nmol per ra t is three times la rger than 
the to ta l glucagon content of ra t pancreas and almost 90 times 
larger than the to ta l glucagon production over 60 min of the mod­
erate ly  stimulated ra t pancreas quoted to be 0.032 -  0.052 nmol/hour 
(Luyckx, 1974).
(b) the a f f in ity  for glucagon antibodies (high a f f in i ty  class) which
was calculated to be 2.9 x 1 0 ^  litres /m ol is much higher than that
reported for the hepatic glucagon receptor of the ra t by Rodbell
et a l , (1971) (2 .5  x 10^ litre s /m o l) and Cautrecases (1974)
9(4 x 10 litre s /m o l). This would favour the binding o f c ircu la tin g  
glucagon to antibody rather than to the target organ receptor.
(c) in e a r lie r  studies, using the same anti serum MF/Y6, the e ffe c t o f 
exogenous glucagon administered in a dose of 5 jjg per ra t  
(0.47 nmol/kg body weight) which in controlled rats produced sign­
if ic a n t  hyperglycaemia reaching a peak of 12 mmol/L, was masked by 
the antibodies injected (Tsiolakas, 1979). This suggests that the 
dose of antibodies used is capable of neutralising both endogenous 
and the exogenously added glucagon.
Evidence for the monospecificity of antiglucagon, MF/Y6 were pre­
sented. In p articu la r the absence of any insulin binding capacity 
in MF/Y6 was shown not only by the lack of c ross-reactiv ity  with
unlabelled in su lin , but also by the absence of any binding with 
125 I-m s u lm . This was considered to be important because the pre­
sence of insulin  antibodies in the glucagon anti serum might in f lu ­
ence pancreatic function d ire c tly  and in terfe re  with plasma insu lin  
measurements by radioimmunoassay.
4 .2 .2  Animal experimentation in vivo
Male Wistar albino rats weighing around 200 g were anaesthetised with 
sodium pentobarbitone (50 mg/kg body weight; Sagatal, May and Baker L td ., 
England). 0.5 mis of antiglucagon immunoglobulins (Ig ) or normal rabbit 
Ig , reconstituted in saline were in jected into the femoral vein. The 
animals were then le f t  fo r 20 minutes before fu rther experimentation.
All animals were bled from the ta i l  vein. Blood was collected in to  
polyethylene microfuge tubes that had been precoated with heparin 
(500 U/ml). Plasma was separated by centrifugation fo r 10 seconds at 
approximately 900 g using a microfuge (Type B, Beckman L td ., High Wycombe)
and stored at -20°C u n til glucose and insu lin  analyses were performed.
4 .2 .3  Iso lation of is le ts  of Langerhans in v itro  
Introduction
The insulinotrophic e ffe c t of glucagon in the in v itro  isolated pan­
creatic  is le ts  was investigated by neutralis ing A -cell glucagon with 
an antiglucagon Ig frac tio n . Insulin secretion by is le ts  in response 
to glucose, arginine and glucagon in the presence and absence o f a n ti-  
glucagon Ig were studied.
Unlike other studies where incubation with the anti serum only takes 
place a fte r  iso lation of is e lts , (Tanigawa et a l , 1981; Taniguchi e t a l ,
1980), the is le ts  in th is study were prepared from rats previously in ­
jected with 0.5 ml ( iv )  o f the antiglucagon Ig . This u tilis e s  the ra t's  
own c ircu lation  system to fa c i l i ta te  the transport o f the anti-glucagon 
Ig to the is le t  A -ce lls . This approach is to be preferred as i t  ensures 
an even d istrib u tio n  of antiserum throughout the whole is le t  mass. A fter 
iso lation of is le ts , fu rther incubation with antiserum was carried out 
during the pre-incubation and incubation stages.
The method of iso lating  is le ts  used in th is study is essen tia lly  that 
of Lacy e t a l , (1967, 1972) and Buitrago e t a l , (1977) involving c o lla -  
genase digestion.
Enzymes
Pancreatic fragments were digested with collagenase (Type V, 2 mg/ml; 
Sigma Chemical Co., St. Louis, USA) and DNAase (20 ug/ml; Sigma Chemical
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Co., St. Louis, USA). Addition of DNAase to the collagenase digest is 
a pre-requis ite  fo r successful separation of is le ts  by preventing clumping 
of the ce lls  (Buitrago, 1977). Rupture of the cell nucleus leads to 
release o f DNA which tends to aggregate c e lls . DNAase acts on the DNA 
released during enzymic digestion with the collagenase.
Buffers
Hank's physiological medium (Wellcome Reagents L td ., Beckenham, U.K.) 
was used in the preparation of the is le ts . A ll incubations were carried  
out in a Kreb-Ringer physiological buffer pH 7.4 + 0.2% BSA.
Percoll™
In th e ir  f i r s t  report, Lacy and Kostianovsky (1967) suggested the use 
of a sucrose gradient fo r  the separation of is le ts  from exocrine tissue  
during c e n trifig a tio n . This was la te r  replaced by F ico ll because o f its  
lower viscosity and osm olality. F ico ll was, however, of lim ited  use with  
biological materials because o f its  to x ic ity . For th is  reason, a new 
non-toxic density medium called Percoll was developed (P e rto ft and 
Laurent, 1977; Buitrago e t a l , 1977).
TMPercoll (Pharmacia Fine Chemicals, Uppsala) is a medium based on c o ll­
oidal s i l ic a . The advantages of using s ilic a  fo r density gradient cen­
trifu g a tio n  have been reviewed by Wolff (1975) and P erto ft and Laurent 
(1977). The mode of action o f Percoll is  a d irec t consequence of the 
size heterogeneity among Percoll p a rtic le s , resulting in th e ir  sedimenting 
at d iffe ren t rates in a gravitational f ie ld  creating a density gradient. 
Sample partic les layered on top of a preformed gradient w ill be separated 
on the basis of th e ir  re la tiv e  densities. Is le ts  with densities between 
1.065 -  1.075 g/ml sediment at the bottom, whereas exocrine tissues with 
densities between 1.015 - 1.045 g/ml remain at the top o f the gradient.
A 3.5% Percoll solution (Buitrago et a l , 1977) diluted in Hank’s medium 
was used throughout th is  study.
Method
A flow diagram of the methodology is shown in Fig. 55. 0.5 ml o f the
rabbit anti glucagon Ig , MR/Y6 was injected into the femoral vein of 
200 g male w istar albino ra ts . Controls received 0.5 ml of the normal 
rabbit Ig . A fter 20 minutes, the rats were k ille d  by cervical d is lo ­
cation and the pancreas immediately removed and placed in c h illed  Hank's 
medium. Fatty tissues were trimmed o ff  and m ultiple point in jections  
made with d iluted Hank's solution to distend the pancreas.
The pancreas was then sliced as fin e ly  as possible with a p a ir  o f fin e  
scissors, placed in a tube and washed twice with ch illed  Hank's medium. 
Collagenase (2 mg/ml) and DNAase (20 jjg /m l) was added.
The tube was stoppered and hand shaken in a 37°C water-bath fo r 10 min­
utes. Shaking was continued u n til no pieces or threads o f tissue are 
evident on the sides o f the tube. The digest was then d ilu ted with 
20 ml o f ch illed  Hank's medium and stood on ice fo r 2 minutes to allow  
the heavier is le ts  to sediment. The supernatant was then discarded.
This washing was repeated 4 times.
At the end of th is , the crude is le t  preparation was ca re fu lly  layered  
on top of the 3.5% Percoll medium contained in a wide-diameter 50 ml 
glass beaker. Is le ts  sediment through the Percoll medium w ith in  
10 minutes a t unit gravity .
0.5 ml anti-glucagon Ig ( i .v . )
0 .5m l normal rabbit I g ( i . v . )
20 mi n.
VPreparation of is le ts
2 mg/ml collagenase 
Percoll gradient
¥
Preincubation 37 C, 0 ^
Kreb's bicarbonate bu ffer, 
pH 7.4 + 0.2% BSA
45 min
Incubation
Flow diagram fo r the iso lation  of ra t 
pancreatic is le ts  following administration  
of immunoglobulins(i.v.)
The is le ts  were harvested and subsequently pre-incubated a t 37°C in 
Krebs bicarbonate buffer containing 0.2 % bovine serum albumin (BSA) 
fo r a period of 45 minutes with oxygenation (95% 0^:5% CO^). Also at 
th is  stage, is le ts  were incubated in the presence e ith e r o f anti glucagon 
Ig (1 :5 0 ), or normal rabbit Ig (1 :50 ).
At the end of the pre-incubation, is le ts  were placed on a petri dish with 
fresh oxygenated Krebs bicarbonate b u ffe r, and transferred to te s t-  
tubes with the aid of a fine  ca p illa ry  tube and a dissecting microscope.
The incubation medium consists of pre-oxygenated Krebs bu ffer a t 37°C 
with 0.2% BSA. Antiglucagon Ig (1:20) and normal rabbit Ig (1:20) were 
added to the appropriate tubes. A ll s ta tic  incubations were carried out 
in a shaking water bath a t 37°C.
Insulin  secretion in the incubation medium was measured by radioimmuno­
assay as described in section 2 .2 .4 . Is le t  protein was determined 
according to the method of Lowry e t a l , (1951) and results expressed as 
ng insulin/mg is le t  protein.
4 .2 .4  Preparation of ce ll suspensions from the tranplantable ra t insulinoma 
Methodology
Rat insulinoma cell suspensions were prepared according to the method 
described by Erlichman et a l , (1979). Insulinoma-bearing rats were 
k ille d  by cervical dislocation and the tumour removed, dissected free  
of capsule and minced fin e ly  in Hepes b u ffe r, pH 7.4 (3 mM Hepes, 144 mM 
NaCl, 4 mM KC1 y 1 mM MgC^ and 5.5 mM glucose; Hepes was purchased from 
Sigma Chemical Co., St. Louis, USA; a ll  other chemicals were obtained 
from BDH Chemicals, Poole, U .K .). The minced tumour was rinsed four
194
times by suspension in ch illed  Hepes bu ffer. This washing procedure 
removed most of the dead and broken c e lls .
The minced tumour fragments were then suspended in Hepes buffer which 
contained 0.02% collagenase and 0.1% bovine serum albumin (BSA) and 
incubated at 37°C with gentle s t ir r in g . A fter 10 minutes, the ce ll 
suspension was allowed to stand in ice fo r 5 minutes, and the super­
natant was centrifuged at 250 g to p e lle t the dispersed c e lls .
The undigested fragments were again incubated with collagenase u n til 
an adequate quantity of ce lls  was obtained. The harvested ce lls  were 
washed four times with Hepes bu ffer. Single ce lls  were obtained by 
f i l te r in g  the washed ce lls  through two layers of lens-cleansing tissue. 
Lens-cleansing tissues permit the passage of single ce lls  while re ta in ­
ing ce ll aggregates and large debris.
The single ce ll suspensions were then washed and reconstituted in Hepes 
buffer to which 1 mM CaCl^ was added. At least 90% o f the c e lls  obtained 
by th is procedure were v ia b le , as judged by th e ir  capacity to exclude 
trypan blue.
S ta tic  incubations were performed a t 37°C in a shaking water bath. At 
the end of the incubation, ce lls  were separated by centrifugation and 
the supernatants assayed for immunoreactive insu lin  by RIA, as previously 
described in section 2 .2 .4 .
4.3 Results
( a) Role of glucagon in insu lin  secretion and glucose homeostasis in vivo 
Effect of L-Arginine
The e ffe c t o f  arginine stim ulation on plasma insulin  concentrations were 
studied in rats passively immunised with 0.5 ml of anti glucagon Ig . Con­
tro l rats received an in jection  of 0.5 ml of normal rabbit Ig . A ll an i­
mals received an in traperitoneal in jec tio n  of L-arginine monochiorhydrate 
(1 .5  g/kg body weight; Sigma Chemical Co., S t. Louis, USA) 20 minutes 
a fte r  Ig in jections.
Arginine administration resulted in a s ig n ifican t increase ( p < 0.001) 
in plasma insulin  concentrations in the control ra ts . However, the 
insulin  repsonse to arginine was inh ib ited  in rats passively immunised 
with anti glucagon Ig (F ig . 56).
E ffect of glucagon
The insulinotrophic e ffe c t o f glucagon was investigated by in trap erito n - 
eal administration o f glucagon (1 .5  mg/kg; E li L i l ly  & Co., USA) in to  
tes t animals. The control group Was given i.p. saline in jec tio n s . Both 
groups were passively immunised with normal rabbit Ig 20 minutes before 
stim ulation. Glucagon stimulated an insu lin  release in the te s t animals 
that was s ig n ific a n tly  higher ( p< 0.001) than control levels (F ig . 57).
E ffect on plasma glucose a fte r  neutra lisation of endogenous glucagon 
and insulin
Five groups of 6 rats were used in th is  experiment. Twenty minutes a fte r  
being anaesthetised, the following were administered:
Group (a) 0.5 ml rabbit antiglucagon Ig;
Group (b) 0.5 ml normal rabbit Ig as a control fo r Group (a );
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Fig.57 Effects of glucagon (1 .5  mg/kg, ip ) on 
plasma insu lin  in rats [ •  ) .  Control ( o ) 
ra ts , received an in jection  of saline. Both 
groups were administered 0.5 ml of normal rab b it 
Ig , Mean - SEM (n=6).
Group (c) 0.5 ml guinea pig an ti-in s u lin  Ig (see section 2 .2 .4 );
Group (d) 0.5 ml normal guinea-pig Ig as a control fo r Group (c );
Group (e) combination of antiglucagon (0 .5  ml) and a n ti-in s u lin  
(0 .5  ml) Ig .
Animals were bled from the ta i l  vein and plasma samples assayed fo r  
glucose as previously described (see section 2 .2 .3 ) .
No depression of plasma glucose concentrations were observed a fte r  
anti glucagon Ig administration (F ig . 58). Plasma glucose concentrations 
of the tes t group were s im ilar to control levels throughout the duration 
of the experiment. The rise in glucose concentration in both groups 
at 150 minutes was due to the animals regaining consciousness at that 
time. S im ilar hyperglycaemic peaks have also been reported in mice 
recovering from pentobarbitone induced anaesthesia (Bailey & F la t t ,  1980).
Administration of a n ti-in s u lin  Ig (Group c ) , resulted in a s ig n ific a n t  
hyperglycaemia lasting 60 minutes (F ig . 58). Plasma glucose concentra­
tions at 20 and 40 minutes were s ig n ific a n tly  (p< 0.001) raised compared 
with control levels (Group d).
Administration of a combination of a n ti-in s u lin  and antiglucagon Ig 
(Group e) resulted in a s im ilar hyperglycaemia over the same time period 
(F ig . 58). Plasma glucose concentrations a t 20 and 40 minutes were sign­
if ic a n t ly  raised (p< 0.001) compared with concentrations a t zero time. 
However, plasma glucose concentrations at 20 and 40 minutes in Group (e) 
were not s ig n ific a n tly  d iffe re n t from concentrations a t the same time 
point in rats given the an ti-in s u lin  Ig on its  own (Group c ). This
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suggests that the plasma glucose p ro file  of groups (c) and (e) are in 
fac t superimposable.
(b) Role of glucagon in insu lin  secretion in isolated is le ts  in v itro  
Effects of Arginine and Glucose
Is le ts  from rats pretreated with e ith er anti glucagon Ig or normal rabbit 
Ig (0 .5  ml, iv ) were isolated and further incubated in the appropriate 
immunoglobulins (1 :20 ). Time course studies of insu lin  release were 
carried out.
In the control is le ts , i . e .  is le ts  prepared from rats given normal 
rabbit Ig and further incubated with normal rabbit Ig , there was a b i-  
phasic insu lin  response to L-arginine hydrochloride (4 mM) (F ig . 59).
This insulinotrophic e ffe c t was almost completely abolished in is le ts  
from the antiglucagon pretreated rats (p< 0.001) although insu lin  secre­
tion at 25 min. was s ig n ific a n tly  higher ( p < 0.001) than levels a t zero 
time.
A further series of experiments were conducted in which s ta tic  incuba­
tions of is le ts  were carried out in the presence and absence o f a n ti-  
glucagon Ig . At the end of 30 minutes incubation, aliquots o f the 
incubation medium were assayed for insu lin .
In the presence of normal rabbit Ig (1:20)., arginine hydrochloride 
(4 mM) stimulated insulin  secretion (50.0 + 2.0 ng/mg is le t  protein) 
compared with controls (17.2 + 1.1 ng/mg is le t  protein) (F ig . 60 ).
This insulinotrophic e ffe c t was abolished by addition of antiglucagon 
Ig to the medium (17.8 + 0.4 ng/mg is le t  protein; p < 0 .001 ). In contrast,
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D-glucose (20 mM) in the medium stimulated insu lin  secretion both from 
is le ts  incubated with normal rabbit Ig (37.8 + 2.2 ng/mg is le t  protein) 
or antiglucagon Ig (38.8 + 2.6 ng/mg is le t  pro te in ).
Effects o f glucagon
The insulinotrophic e ffe c t o f glucagon in isolated is le ts  was investigated. 
Is le ts  from rats previously infused with normal rabbit Ig (0 .5  ml) were 
isolated and further incubated in 1:20 normal rabbit Ig . Glucagon stim­
ulation (1 .5  rM) resulted in a biphasic pattern of insu lin  secretion  
(F ig . 61).
(c) Insulin  release by insulinoma ce ll suspension in v itro  
Insulin secretion by insulinoma ce ll suspensions in response to glucose 
(20 mM), arginine (10 mM), tryptophan (10 mM) and glucagon (3 nM) was 
studied. Neither glucose nor arginine stimulated insu lin  secretion above 
high basal levels (Fig.; 62). However, tryptophan stimulated a small but 
s ig n ifica n t insu lin  response ( p< 0 .0 1 ) ,  whereas glucagon evoked an 
exaggerated insu lin  secretion (p< 0 .001).
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4.4 Discussion
The aim of this study was to investigate the role of glucagon in insu lin  
secretion. Although the insulinotrophic e ffe c t of glucagon is now widely 
accepted, there is s t i l l  no proof that i t  is physiologically important. 
Evidence fo r its  role in insu lin  secretion has been based mainly on 
pharmacological experiments.
A major obstacle to elucidating the physiological role o f glucagon has 
been the absence of any method that can se lec tive ly  block A -cell secre­
tio n . In recent years however, glucagon specific  antibodies have been 
used fo r th is  purpose and is proving to be a powerful tool in elucidating  
glucagon physiology by neutralis ing the effects  o f endogenously c irc u l­
ating glucagon (Holst e t a l , 1978).
In e a r lie r  work from th is  laboratory, i t  was shown that arg in ine- 
stimulated and oral tryptophan-stimulated insu lin  release was blocked 
by glucagon anti serum in vivo in rabbits and in rats (Al Tamer, 1978; 
Tsio lak is , 1979). This study d iffe rs  from the previous two in experi­
mental design. Anti glucagon Ig was in jected in to  the femoral rather 
than the jugular vein, and the arginine was administered as a single  
in traperitoneal in jection  rather than an intravenous infusion over 
30 minutes via the jugular vein.
The in h ib itio n  o f arginine-stim ulated insu lin  release by glucagon spec­
i f i c  antibodies was confirmed in the present study. Administration o f 
glucagon antibodies in vivo almost completely abolished the in su lin  
response a fte r  arginine stim ulation in ra ts . In addition, the stimu- 
a ltio n  of insulin  release by exogenous glucagon was also demonstrated.
These observations can be explained in one of two ways (F ig . 63 ). The 
results are consistent with the hypothesis that arginine and other 
amino acids that stim ulate both glucagon and insu lin  secretion do so 
in a step-wise manner -  with glucagon serving as a mediator or potent­
ia to r  of the insulinotrophic e ffe c t (Samols e t a l , 1972). Antibodies 
entering the is le ts  block the secretion of A -cell glucagon thus pre­
venting its  stim ulation o f the B -c e ll. A lte rn a tiv e ly , the above data 
could be explained by the glucagon that is  released from the A -cells  in  
response to arginine stim ulation , acting on the liv e r  to stim ulate g ly- 
cogenolysis and gluconeogenesis. The resu ltant rise in blood glucose 
concentrations in turn acts on the pancreatic B-cell to stim ulate insu lin  
release. In th is  case, antibodies act by neutralis ing the glucagon 
released and prevents its  stim ulation o f hepatic glycogenolysis and 
gluconeogenesis.
To further c la r ify  the mechanism of arginine-stim ulated insu lin  secre­
tio n , s im ilar experiments were conducted in isolated pancreatic is le ts .  
Arginine stimulated a biphasic insu lin  response in the control is le ts .
In agreement with the in vivo data, th is  insulinotrophic e ffe c t was 
almost completely abolished in is le ts  incubated with glucagon antiserum. 
Furthermore, exogenous glucagon stimulated a biphasic insu lin  response 
in the control is le ts . These results provide further evidence fo r  the 
paracrine role of A -cell glucagon in insu lin  secretion. Antibodies in  
the is le ts  block the secretion o f A -cell glucagon and prevents its  
stim ulation o f the B -c e ll.
In contrast to argin ine, the glucose-stimulated insu lin  secretion was
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not abolished by glucagon anti serum. This divergence suggests that 
d iffe re n t mechanisms are involved in insulin  release by glucose and by 
arginine. There is general agreement that glucose has a d irec t action 
on the B -cell (review by Lacy, 1977) e ith er through being metabolised 
and forming specific  metabolites or cofactors which in i t ia te  insulin  
release (Grodsky e t a l , 1963) or by activating glucoreceptors on the 
B-cell membrane (Matschinsky et a l , 1971). This would explain why 
glucagon anti serum had no e ffe c t on its  insulinotrophic a c t iv ity . In 
contrast, evidence from the present study suggests that the in su lin -  
otrophic e ffec t of arginine is mediated by the A -ce lls . The possible 
mechanisms involved in B-cell stimulation are summarised in the following  
(F ig . 64).
A major problem to a more general acceptance of the insulinotrophic  
e ffec t of glucagon as being physiological,is associated with the d i f f i ­
cu lties  involved in demonstrating the secretion of glucagon that pre­
cedes the insu lin  release (Gerich e t a l , 1974). Furthermore, i t  was 
argued that glucose, a major regulator of both ce ll types in vivo and 
in v it r o , stimulates insulin  release without a corresponding release of 
glucagon. Recently however, Pek et a l , (1976) have demonstrated that 
glucagon release does precede insulin secretion in response to a number 
of common secretogogue in the isolated perfused ra t pancreas. Dencker 
e t a l , (1975 ) studying insulin and glucagon release in human subjects 
in response to a test mixed meal, found that in two o f the three subjects, 
portal venous plasma glucagon, sampled through an indwelling catheter, 
showed an early  increase before decreasing to below basal values as 
insulin  concentrations rose. S im ila rly , in gastric in h ib ito ry  polypep­
tide (GlP)-stimulated insu lin  secretion, glucagon release has been re­
ported to occur simultaneously or preceding insu lin  release (Dupre e t a l ,
1980).
Despite these attempts, there remains a fundamental d if f ic u lty  inherent 
in the measurement of glucagon release p rio r to insu lin  secretion. I f  
as i t  is  proposed here, the major role of glucagon is the stimulation  
of insulin  secretion, then the vast proportion of the glucagon released 
by the A -cell w ill be aimed a t the is le t  B -ce lls . What is measured in 
the peripheral c ircu lation  represents only a small proportion of the 
glucagon release -  a sort of "s p ill over" from the is le ts . The con­
centration o f glucagon in the in t ra - is le t  in te r s t i t ia l  f lu id  is about 
100 times that of the plasma. Therefore large changes of glucagon con­
centration within the is le ts  themselves w ill resu lt in re la tiv e ly  small 
ones in the peripheral c ircu la tio n . There could therefore be consider­
able d if f ic u lt ie s  in measuring such small changes in plasma glucagon 
concentrations. Conversely, i t  could be argued that in order to obtain 
glucagon concentrations of the magnitude needed in the is le ts  to stim ulate  
B -ce lls , large pharmacological doses have to be administered in to  the 
peripheral c ircu la tio n . Therefore the administration of exogenous glu­
cagon several fold higher than the plasma "physiological leve l"  is not 
an argument against its  role in insulin secretion. A second problem is 
one of timing. The early phase of insulin secretion occurs less than 
2 minutes a fte r  stimulation (Lacy, 1977). Glucagon secretion would 
have to take place before this time. Whether such rapid secretions 
intended for the is le t  B-cells can be measured accurately in the p e r i­
pheral c ircu lation  is seriously doubted.
The view of glucagon as a counter-regulatory hormone to insu lin  in 
maintaining glucose homeostasis is widely accepted (Unger and O rc i, 1981; 
von Schlenck, 1981). I t  is believed that the primary role o f glucagon 
is to "reverse" the hypoglycaemic e ffe c t of insu lin  by stim ulating
glycogenolysis and gluconeogenesis. However, th is bihormonal theory 
is d i f f ic u lt  to reconcile with the evidence from the present study that 
glucagon is a potent in su lin  secretogogue, and that i t  plays an essential 
role in the stim ulation of insu lin  secretion by arginine.
In order to elucidate the possible role of glucagon as a counter- 
regulatory hormone in glucose homeostasis, insulin  and glucagon a n t i­
bodies were administered simultaneously in vivo into ra ts . I t  is well 
established that experimental diabetes can be induced by insu lin  a n ti­
bodies (Wright, 1965). I t  is possible that the increased release of 
glucose from the l iv e r  is due to glycogenolysis and gluconeogenesis 
stimulated by glucagon. I f  th is were tru e , the presence o f anti-glucagon 
should prevent, or a t least grossly diminish the hyperglycaemia produced by 
insulin  anti serum.
In agreement with e a r lie r  studies (Barling & Beloff-Chain, 1973; Holst 
e t a l , 1978; Ts io lak is , 1979), neutralisation of endogenous glucagon 
by glucagon anti serum did not resu lt in changes in the plasma glucose 
concentrations. As expected, a rise  in plasma glucose concentrations 
was induced by the insu lin  antiserum (Wright, 1965). However, the 
administration of glucagon antibodies simultaneously with in su lin  a n ti­
bodies did not abolish or diminish the hyperglycaemia induced by the 
insulin  anti serum.
The absence of hypoglycaemia, and the fa ilu re  to attenuate the hyper­
glycaemia caused by insulin  anti serum could be due to incomplete neutra­
lisa tio n  of endogenous glucagon by glucagon antibodies. Data presented 
and discussed in section 4.2 would indicate that incomplete neu tra lisa tio n
by glucagon antibodies is  un like ly  to be the reason fo r these observations 
On the contrary, the administration of a glucagon anti serum with a 
binding capacity, av id ity  and t i t r e  more potent than the anti sera used 
in previous studies was calculated to be capable o f neutralising some 
12 times the to ta l glucagon content of the ra t pancreas. A comparison 
of the characteristics and variable effects  o f glucagon anti sera on 
blood glucose levels in rats reported in previous studies is summarised 
in Table 7. Furthermore, i t  was demonstrated that under the same con­
d itio n s , glucagon antibodies abolished the arginine stimulated insu lin  
release in v ivo . This suggests that the quantity of glucagon antibodies 
administered was s u ffic ie n t to neutralise the arginine stimulated glu­
cagon release in the is le ts  which are about 100 times higher than plasma 
glucagon concentrations. F in a lly , that s u ffic ie n t antibodies was indeed 
in jected into the rats is  indicated by the presence of excess glucagon 
antibodies 2 \ hours a fte r  in jec tion  (about 70% of the to ta l antibodies 
availab le  5 min a fte r  adm inistration).
Thus, the lack o f a physiological e ffe c t of glucagon antibodies on blood 
glucose levels could mean e ith e r :-
(a) that the effects  of glucagon on the liv e r  may be read ily  compensated 
fo r  by other mechanisms such as reduced insu lin  secretion (Epand & 
Douglas, 1973) or adrenal stim ulation (Garber e t a l , 1976), or
(b) that glucagon is not that important fo r the maintenance of euglycaemi 
in the ra t .  In e a r lie r  studies (T s io lak is , 1979) no reduction in  
plasma insu lin  concentrations was detected in the glucagon antibody- 
treated ra ts . On the contrary, in the present s ituatio n  of insu lin  
deficiency and hyperglycaemia induced by the insu lin  antibodies, an 
increase rather than a decrease insu lin  secretion would be expected.
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In the absence of a ra t C-peptide assay, i t  has not been possible to 
confirm that this was indeed the case.
According to Garber e t a l , (1976) the f i r s t  hormonal response to hypo- 
glycaemia is increased catecholamine secretion and that increased glu­
cagon secretion may serve only as a reinforcement to the mechanism 
responsible fo r the recovery from hypoglycaemia. The primary role of 
catecholamine secretion in in it ia t in g  the counter-regulatory response 
to insulin-induced hypoglycaemia is supported by the fac t that i t  pre­
cedes or coincides with the increase of glucose production by the liv e r  
and that enhancement of plasma cyclic AMP levels is mediated by catechol­
amines w h ils t glucagon does not contribute s ig n ific a n tly  to th is  increase 
(Brodows et a l , 1976). However, since no hypoglycaemia occurred in the 
glucagon antibody-treated ra ts , no increased adrenergic a c tiv ity  would 
be expected. This was confirmed by Holst e t a l , (1978) who found no 
s ig n ific an t changes in blood glucose when glucagon antibodies were admini­
stered to adrenalectomised and normal ra ts . In the hyperglycaemic state  
induced by insulin antiserum, catecholamine concentrations are probably 
reduced. Glucagon antibodies did not abolish or diminish the induced 
hyperglycaemia. Whether in h ib itio n  of catecholamines w ill do so remains 
to be studied.
I t  is  c lear however, that insulin remains the single most important facto r  
in glucose homeostasis. I t  is postulated that because insu lin  is  d ire c tly  
involved in the maintenance of euglycaemia, neutralisation of insu lin  by 
antibodies w ill resu lt in a profound disturbance of glucose homeostasis. 
Insulin acts d ire c tly  at the c e llu la r  level to fa c i l i ta te  entry o f glucose
into c e lls . Neutralisation by insu lin  antibodies e ffe c tiv e ly  prevents 
th is and results in an increase in the glucose pool. The hyperglycaemia 
has a positive feedback on the pancreatic B-cell stimulating i t  to 
secrete more insulin  in an attempt to reverse the hyperglycaemia. In 
the event that the B-cell is unable to respond to the hyperglycaemic 
stimulus (as in the diabetic state or when insu lin  secretion is inh ib ited  
by drugs e.g. diazoxide), or i f  in s u ffic ie n t is produced to overcome the 
neutralising e ffe c t of insu lin  antibodies, the hyperglycaemia is main­
tained. Hence in the insulin-dependent diabetic s ta te , the single most 
important factor needed to reverse the hyperglycaemia is not the blocking 
of catecholamines e ith er by drugs or adrenalectomy, nor is i t  the neutra­
lisa tio n  of glucagon by glucagon antibodies, but i t  is the administration  
of the appropriate amount of in su lin .
The postulated interactions of in su lin , glucagon, catecholamines and 
somatostatin in glucose homeostasis is  il lu s tra te d  in Fig. 65. Hyper­
glycaemia, whatever its  cause i . e .  from a meal or resu lting from neutra­
lisa tio n  by insulin antibodies, has a positive feed-back on the pancre­
a tic  B -c e ll. Certain amino acids such as arginine and tryptophan, and 
enteric factors released following a meal, stim ulate B-cell secretion  
via the A -c e ll. The net resu lt of these stim uli is the release o f 
insulin  which increases the outflow from the glucose pool by f a c i l i t a ­
ting entry of glucose into ce lls  and in h ib itin g  hepatic glycogenolysis 
and gluconegenesis. At the same tim e, hyperglycaemia is postulated to 
have an inh ib itory  e ffec t on the catecholamines. Hypoglycaemia on the 
other hand, stimulates catecholamine release, and these act by stim ulating  
hepatic glycogenolysis and gluconeogenesis thereby increasing the size  
of the glucose pool. Hypoglycaemia has a negative feedback on insu lin  
secretion. The exact mechanism of th is feedback is not c lear.
Catecholamines and somatostatin are / ...............
Catecholamines 
Somatostatin ?? 
Other factors ??
Amino acids ?? 
Enteric factors ??Glucagon
Insulin
Glucose
Pool
Catecholamines
F ig .65 Postulated interactions of in su lin , glucagon,catechol amines 
and somatostatin in glucose homeostasis.
possible candidates fo r th is ro le . Blocking of adrenergic a c tiv ity  
delayed the recovery from insulin-induced fiypoglycaemia in rats 
(Ts io lak is , 1979; Garber e t a l , 1976).
Whether this applies fo r somatostatin has not been reported. However, 
in the insulinoma ra ts , where the negative feedback of hypoglycaemia 
is e ith er lo st or grossly defective, responsiveness of the tumour to 
catecholamines (present study) and somatostatin (Sopwith e t a l , 1981) 
is retained, suggesting that other factors beside catecholamines and 
somatostatin may be involved. Future studies w ill e ith e r prove or 
disprove this hypothesis.
Insulin Secretion in insulinoma cell suspensions in v itro  
The divergent responses of arginine and glucose in vivo were confirmed 
in the in v itro  experiments with insulinoma ce ll suspensions. Gluca­
gon stimulated a marked insulin response whereas the insu lin  response 
to arginine was lo s t. This divergence may be related to the tumour 
defect or the absence of A -cells in the tumour.
Impaired arginine stimulation even a fte r  surgical resection o f the 
insulinoma would suggest that i t  was not due to the tumour defect.
These results are however, consistent with the suggestion proposed in  
the present study, that the insulinotrophic e ffec t of arginine is 
mediated via the A -c e ll. The hyperinsulinaemia and hypoglycaemia of 
the ra t insulinoma is associated with pancreatic is le t  A -cell atrophy. 
This e ffe c tiv e ly  means that the glucagonotrophic e ffe c t of arginine is  
absent in these rats as confirmed by d irec t plasma glucagon measurements. 
Hence, even a fte r  tumour resection, because of the A -cell atrophy in the
host's pancratic is le ts , the glucagonotrophic and hence the in su lin - 
otrophic e ffec t of arginine is lo s t.
The in v itro  results are also consistent with the above explanation.
The absence of A-cells in the insulinoma was confirmed by radioimmuno­
assay of the tumour extracts and by immunocytochemical stainings. Under 
these circumstances, the insu lin  response to arginine, but not to exo­
genous glucagon, is impaired. These results provide fu rther evidence 
fo r the physiological role of glucagon in insu lin  secretion.
In agreement with the in vivo resu lts , glucose fa ile d  to stim ulate insu lin  
release in in v itro  experiments. The observation that the glucose 
response was restored in rats a fte r  tumour resection would suggest that 
the unresponsiveness to glucose may be related to the tumour defect.
CHAPTER 5 
FINAL DISCUSSION AND CONCLUSIONS
Transplantable Rat Insulinoma
In the present study, a radiation-induced transplantable ra t insulinoma 
(Chick e t a l , 1977) was characterised and its  functional properties 
investigated. Immunocytochemical staining and radioimmunoassay of tumour 
extracts confirmed that the tumour was composed predominately of B -cells  
with small numbers of D -ce lls , but no glucagon secreting A -ce lls . In su lin , 
glucagon and somatostatin concentrations were s ig n ific a n tly  lower in the 
pancreas of the tumour-bearing rats than in control animals. This pro­
vides fu rther evidence fo r the in t r a - is le t  negative feedback o f insu lin  
on B, A and D-cell secretion. HPLC analysis suggests the presence of 
only one molecular form of somatostatin, S-14 in the tumour. In contrast, 
several molecular species of immunoreative insulins ( IR I)  were detected.
The exact nature of these IR I's  were not id e n tif ie d . Prelim inary studies 
reported the presence of an IRI component that co-elutes with insu lin  
standard (^6000 mol. w t.) on gel f i l t r a t io n  but not on HPLC, suggesting 
differences in molecular charge properties. Whether these observations 
indicate the presence of abnormal insulins in the tumour remains to be 
confirmed.
Changes in glucose homeostasis which accompany p ro life ra tio n  o f the 
insulinoma were studied. Subcutaneous implantation o f small tumour 
fragments resulted in increased weight gain, hyperphagia, defective  
diurnal changes in glucose homeostasis, progressive hyperinsulinaemia 
with death from hypoglycaemia by 22-27 days. Contrary to expectation, 
plasma glucagon concentrations were not raised despite severe hypogly­
caemia suggesting that its  role in glucose homeostasis, a t le a s t under 
these pathological conditions, is questionable.
Metabolic studies were conducted to investigate the functional propert­
ies of the insulinoma. Evidence that the insu lin  response to glucose 
was impaired in the insulinoma-bearing rats but restored a fte r  tumour 
resection, and the fa ilu re  of glucose to stimulate insu lin  secretion 
in v it r o , suggest that the impaired insu lin  response to glucose may be 
related to the tumour defect. Failure of glibenclamide to stim ulate 
insulin  release in vivo could be due to the tumour defect or the hypo­
glycaemia because its  action is dependent on the prevailing glucose 
concentrations (Heilman and T a ljed a l, 1975). In both in vivo and 
in v itro  experiments, glucagon evoked a marked insu lin  response. In 
contrast, arginine fa ile d  to stimulate insu lin  above high basal concen­
tra tio n s . I t  was suggested that th is divergence was due to the absence 
of A -cells in the tumour rather than to an in tr in s ic  defect of the 
tumour. Further evidence fo r th is  comes from the observation that the 
impaired insu lin  response to arginine was not restored even a fte r  
surgical resection of the tumour. The role of glucagon as a counter- 
regulatory hormone to "reverse" the hypoglycaemia caused by insu lin  
was not substantiated under these pathological conditions. Glucagon 
severely exacerbated the hypoglycaemia by stim ulating an exaggerated 
insu lin  response. These observations support the hypothesis proposed 
by Samols (1972) that glucagon plays an important physiological role  
in insu lin  secretion but may not be that important in the maintenance 
of glucose homeostasis. The a b il i ty  of adrenaline and propranolol to 
suppress insu lin  secretion in the insulinoma ra t was retained.
The effects of surgical resection and chemotherapy of the insulinoma on 
glucose homeostasis were studied. Surgical resection caused a rapid and 
marked reversal of the hyperinsulinaemia, a rebound hyperglycaemia lasting  
1-2 days and a 20-60 day prolongation of l i f e .  The cause o f th is
transient hyperglycaemic rebound is not known. In view of the inev itab le  
tumour recurrence, the short-term effects of methotrexate, alloxan and 
streptozotocin were examined. The results show that the tumour is 
unresponsive to the administered doses of methotrexate and alloxan, but 
acutely sensitive to streptozotocin. The divergence between the e ffe c tiv e  
ness o f alloxan and streptozotocin emphasises the d iffe re n t character­
is tic s  of the pancreatic and tumour B -ce lls . Furthermore, because 
streptozotocin is thought to act in tra c e llu la r ly , and alloxan, ex tra - 
ce ll u la rly  on the plasma membrane, these observations may indicate some 
membrane defects in the insulinoma.
I t  is  concluded that the metabolic changes induced by the transplant­
able insulinoma are s im ilar to those reported from numerous studies in  
man (Boucher e t a l , 1970; Frerichs and C reu tzfe ld t, 1976; Marks and Rose,
1981). They indicate the s u ita b ility  of these rats as an animal model 
fo r studies on the basic nature and properties o f spontaneous insulinoma. 
There can be no doubt that the tumour B-cells exh ib it a fundamental 
insu lin  secretory defect which makes them quite d iffe re n t from the 
pancreatic B-cells of normal animals as evidence by th e ir  impaired 
responses to glucose, alloxan and possibly glibenclamide. Although the 
ra t insulinoma has been used fo r iso la ting  large amounts of B -cells  as 
an a lte rn a tive  to normal pancreatic B -ce lls , (Duguid e t a l , 1976);
Gazdar e t a l , 1980; Eisenbarth e t a l , 1981; Sopwith e t a l , 1981) never­
theless, metabolic studies with tumour B-cells should be in terpreted  
in the lig h t of functional abnormalities reported in th is study. Further­
more, i t  should also be noted that ce ll suspensions prepared from the 
ra t insulinomas are not homogenous preparations o f B -ce lls , but also 
contain small numbers of somatostatin-secreting D-cell s. The p o s s ib ility  
that some metabolic changes may be due to the D -cells should be considered
Role of glucagon in glucose homeostasis
The bihormonal concept that glucagon and insulin jo in t ly  regulate glucose 
homeostasis in normal physiology was proposed by;Unger (1974), Unger and 
Orci (1981). Studies with the use of doses of glucagon which are 100-1000 
times the normal secretory rate have suggested that glucagon is a potent 
insulin antogonist in man. Glucagon consistently stimulates glycogenolysis 
and gluconeogenesis in v it ro  (Park and Exton, 1972). In man, supra- 
physiological doses of glucagon, causing plasma levels of 5000 pg/ml, 
augment hepatic output of glucose and cAMP (L i l je n q u is t  et a l , 1974). 
Although the pharmacological effects of glucagon on glucose homeostasis 
are well established, the significance of these observations to normal 
physiology remains uncertain.
Studies using physiological doses of glucagon (3 ng/kg/min) in normal 
subjects, which resu lt in increments in plasma glucagon comparable to 
those reported in a varie ty  of hyperglucagonaemic states produce only 
small, transient increases in blood glucose levels (Sherwin et a l , 1976). 
Hepatic glucose output rapidly increases by 2-3 fold within 7-15 min, 
but returns to base-line within 30 minutes despite hyperglucagonaemia 
and normal peripheral levels of insulin (Felig  e t  a l , 1976; Sherwin 
et a l , 1976). The transient rise in blood glucose concentrations a f te r  
physiological infusions of glucagon is a consequence of an evanescent 
increase in hepatic glucose production. Thus, hyperglucagonaemia causes 
no permanent changes in blood glucose concentrations even when maintained 
by infusion fo r  several days, and does not influence glucose tolerance 
(Felig e t  a l , 1976a).
In contrast to glucagon, the effects of physiological increments in 
plasma insulin persist during periods of insulin  administration lasting  
1 hour or more, and continue fo r  30-45 min a f te r  cessation of an insulin  
infusion (Sherwin e t a l , 1974; Insel et a l , 1975). These differences
in the time course of the biological action of physiological rather than 
pharmacological doses of glucagon, raise serious questions about the 
significance of the insulin to glucagon ra tio  in determining normal 
glucose homeostasis (Sherwin and F e lig , 1977).
In the present study, neutralisation of c ircu lating  glucagon by glucagon 
antibodies in rats fa iled  to depress basal blood glucose levels . These 
results , in agreement with previous studies (Barling and Beloff-Chain, 
1973; Holst et a l , 1978; Tsio lakis, 1979) indicate that the absolute 
concentration of glucagon in the plasma is of minor importance fo r  the 
maintenance of glucose homeostasis otherwise i ts  neutralisation would 
have resulted in s ign ificant blood glucose changes. In contrast, neutra­
lisa tion  of endogenous insulin by insulin antibodies induced a rapid 
hyperglycaemic response. Because insulin fa c i l i ta te s  the entry of 
glucose into cells  and inhib its  hepatic glucose glycogenolysis and 
gluconeogenesis, neutralisation with insulin antibodies w i l l  resu lt in 
an increase in the size of the glucose pool. I t  is however possible 
that the increased release of glucose is due to glycogenolysis and glu­
coneogenesis stimulated by glucagon rather than by the removal of the 
inh ib itory  e ffec t of insulin on these processes by insulin anti serum.
I f  this were true, the presence of glucagon anti serum should prevent, 
or at least grossly diminish the hyperglycaemia produced by insulin  
anti serum. This was however not the case. Animals administered insulin  
and glucagon antibodies simultaneously, showed an identical hypergly- 
caemic response as those given insulin antibodies on i ts  own. I t  is 
concluded that the essentia lity  of normal concentrations of glucagon 
for the maintenance of blood glucose levels in the basal state remains 
unproven, and that our current understanding of glucagon as a counter- 
regulatory hormone in glucose homeostasis as summarised by Unger and 
Orci (1981) may need to be revised.
Role o f  Glucagon in  in s u l in  secre tion
The "bihormonal Ying-Yang” hypothesis of glucose homeostasis being 
regulated by two mutually antagonistic hormones, insulin and glucagon, 
is d i f f i c u l t  to reconcile with the fac t that glucagon is an extremely^ 
potent insulin secretogogue, (Samols e t a l ,  1972). A physiological role  
fo r glucagon in the regulation of insulin secretion by certain amino 
acids is proposed by these authors. I t  is suggested that arginine and 
other amino acids that stimulate both glucagon and insulin secretion do 
so in step-wise manner with glucagon from the A-cells serving as media­
tor or potentiator of the insulinotrophic e ffe c t.
Evidence fo r a major physiological role o f glucagon in insulin  secretion 
but not in glucose homeostasis are obtained from various studies:
1) Direct Stimulation
In the present study, exogenous glucagon was shown to be a potent insulin  
secretogogue in vivo and in v itro  in isolated is le ts  and insulinoma cell  
suspensions. These results confirm e a r l ie r  reports of Samols e t  a l ,
(1965), Turner and McIntyre (1966), Crockford et a l , (1966).
2) Active Immunisation
In the fed-state , in rabbits immunised against glucagon fo r  antibody 
production, the insulinotrophic a c t iv ity  of arginine was inhib ited  
(Al-Tamer, 1978; Tsiolakis, 1979) giving support to the hypothesis that
arginine stimulates insulin secretion in d ire c tly  via the A -c e l l .
3) Passive Immunisation
In the present study, arginine stimulated insulin release was also 
inhibited in rats passively immunised with glucagon antibodies. Further­
more, under these conditions, neutralisation of endogenous glucagon by
u.ix . ^ u i w  uiu nut depress Diood glucose concentrations. In addition, 
glucagon antibodies when given simultaneously with insulin antiserum did 
not abolish or diminish the hyperglycaemia induced by the neutralisation  
of endogenous insu lin . These observations suggest that glucacon may not 
be important in the maintenance of glucose homeostasis but plays an 
important intermediate role in the stimulation of insulin secretion by 
arginine.
4) Isolated Is le ts  of Langerhans
The in vivo data described above could be explained by the antibodies 
blocking the action of glucagon in stimulating hepatic glucose output 
and hence preventing any insulin secretion or a l te rn a t iv e ly ,  the a n t i ­
bodies could be blocking the paracrine stimulation of insulin  secretion 
by A-cell glucagon. In order to c la r i fy  the mechanisms involved in the 
stimulation of insulin release by glucagon, isolated pancreatic is le ts  
were incubated with glucagon anti serum. Glucagon antibodies inhib ited  
the insulinotrophic e ffe c t of arginine but did not a f fe c t  the stimulation  
of insulin secretion by glucose. These observations suggest tha t glu^ 
cagon stimulate the B-cell via a paracrine route, and that d i f fe re n t  
mechanisms are involved in the stimulation of insulin secretion by 
arginine and glucose. Whilst arginine stimulates insulin  release via 
the A -c e l l ,  current evidence suggests that glucose acts d ire c t ly  on the 
B -cell.
5) Transplantable Rat Insulinoma
The observation that the pancreas of insulinoma-bearing rats contains 
lower concentrations of insu lin , glucagon and somatostatin provides 
further support for  a negative feedback of insulin on B, A and D-cell s. 
Moreover the decreased pancreatic glucagon content associated with the
hyperinsulinaemia, is consistent with the hypothesis that whilst glucagon 
stimulates the B -ce l l ,  insulin has a negative feedback on the A -c e l l .
I t  was suggested that the absence of an insulin response to arginine in 
the tumour ra ts , both in vivo and in v i t r o , was due to the absence of 
A-cells in the tumour. Plasma glucagon concentrations in the tumour 
rats in response to arginine stimulation was s ig n if ican tly  lower than 
controls.
F in a lly , glucagon rather than stimulating hyperglycaemia provoked a 
severe hypoglycaemia in the insulinoma ra ts , and basal glucagon concen­
trations were not raised in these rats despite the severe hypoglycaemia. 
These observations further support the contention that glucagon may not 
be important in the regulation of glucose homeostasis, but plays an 
important physiological role in the regulation of insulin secretion.
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